U.S. patent application number 12/295848 was filed with the patent office on 2009-10-01 for process for concentration of a polypeptide.
This patent application is currently assigned to SHIRE PHARMACEUTICALS IRELAND LIMITED. Invention is credited to Stefan Nilsson.
Application Number | 20090246187 12/295848 |
Document ID | / |
Family ID | 38472949 |
Filed Date | 2009-10-01 |
United States Patent
Application |
20090246187 |
Kind Code |
A1 |
Nilsson; Stefan |
October 1, 2009 |
PROCESS FOR CONCENTRATION OF A POLYPEPTIDE
Abstract
The present invention comprises a method of concentrating a
composition comprising a polypeptide of interest and the use of
such a concentrated composition for the treatment of diseases in
mammals, in particular by subcutaneous injection.
Inventors: |
Nilsson; Stefan; (Lidingo,
SE) |
Correspondence
Address: |
FOLEY AND LARDNER LLP;SUITE 500
3000 K STREET NW
WASHINGTON
DC
20007
US
|
Assignee: |
SHIRE PHARMACEUTICALS IRELAND
LIMITED
Dublin
IE
|
Family ID: |
38472949 |
Appl. No.: |
12/295848 |
Filed: |
April 4, 2007 |
PCT Filed: |
April 4, 2007 |
PCT NO: |
PCT/DK2007/000177 |
371 Date: |
October 2, 2008 |
Current U.S.
Class: |
424/94.6 ;
435/196 |
Current CPC
Class: |
A61K 38/465 20130101;
A61K 38/47 20130101; C12Y 301/06001 20130101; C12Y 301/06008
20130101; A61P 25/28 20180101; A61P 7/00 20180101; C12Y 302/01046
20130101; C12Y 205/01061 20130101; C07K 1/36 20130101; C12Y
302/01024 20130101; A61P 43/00 20180101; A61P 25/02 20180101; A61K
38/45 20130101; A61P 7/06 20180101; C07K 1/34 20130101; C12N 9/1085
20130101; A61P 25/00 20180101 |
Class at
Publication: |
424/94.6 ;
435/196 |
International
Class: |
A61K 38/46 20060101
A61K038/46; C12N 9/16 20060101 C12N009/16 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 4, 2006 |
DK |
PA 2006 00488 |
Jul 5, 2006 |
DK |
PA 2006 00922 |
Claims
1-28. (canceled)
29. A composition comprising 50-300 mg/ml Aryl sulfatase A for the
manufacture of a medicament for subcutaneous injection into a
mammal.
30. A method of treating a mammal for metachromatic leukodystrophy
comprising a subcutaneous injection of a composition according to
claim 29.
31. A composition comprising 50-300 mg/ml porphobilinogen deaminase
for the manufacture of a medicament for subcutaneous injection into
a mammal.
32. A method of treating a mammal for porphobilinogen deaminase
acute intermittent porphyria comprising a subcutaneous injection of
a composition according to claim 31.
33. A composition comprising 50-300 mg/ml alpha-mannosidase for the
manufacture of a medicament for subcutaneous injection into a
mammal.
34. A method of treating a mammal for the lysosomal storage
disorder alpha-mannosidosis comprising a subcutaneous injection of
a composition according to claim 33.
35. A composition comprising 50-300 mg/ml galactosylcerebrosidase
for the manufacture of a medicament for subcutaneous injection into
a mammal.
36. A method of treating a mammal for Krabbe disease comprising a
subcutaneous injection of a composition according to claim 35.
37. A method of concentrating a composition comprising Aryl
sulfatase A, functionally equivalent parts and analogues hereof,
said method comprising: (i) centrifugation and/or filtration of a
composition comprising Aryl sulfatase A and/or a functionally
equivalent part or analogue hereof, to obtain a resulting solution;
and (ii) concentrating said resulting solution.
38. A method of concentrating a composition comprising
porphobilinogen deaminase, functionally equivalent parts and
analogues hereof, said method comprising: (i) centrifugation and/or
filtration of a composition comprising prophobilinogen deaminase
and/or a functionally equivalent part or analogue hereof, to obtain
a resulting solution; and (ii) concentrating said resulting
solution.
39. A method of concentrating a composition comprising alfa
mannosidase, functionally equivalent parts and analogues hereof,
said method comprising: (i) centrifugation and/or filtration of a
composition comprising alfa mannosidase and/or a functionally
equivalent part or analogue hereof, to obtain a resulting solution;
and (ii) concentrating said resulting solution.
40. A method of concentrating a composition comprising
galactosylcerebrosidase, functionally equivalent parts and
analogues hereof, said method comprising: (i) centrifugation and/or
filtration of a composition comprising galactosylcerebrosidase
and/or a functionally equivalent part or analogue hereof, to obtain
a resulting solution; and (ii) concentrating said resulting
solution.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to a method for concentrating
a polypeptide of interest, to the use of a composition comprising a
concentrated polypeptide of interest as a medicament for
subcutaneous injection and to a composition comprising at least 10
mg/ml polypeptide of interest.
BACKGROUND OF THE INVENTION
[0002] Some polypeptides are useful as a medicament for the
prevention and/or treatment of certain diseases. The ability to
inject a medicament subcutaneously is an advantage as it makes it
easy for the patients to administer the medication to
themselves.
[0003] As there are physiological restrains on how large a volume
it is possible to inject subcutaneously. Thus it is an advantage
for medicaments which are to be administered subcutaneously that
they are available in a high concentration so as to ensure that the
patient receives an adequate amount of the medicament and/or to
avoid multiple subcutaneous injections.
[0004] WO 99/37325 discloses methods of treating and preventing
disease caused by absence or deficiency of the activity of enzymes
belonging to the heme biosynthetic pathway. WO 03/002731 discloses
a process for purification of recombinant porphobilinogen deaminase
on an industrial scale and to the use of the purified product for
the preparation of a medicament. Similarly, WO 02/099092 and WO
2005/094874 provides lysosomal alpha-mannosidase and therapeutic
use hereof. Finally, WO 2005/073367 provides a process for
purification of aryl sulfatase A and use of the enzyme in the
treatment of metachromatic leukodystrophy.
[0005] The present invention relates to a method for concentrating
a polypeptide of interest and to the use of a composition
comprising a concentrated polypeptide of interest for the
manufacture of a medicament for subcutaneous injection into
mammal.
SUMMARY OF THE INVENTION
[0006] The present invention relates in one aspect to a method of
concentrating a composition comprising a polypeptide of interest
comprising: [0007] a) Centrifugation and/or filtration of a
composition comprising a polypeptide of interest [0008] b)
Concentrating the supernatant or retentate, respectively, obtained
from step a).
[0009] In another aspect the present invention relates to a
composition comprising at least 10 mg/ml polypeptide of
interest.
[0010] In yet another aspect the present invention relates to use
of a composition comprising 75-250 mg/ml polypeptide of interest
for the manufacture of a medicament for subcutaneous injection into
a mammal.
[0011] In yet another aspect the present invention relates to a
method of treating a mammal for Acute Intermittent Porphyria
comprising injecting subcutaneously a composition of 500-300 mg/ml
PBGD.
[0012] In yet another aspect the present invention relates a method
of treating a mammal for metachromatic leukodystrophy comprising
subcutaneous injection of a composition of 50-300 mg/ml aryl
sulfatase A.
[0013] In yet another aspect the present invention relates a method
of treating a mammal for the lysosomal storage disorder
alpha-mannosidosis comprising subcutaneous injection of a
composition of 50-300 mg/ml lysosomal alpha-mannosidase.
[0014] In yet another aspect the present invention relates a method
of treating a mammal for Krabbe disease comprising subcutaneous
injection of a composition of 50-300 mg/ml
galactosylcerebrosidase.
DEFINITIONS
[0015] For purposes of the present invention, alignments of
sequences and calculation of homology scores may be done using a
full Smith-Waterman alignment, useful for both protein and DNA
alignments. The default scoring matrices BLOSUM50 and the identity
matrix are used for protein and DNA alignments respectively. The
penalty for the first residue in a gap is -12 for proteins and -16
for DNA, while the penalty for additional residues in a gap is -2
for proteins and -4 for DNA.
[0016] Alignment may be made with the FASTA package version v20u6
(W. R. Pearson and D. 3. Lipman (1988), "Improved Tools for
Biological Sequence Analysis", PNAS 85:2444-2448, and W. R. Pearson
(1990) "Rapid and Sensitive Sequence Comparison with FASTP and
FASTA", Methods in Enzymology, 183:63-98).
[0017] Multiple alignments of protein sequences may be made using
"ClustalW" (Thompson, 1. D., Higgins, D. G. and Gibson, T J. (1994)
CLUSTAL W: improving the sensitivity of progressive multiple
sequence alignment through sequence weighting, positions-specific
gap penalties and weight matrix choice. Nucleic Acids Research,
22:4673-4680). Multiple alignment of DNA sequences may be done
using the protein alignment as a template, replacing the amino
acids with the corresponding codon from the DNA sequence.
[0018] In the context of the present invention, the term "E. C."
(Enzyme Class) refers to the internationally recognized enzyme
classification system, Recommendations of the Nomenclature
Committee of the International Union of Biochemistry and Molecular
Biology, Academic Press, Inc.
[0019] The term "origin" used in the context of amino acid
sequences, e.g. proteins, or nucleic acid sequences is to be
understood as referring to the organism from which it derives. Said
sequence may be expressed by another organism using gene technology
methods well known to a person skilled in the art. This also
encompasses sequences which have been chemically synthesized.
Furthermore, said sequences may comprise minor changes such as
codon optimization, i.e. changes in the nucleic acid sequences
which do not affect the amino acid sequence.
DETAILED DESCRIPTION OF THE INVENTION
Polypeptide of Interest
[0020] The polypeptide of the present invention may in particular
be a hormone or hormone variant, an enzyme, a receptor or portion
thereof, an antibody or portion thereof, an allergen or a reporter.
The polypeptide of interest may in particular be an enzyme selected
from one of six major enzyme groups, such as an oxidoreductase
(E.C. 1), a transferase (E.C. 2), a hydrolase (E.C. 3), a lyase
(E.C. 4), an isomerase (E.C. 5), or a ligase (E.C. 6). In a more
particular aspect, the polypeptide of interest may be an
aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase,
cellulase, cellobiohydrolase, chitinase, cutinase, cyclodextrin
glycosyltransferase, deoxyribonuclease, endoglucanase, esterase,
alpha-galactosidase, beta-galactosidase, glucoamylase,
alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase,
mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase,
phospholipase, phytase, polyphenoloxidase, proteolytic enzyme,
ribonuclease, transglutaminase, xylanase, or beta-xylosidase.
[0021] The polypeptide of interest may in particular be a
polypeptide which is useful as a medicament.
[0022] Examples of a suitable polypeptide of interest include but
is not limited to one selected from the group consisting of a
phorphobilinogen deaminase, an aryl sulfatase, an alpha-mannosidase
and a galactocerebrosidase.
[0023] In principle a polypeptide of interest derivable from any
source may be treated according to the methods of the present
invention.
[0024] In a particular embodiment the polypeptide of interest may
be of human origin. Especially in the context of using a
polypeptide of interest for the manufacture of a medicament which
is to be administered to humans may the polypeptide be of human
origin as this may minimize the risk of unwanted allergic
reactions. Natural variations of human polypeptide due to e.g.
polymorphism are in the context of the present invention included
in the term "human origin".
[0025] The polypeptide of interest may in particular be produced as
a recombinant protein, i.e. a nucleotide sequence encoding the
polypeptide of interest may be introduced into a cell for
expression of the polypeptide of interest. The recombinant
expression may be homologous or heterologous, i.e. the polypeptide
of interest may be expressed in cell which it is naturally
expressed by (homologous expression) or it may be expressed by a
cell which it is not naturally expressed by (heterologous
expression).
[0026] The recombinant polypeptide of interest may be expressed by
any cell suitable for recombinant production of the particular
polypeptide of interest. Examples of suitable cells include but are
not limited to prokaryotic cells, such as an E. coli cell or a
Bacillus cell. Examples of suitable eukaryotic cells include but
are not limited to a yeast cell or a mammalian cell such as a
Chinese Hamster Ovary (CHO). Alternatively, it may be a human
cell.
[0027] Suitable host cells for the expression of glycosylated
polypeptide are derived from multicellular organisms. Examples of
invertebrate cells include plant and insect cells. However, the
host cell may also be a vertebrate cell, and propagation of
vertebrate cells in culture (tissue culture) has become a routine
procedure
[0028] The term "recombinant polypeptide" or "recombinant
polypeptide of interest" denotes herein a recombinant produced
polypeptide.
[0029] Reference to a particular polypeptide of interest includes
in the context of the present invention also functionally
equivalent parts or analogues of the polypeptide of interest. For
example, if the polypeptide of interest is an enzyme a functionally
equivalent part of the enzyme could be a domain or subsequence of
the enzyme which includes the necessary catalytic site to enable
the domain or subsequence to exert substantially the same enzymatic
activity as the full-length enzyme or alternatively a gene coding
for the catalyst. The term "substantially the same enzymatic
activity" refers to an equivalent part or analogue having at least
50%, preferably at least 60%, more preferably at least 70%, more
preferably at least 75%, more preferably at least 80%, more
preferably at least 85%, more preferably at least 90%, more
preferably at least 95% and most preferably at least 97%, at least
98% or at least 99% of the activity of the natural enzyme. An
example of an enzymatically equivalent analogue of the enzyme could
be a fusion protein which includes the catalytic site of the enzyme
in a functional form, but it can also be a homologous variant of
the enzyme derived from another species. Also, completely synthetic
molecules that mimic the specific enzymatic activity of the
relevant enzyme would also constitute "enzymatic equivalent
analogues".
[0030] Generally, the skilled person will be able to readily devise
appropriate assays for the determination of enzymatic activity. For
PBGD, however, a suitable assay is described in WO 03/002731, in
example 2, as well as in the experimental sections of the present
applications. Aryl sulfatase, in addition to its natural
substrates, is also able to catalyze the hydrolysis of the
synthetic, chromogenic substrate, para-Nitrocatechol sulfate
(pNCS). The product, para-Nitrocatechol (pNC), absorbs light at 515
nm. An assay for determination of aryl sulfatase activity is
described in details in WO 2005/073367 and in Fluharty et al. 1978,
Meth. Enzymol. 50:537-47. For LAMAN, an appropriate enzyme activity
assay is disclosed in WO 02/099092.
Porphobilinogen Deaminase
[0031] In one embodiment the polypeptide of interest of the
invention may be porphobilinogen deaminase, (also known as
porphobilinogen ammonia-lyase (polymerizing)), E.C. 4.3.1.8.
(Waldenstrom 1937, 3. Acta. Med. Scand. Suppl. 8). Porphobilinogen
deaminase is the third enzyme in the heme biosynthetic pathway.
E.C. 4.3.1.8 has been transferred to E.C. 2.5.1.61, so
porphobilinogen deaminase (PBGD) is now placed under this E.C.
number.
[0032] Porphobilinogen deaminase catalyzes the reaction of 4
porphobilinogen+H.sub.2O hydroxymethylbilane+4 NH.sub.3.
[0033] PBDG is important in relation to Acute intermittent
porphyria (AIP), which is an autosomal dominant disorder in man
caused by a defect (50% reduction of activity) of PBDG (see
WO01/07065 for further details in relation to this).
Porphobilinogen deaminase is in short known as PBGD and in the
context of the present invention these two terms may be used
inter-changeably with one another.
[0034] For recombinant expression of PBGD a host cell may in
particular be a yeast cell or an E. coli cell.
[0035] For a detailed example of construction of a recombinant E.
coli cell reference is made to example 1 of WO01/07065 and for
construction of recombinant HeLa cells and NIH 3T3 cells capable of
expressing mouse PBGD reference is made to example 6 of
WO01/07065.
[0036] The term "recombinant porphobilinogen deaminase (rPBGD)"
denotes herein a recombinant produced PBGD. In the following, this
enzyme and the recombinant human form will be termed "PBGD" and
"rhPBGD", respectively. Within this term is also included an
enzymatically equivalent part or analogue of PBGD. One example of
an enzymatically equivalent part of the enzyme could be a domain or
subsequence of the enzyme which includes the necessary catalytic
site to enable the domain or subsequence to exert substantially the
same enzymatic activity as the full-length enzyme or alternatively
a gene coding for the catalyst. The term "substantially the same
enzymatic activity" refers to an equivalent part or analogues
enzyme having at least 50%, preferably at least 60%, more
preferably at least 70%, more preferably at least 75%, more
preferably at least 80%, more preferably at least 85%, more
preferably at least 90%, more preferably at least 95% and most
preferably at least 97%, at least 98% or at least 99% of the
activity of natural human rhPBGD measured in the rhPBGD activity
assay described in example 2 of WO 03/002731. An example of an
enzymatically equivalent analogue of the enzyme could be a fusion
protein which includes the catalytic site of the enzyme in a
functional form, but it can also be a homologous variant of the
enzyme derived from another species. Also, completely synthetic
molecules that mimic the specific enzymatic activity of the
relevant enzyme would also constitute "enzymatic equivalent
analogues".
[0037] An example of PBGD which may be used in the present
invention includes any of those shown in Sequence 1-10 of the
present application, or in Genebank no. X04217, X04808 or
M95623.
Aryl Sulfatase
[0038] In another embodiment of the present invention the
polypeptide of interest may be an arylsulfatase A.
[0039] Arylsulfatase A catalyzes the reaction of a cerebroside
3-sulfate+H2O=a cerebroside+sulphate.
[0040] ASA has been purified from a variety of sources including
human liver, placenta, and urine. It is an acidic glucoprotein with
a low isoelectric point. Above pH 6.5, the enzyme exists as a dimer
with a molecular weight of approximately 110 kDa. ASA undergoes a
pH-dependent polymerisation forming an octamer at pH 4.5. In human
urine, the enzyme consists of two nonidentical subunits of 63 and
54 kDa. ASA purified from human liver, placenta, and fibroblasts
also consist of two subunits of slightly different sizes varying
between 55 and 64 kDa. As in the case of other lysosomal enzymes,
ASA is synthesised on membrane-bound ribosomes as a glycosylated
precursor. It then passes through the endoplasmic reticulum and
Golgi, where its N-linked oligosaccharides are processed with the
formation of phosphorylated and sulfated oligosaccharide of the
complex type (Waheed A et al. Biochim Biophys Acta. 1985, 847,
53-61, Braulke T et al. Biochem Biophys Res Commun. 1987, 143,
178-185). In normal cultured fibroblasts, a precursor polypeptide
of 62 kDa is produced, which translocates via mannose-6-phosphate
receptor binding (Braulke T et al. 3 Biol. Chem. 1990, 265,
6650-6655) to an acidic prelysosomal endosome (Kelly B M et al. Eur
J Cell Biol. 1989, 48, 71-78).
[0041] The arylsulfatase A may in particular be of human origin.
The length (18 amino acids) of the human ASA signal peptide is
based on the consensus sequence and a specific processing site for
a signal sequence. Hence, from the deduced human ASA cDNA (EMBL
GenBank accession numbers J04593 and X521151) the cleavage of the
signal peptide should be done in all cells after residue number 18
(Ala), resulting in the mature form of the human ASA. In the
following, recombinant arylsulfatase A will be abbreviated rASA,
the mature form of arylsulfatase A including the mature form of
human ASA will be termed "mASA" and the mature recombinant human
ASA will be termed "mrhASA".
[0042] A protein modification has been identified in two eukaryotic
sulfatases (ASA and arylsulfatase B (ASB)) and for one from the
green alga Volvox carteri (Schmidt B et al. Cell. 1995, 82,
271-278, Selmer T et al. Eur J Biochem. 1996, 238, 341-345). This
modification leads to the conversion of a cysteine residue, which
is conserved among the known sulfatases, into a
2-amino-3-oxopropionic acid residue (Schmidt B et al. Cell. 1995,
82, 271-278). The novel amino acid derivative is also recognised as
C*-formylglycin (FGly). In ASA and ASB derived from MSD cells, the
Cys-69 residue is retained. Consequently, it is proposed that the
conversion of the Cys-69 to FGly-69 is required for generating
catalytically active ASA and ASB, and that deficiency of this
protein modification is the cause of MSD. Cys-69 is referred to the
precursor ASA which has an 18 residue signal peptide. In the mASA
the mentioned cysteine residue is Cys-51. Further investigations
have shown that a linear sequence of 16 residues surrounding the
Cys-51 in the mASA is sufficient to direct the conversion and that
the protein modification occurs after or at a late stage of
co-translational protein translocation into the endoplasmic
reticulum when the polypeptide is not yet folded to its native
structure (Dierks T et al. Proc Natl Acad. Sci. 1997, 94,
11963-1196, Wittke, D. et al. (2004), Acta Neuropathol. (Berl.),
108, 261-271).
[0043] Multiple forms of ASA have been demonstrated on
electrophoresis and isoelectric focusing of enzyme preparations
from human urine, leukocytes, platelets, cultured fibroblasts and
liver. Treatment with endoglycosidase H, sialidase, and alkaline
phosphatase reduces the molecular size and complexity of the
electrophoretic pattern, which suggests that much of the charge
heterogeneity of ASA is due to variations in the carbohydrate
content of the enzyme.
[0044] The arylsulfatase A may in particular be a form of
arylsulfatase A, which is capable of crossing the blood brain
barrier and/or a form of rASA, which possesses specific tags for
entry into target cells within the brain. In particular, it may be
a rASA, which is efficiently endocytosed in vivo via the
mannose-6-phosphate pathway.
[0045] Thus the ASA may in particular be covalently bound to a
so-called tag, peptides or proteins as vehicles or toxins as
vehicles which are capable of increasing and/or facilitating
transport of ASA over the blood-brain barrier and/or across
cellular membranes in general (Schwarze et al., Trends Cell Biol.
2000; 10(7): 290-295; Lindgren et al., Trends Pharmacol. Sci. 2000;
21(3): 99-103). An ASA molecule containing such peptide sequences
can be produced by expression techniques. The protein transduction
process is not cell type specific and the mechanism by which it
occurs is not fully elucidated, however, it is believed that it
takes place by some sort of membrane perturbation and penetration
process that is receptor independent. A partially unfolded state of
the molecule may facilitate the process but is not essential.
[0046] An example of a suitable tag includes but is not limited to
the mannose-6-phosphate tag.
[0047] Examples of peptides or proteins as vehicle include but are
not limited to so-called protein-transducing domains. Examples of
suitable protein-transducing domains include but are not limited to
those mentioned in WO 2005/073367, which is incorporated herein by
reference. Hence the protein-transducing domain may be the 11
residue basic peptide from the HIV TAT protein -YGRKKRRQRRR
(Schwarze et al., Trends Cell Biol. 2000; 10(7): 290-295), a
synthetic version of TAT-YARAAARQARA that confers more
alpha-helicity and amphipathic nature to the sequence (Ho et al.,
Cancer Res. 2001; 61(2):474-477), a synthetic leader peptide
composed of poly -R or a mixture of basic -R and -K residues in
combination with other amino acids and peptides based on
hydrophobic signal sequence moieties from either beta-3 integrin or
Kaposi's sarcoma FGF (Dunican et al. Biopolymers 2001; 60(1):
45-60).
[0048] Examples of suitable toxins as vehicles include but are not
limited to those described in WO 2005/073367, which is incorporated
herein by reference.
[0049] The ASA may in particular comprise a nucleic acid sequence,
which encodes: [0050] (a) the amino acid sequence of SEQ ID NO:2 in
WO 2005/073367; [0051] (b) a portion of the sequence in (a), which
is enzymatically equivalent to recombinant human arylsulfatase A
[0052] (c) an amino acid sequence analogue having at least 75%
sequence identity to any one of the sequences in (a) or (b) and at
the same time comprising an amino acid sequence, which is
enzymatically equivalent to recombinant human arylsulfatase A.
[0053] In the present context, an amino acid sequence or a portion
of an amino acid sequence which is a polypeptide capable of
hydrolysing an amount of the arylsulfatase A substrate pNCS at
37.degree. C. a rate corresponding to a specific activity of at
least 20 U/mg polypeptide (preferably 50 U/mg polypeptide) when
determined in an assay for measuring arylsulfatase A activity as
described in example 1 of WO 2005/073367, and/or a polypeptide,
which is capable of hydrolysing at least 40% of labelled
arylsulfatase A substrate, fx. 14C palmitoyl sulfatide, loaded into
MLD fibroblasts, when assayed by incubation at a dose level of 25
mU/ml in an assay as described in example 2 of WO 2005/073367.
[0054] The ASA may in another embodiment in particular comprise:
[0055] (a) the nucleic acid sequence of SEQ ID NO: 1 in WO
2005/073367 [0056] (b) a portion of the sequence in (a), which
encodes an amino acid sequence, which is enzymatically equivalent
to recombinant human arylsulfatase A [0057] (c) a nucleic acid
sequence analogue having at least 75% sequence identity to any one
of the sequences in (a) or (b) and at the same time encoding an
amino acid sequence, which is enzymatically equivalent to
recombinant human arylsulfatase A
[0058] It may be preferred that the degree of sequence identity
between the above mentioned nucleic acid sequence and SEQ ID NO: 1
of WO 2005/073367 is at least 80%, such as at least 85%, at least
90%, at least 95%, at least 97%, at least 98%, or at least 99%. It
may be equally preferred that the degree of sequence identity
between the amino acid sequence encoded by the above mentioned
nucleic acid sequence and SEQ ID NO: 2 WO 2005/073367 is at least
80%, such as at least 85%, at least 90%, at least 95%, at least
97%, at least 98%, or at least 99%.
[0059] For the purpose of the present invention it is preferred
that the arylsulfatase A is a recombinant enzyme, particularly
preferred is recombinant human arylsulfatase A (rhASA).
[0060] It is preferred that rASA is produced in a mammalian cell or
cell line and that said mammalian cell or cell line produces a
glycoform of rASA, which is efficiently endocytosed in vivo via the
mannose-6-phosphate receptor pathway. Specifically, the preferred
glycoform of rASA comprises an amount of exposed
mannose-6-phosphate, which allows efficient endocytosis of rASA in
vivo via the mannose-6-phosphate pathway.
[0061] In a particular embodiment at least one of the produced
glycoforms of rASA is similar to a glycoform produced in CHO
cells.
[0062] The post translational modification of the cysteine residue
in position 51 in the mature human arylsulfatase A is relevant for
the activity of the enzyme. Accordingly, in a preferred embodiment
of the present invention production of the arylsulfatase A or its
equivalent occurs at a rate and under conditions, which result in a
product comprising an isoform of the enzyme in which the amino acid
corresponding to Cys-69 in SEQ ID NO: 2 of WO 2005/073367 is
converted to Formylglycine, corresponding to Fgly-51 in SEQ ID NO:
3 of WO 2005/073367. SEQ ID NO: 4 of WO 2005/073367 represents
mature human arylsulfatase A after cleavage of the 18 amino acid
signal peptide but prior to modification of C-51.
[0063] Thus in another embodiment of the present invention the ASA
or its enzymatical equivalent may be selected from the group
consisting of [0064] (a) the amino acid sequence of SEQ ID NO:3 of
WO 2005/073367; [0065] (b) a portion of the sequence in (a), which
is enzymatically equivalent to recombinant human arylsulfatase A
[0066] (c) an amino acid sequence analogue having at least 75%
sequence identity to any one of the sequences in (a) or (b) and at
the same time being enzymatically equivalent to recombinant human
arylsulfatase A.
[0067] It may be preferred that the degree of sequence identity
between the enzyme produced according to the invention and SEQ ID
NO: 3 of WO 2005/073367 or SEQ ID NO: 4 of WO 2005/073367 is at
least 80%, such as at least 85%, at least 90%, at least 95%, at
least 97%, at least 98%, or at least 99%.
[0068] For the biological activity and the effects of the enzyme in
vivo requires to be optimal it is an advantage if an adequate
amount of the enzyme has acquired a glycosylation pattern as
described above and has been modified post translationally at
position 51. Thus at least 50%, 60%, 70%, 80%, 90%, 95% or 98% of
the ASA of the present invention may be in the above described
glycoform/isoform.
[0069] The ASA of the present invention may in terms of its
structure be different from the rASA according to SEQ ID NO: 3 of
2005/073367. It may be an advantage that the sequence of amino acid
residues surrounding the Cys-51 is identical or has a high degree
of sequence identity to the corresponding sequence in SEQ ID NO: 3.
Thus, it may be preferred that a linear sequence of 20 amino acids,
such as 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5 or 4
amino acid residues surrounding the Cys-51 in the arylsulfatase A
is identical or at least 90% identical, such as 95%, 96%, 97%, 98%,
or 99% identical to the corresponding sequence in SEQ ID NO: 3 of
2005/073367. As the active form of rASA within the lysosymes is an
octamer the ASA of the present invention may in particular be a
rASA which is an octamer or assembles into an octamer under
physiological conditions.
[0070] The enzyme activity of ASA, which is to be understood as the
catalytic activity of the rASA, may be measured in an enzyme assay
based on the rASA mediated hydrolysis of either a detectable
substrate or a substrate, which leads to a detectable end product.
In a preferred aspect the assay is based on hydrolysis of the
synthetic, chromogenic substrate, para-Nitrocatechol sulphate
(pNCS) which has an end product, para-Nitrocatechol (pNC) that
absorbs light at 515 nm.
Lysosomal Alpha-Mannosidase
[0071] In yet another embodiment the polypeptide of interest may be
a lysosomal alpha-mannosidase (LAMAN). Lysomal alpha-mannosidase
belongs to EC 3.2.1.24 and is an exoglycosidase which hydrolyses
the terminal, non-reducing alpha-D-mannose residues in
alpha-D-mannosides from the non-reducing end during the ordered
degradation of N-linked glycoproteins (Aronson and Kuranda FASEB J
3:2615-2622. 1989). In the context of the present invention the
term lysosomal alpha-mannosidase may be used interchangeably with
the short term LAMAN.
[0072] The LAMAN of the present invention may in particular be of
human origin. The human enzyme is synthesised as a single
polypeptide of 1011 amino acids with a putative signal peptide of
49 residues that is processed into three main glycopeptides of 15,
42, and 70 kD (Nilssen et al. Hum. Mol. Genet. 6, 717-726.
1997).
[0073] The gene coding for LAMAN (MANB) is located at chromosome 19
(19cen-ql2), (Kaneda et al. Chromosoma 95:8-12. 1987). MANB
consists of 24 exons, spanning 21.5 kb (GenBank accession numbers
U60885-U60899; Riise et al. Genomics 42:200-207. 1997). The LAMAN
transcript is >>3,500 nucleotides (nts) and contains an open
reading frame encoding 1,011 amino acids (GenBank U60266.1).
[0074] The cloning and sequencing of the human cDNA encoding LAMAN
has been published in three papers (Nilssen et al. Hum. Mol. Genet.
6, 717-726. 1997; Liao et all., Biol. Chem. 271, 28348-28358. 1996;
Nebes et al. Biochem. Biophys. Res. Commun. 200, 239-245. 1994).
Curiously, the three sequences are not identical. When compared to
the sequence of Nilssen et al (accession # U60266.1) a TA to AT
change at positions 1670 and 1671 resulting in a valine to aspartic
acid substitution was found by Liao et al. and Nebes et al.
[0075] In a most preferred embodiment, the lysosomal alpha
mannosidase comprises the amino acid sequence of SEQ ID NO.: 1 of
WO 2005/094874.
[0076] For practical and economical reasons it is preferred that
the LAMAN of the present invention is produced recombinant. By
recombinant production it may also be possible to obtain a
preparation of the enzyme wherein a large fraction contains
mannose-6-phosphate. Recombinant production may be achieved after
transfection of a cell using a nucleic acid sequence comprising the
sequence of SEQ ID NO: 2 of WO 2005/094874.
[0077] The alpha-mannosidase is preferably made in a mammalian cell
system as this will result in a glycosylation profile, which
ensures efficient receptor mediated uptake in cells of for instance
visceral organs of the body. In particular, it has been found that
production of the enzyme in CHO, COS or BHK cells ensures adequate
post-translational modification of the enzyme by addition of
mannose-6-phosphate residues. In addition a correct sialylation
profile is obtained. Correct sialylation is known to be important
in order to prevent uptake by the liver, because of exposed
galactose residues.
[0078] In even more preferred embodiments the mammalian cell system
is therefore selected from the group comprising CHO, COS cells or
BHK cells (Stein et al. 3 Biol. Chem. 1989, 264, 1252-1259). It may
further be preferred that the mammalian cell system is a human
fibroblast cell line.
[0079] In a most preferred embodiment, the mammalian cell system is
a CHO cell line.
[0080] In another embodiment the lysosomal alpha-mannosidase may be
a preparation of lysosomal alpha-mannosidase wherein a fraction of
said preparation consists of lysosomal alpha mannosidase having one
or more N-linked oligosaccharides carrying mannose 6-phosphate
groups.
[0081] It is further preferred that a fraction of a preparation of
said lysosomal alpha-mannosidase is capable of binding to mannose
6-phosphate receptors.
[0082] The ability of the enzyme to bind to mannose-6-phosphate
receptors may be determined in an in vitro assay as described in
example 1 of WO 2005/094874. Here, binding of the enzyme to a MPR
affinity 300 Matrix provides a measure of its ability to bind to
mannose-6-phosphate receptors. In a preferred embodiment of the
invention binding of the enzyme to mannose-6-phosphate receptors
occurs in vitro.
[0083] In more preferred embodiments of the invention this fraction
corresponds to from 1 to 75% of the activity of a preparation of
lysosomal alpha-mannosidase, such as from 2 to 70%, such as from 5
to 60%, such as from 10 to 50% such as from 15 to 45%, such as from
20 to 40%, such as from 30 to 35%.
[0084] Accordingly, it is preferred that the lysosomal
alpha-mannosidase has a content of mannose 6-phosphate residues
allowing mannose 6-phosphate dependent binding of from 2 to 100%, 5
to 95%, 10 to 90%, 20 to 80%, 30 to 70% or 40 to 60% of the amount
of enzyme to a Man-6-P-receptor matrix. At present, the degree of
phosphorylation has been analysed in several batches of enzyme and,
typically, from 30 to 45% of the enzyme is phosphorylated and binds
the affinity matrix.
[0085] It is further preferred that a fraction constituting from
2-100%, 5-90%, 10-80%, 20-75%, 30-70%, 35-65% or 40-60% of the
amount of said lysosomal alpha-mannosidase binds to the
Man-6-P-receptor with high affinity. Theoretically, two mannose
6-phosphate groups must be positioned close to each other in order
for the enzyme to bind a Man-6-P-receptor with high affinity.
Recent observations suggest that the distance between the
phosphorylated mannose residues must be 40 .ANG. or less in order
to obtain high affinity binding. In the human lysosomal
alpha-mannosidase according to SEQ ID NO: 1 of WO 2005/094874 the
two mannose 6-phosphate residues may be situated at the asparagines
residues in positions 367 and 766. Accordingly, it is preferred
that the medicament according to the present invention comprises
lysosomal alpha-mannosidase, a fraction of which carries mannose
6-phosphate groups at both of these asparagine residues.
[0086] Preferably, the alpha-mannosidase is made by recombinant
techniques. In a further embodiment, the alpha-mannosidase is of
human origin (hLAMAN) and still more preferred a mature human
alpha-mannosidase (mhLAMAN) or a fragment thereof. The fragment may
be modified, however the active sites of the enzyme should be
preserved.
[0087] It is to be expected that, in preparations of
alpha-mannosidase according to the present invention, one fraction
of the enzyme is represented by its precursor form, while other
fractions represent the proteolytically processed forms of
approximately 55 and 70 kDa.
Galactocerebrosidase
[0088] In another embodiment the polypeptide of interest may be a
galactocerebrosidase, which may be shortended to GALC.
Galactocerebrosidase belongs to E.C. 3.1.6.46 and are enzymes
capable of catalysing the reaction of
D-galactosyl-N-acylsphingosine+H.sub.2O=D-galactose+N-acylsphingosine,
thus GALC catalyzes the degradation of galactolipids in for example
myelin.
[0089] The GALC enzyme derived from humans is a glycosylated
lysosomal enzyme comprising 643 amino acids and with a molecular
weight of 72.8 kDa. The GALC of the present invention may in
particular be of human origin. In a further embodiment the GALC may
be expressed recombinant in one of the previously mentioned host
cells. The host cell for recombinant expression of GALC may in
particular be a CHO cell.
[0090] In the description and in the claims reference is made to
the following amino acid and nucleic acid sequences:
TABLE-US-00001 Sequence Sequence description identifier PBGD coding
sequence 1 SEQ ID NO.: 1 PBGD coding sequence 2 SEQ ID NO.: 2 PBGD
coding sequence 3 SEQ ID NO.: 3 PBGD coding sequence 4 SEQ ID NO.:
4 PBGD coding sequence 5 SEQ ID NO.: 5 PBGD coding sequence 6 SEQ
ID NO.: 6 PBGD coding sequence 7 SEQ ID NO.: 7 PBGD coding sequence
8 SEQ ID NO.: 8 PBGD coding sequence 9 SEQ ID NO.: 9 PBGD coding
sequence 10 SEQ ID NO.: 10 PBGD coding sequence, GenBank Acc. No.
X04217 SEQ ID NO.: 11 PBGD coding sequence, GenBank Acc. No. X04808
SEQ ID NO.: 12 PBGD coding sequence, GenBank Acc. No. M95623 SEQ ID
NO.: 13 PBGD aa sequence from coding sequence, GenBank SEQ ID NO.:
14 Acc. No. M95623, Constitutive form PBGD aa sequence from coding
sequence, GenBank SEQ ID NO.: 15 Acc. No. M95623, Erythropoietic
form ASA coding sequence Genbank Acc. No. J04593 SEQ ID NO.: 16 ASA
coding sequence SEQ ID NO.: SEQ ID NO.: 17 1 of WO 2005/073367 ASA
aa sequence SEQ ID NO.: 2 of WO 2005/073367 SEQ ID NO.: 18 ASA aa
sequence SEQ ID NO.: 3 of WO 2005/073367 SEQ ID NO.: 19 ASA aa
sequence SEQ ID NO.: 4 of WO 2005/073367 SEQ ID NO.: 20 LAMAN aa
sequence SEQ ID NO.: 1 of WO SEQ ID NO.: 21 2005/094874 LAMAN
coding sequence SEQ ID NO.: SEQ ID NO.: 22 1 of WO 2005/094874
Galactocerebrosidase coding sequence SEQ ID NO.: 23
Galactocerebrosidase aa sequence SEQ ID NO.: 24
[0091] With reference to these sequences the polypeptide of
interest, according to preferred embodiments of the invention,
comprises an amino acid selected from the group consisting of:
[0092] i) an amino acid sequence as defined by any of SEQ ID NOs.:
14, 15, 18, 19, 20, 21 and 24; [0093] ii) a functionally equivalent
part of an amino acid sequence as defined in i); and [0094] iii) a
functionally equivalent analogue of an amino acid sequence as
defined in i) or ii), the amino acid sequence of said analogue
being at least 75% identical to an amino acid sequence as defined
in i) or ii).
[0095] In particular embodiments the analogue in iii) is at least
80% identical to a sequence as defined in i) or ii), such as at
least 85%, at least 90%, at least 95%, at least 98%, at least 99%,
or such as at least 99.5% identical to a sequence as defined in i)
or ii).
[0096] Further, the polypeptide of interest may be obtained by
recombinant expression using a nucleic acid sequence comprising a
sequence selected from the group consisting of: [0097] i) a nucleic
acid sequence as defined by any of SEQ ID NOs.: 1-13, 16, 17, 22
and 23; [0098] ii) a nucleic acid sequence which is at least 750%
identical to a nucleic acid sequence as defined in i).
[0099] For recombinant production of the polypeptide it may further
be preferred that the acid sequence in ii) is at least 80%
identical to a sequence as defined in i), such as at least 85%, at
least 90%, at least 95%, at least 98%, at least 99%, or such as at
least 99.5% identical to a sequence as defined in i).
Composition Comprising a Polypeptide of Interest
[0100] The following description of a composition comprising a
polypeptide of interest relates both to a composition comprising a
polypeptide which is concentrated according to a method of the
present invention and it also relates to a composition of the
present invention comprising at least 10 mg/ml polypeptide of
interest.
[0101] The present invention also relates to a composition
comprising at least 10 mg/ml polypeptide of interest, wherein the
polypeptide of interest may be any polypeptide according to the
present invention, such as in particular rhPBGD, aryl sulfatase,
alpha-mannosidase or galactocerebrosidase. Said composition may in
particular comprise at least 25 mg/ml polypeptide of interest, such
as at least 50 mg/ml or at least 75 mg/ml or at least 100 mg/ml
polypeptide of interest. Thus said composition may in particular
comprise between 10-1000 mg/ml polypeptide of interest, such as
between 10-500 mg/ml or between 10-300 mg/ml or between 10-200
mg/ml or between 25-500 mg/ml or between 25-400 mg/ml or between
40-400 mg/ml or between 40-300 mg/ml or between 50-400 mg/ml or
between 50-300 mg/ml or between 75-400 mg/ml or between 75-300
mg/ml or between 100-200 mg/ml or between 100-150 mg/ml polypeptide
of interest.
[0102] The composition comprising a polypeptide of interest may in
particular be an aqueous solution.
[0103] Besides comprising a high concentration of polypeptide of
interest said composition may in particular further comprise no
aggregates of the polypeptide of interest or at least only very few
aggregates. Hence the amount of polypeptide of interest present as
aggregates may in particular constitute less than 5 w/w % of the
total amount of polypeptide of interest in the composition. In
particular said aggregates may constitute less than 4 w/w %, such
as less than 3 w/w %, or less than 2 w/w %, or less than 1 w/w %,
or less than 0.5 w/w %, or less than 0.1 w/w % of the total amount
of polypeptide of interest. In the present context the term
"aggregates" means any form of the polypeptide of interest which is
not monomeric. Thus the term encompasses any dimer or multimer of
the polypeptide of interest.
[0104] Furthermore, it is an advantage if said composition
comprises only the polypeptide of interest or at least only minor
traces of other proteins, i.e. proteins different from polypeptide
of interest. Hence in a particular embodiment said composition
comprises less than 1 w/w %, such as less than 0.5 w/w %, or less
than 0.1 w/w %, or less than 0.05 w/w %, or less than 0.01 w/w %
other proteins than the polypeptide of interest.
[0105] A range of factors affect the stability and activity of
polypeptides and the composition comprising a polypeptide of
interest may therefore in particular be optimized to keep the
polypeptide of interest as stable as possible.
[0106] The pH generally affects the stability of a polypeptide of
interest, thus the pH of a composition comprising a polypeptide of
interest may in particular be in the range of 7.5-8.5, such as in
particular between pH 7.7-8.2, more particularly between pH 7.8-8.0
or between pH 7.85-7.95, such as pH 7.8 or pH 7.9. This may in
particular be the case if the polypeptide of interest is PBGD.
[0107] Thus the composition comprising a polypeptide of interest
may in particular comprise a buffer capable of keeping the
composition within the described pH range. Examples of such buffers
include but are not limited to TRIS-HCL, Na-Citrate and
Na.sub.2HPO.sub.4. The concentration of such a buffer may depend on
the choice of the particular buffer and the presence of other
components in the composition. If the buffer is Na.sub.2HPO.sub.4
the concentration of Na.sub.2HPO.sub.4 may be in the range of
0.5-15 mM, such as in the range of 1-10 mM, or in the range of
1.5-7.5 mM, such as in the range of 1.83-7.4 mM, or in the range of
1.5-3 mM, such as in the range of 1.83-3.7 mM, or in the range of
1.83-2.45 mM, or in the range of 3.5-7.5 mM, such as in the range
of 3.6-7.4 mM, or in the range of 5.4-7.4 mM, such as 1.84 mM, or
2.45 mM, or 3.67 mM or 5.51 mM or 7.34 mM.
[0108] If the buffer is TRIS-HCL the concentration of TRIS-HCL may
in particular be in the range of 2-50 mM, such as 2-40 mM, or 2-30
mM, or 2-20 mM, or 2-10 mM, or 5-25 mM, or 5-20 mM, or 8-12 mM, or
9-11 mM, e.g. 10 mM.
[0109] Examples of other compounds which the composition comprising
a polypeptide of interest may comprise include but are not limited
to amino acids, sugars, alcohols and detergents. Examples of such
suitable compounds include but are not limited to glycine,
mannitol, sucrose, L-serine, Tween 80 or a combination of one or
more of said compounds. The concentration of these compounds depend
on the particular compound, but for glycine the concentration may
in particular be in the range of 1-200 mM, such as in the range of
5-190 mM, or in the range of 10-180 mM, or in the range of 10-170
mM, or in the range of 20-160 mM, or in the range of 20-150 mM, or
in the range of 25-125 mM, or in the range of 5-100 mM, or in the
range of 5-90 mM, or in the range of 5-80 mM, or in the range of
5-70 mM, or in the range of 5-60 mM, or in the range of 10-100 mM,
or in the range of 10-90 mM, or in the range of 10-80 mM, or in the
range of 10-70 mM, or in the range of 10-60 mM, or in the range of
12-60 mM, or in the range of 12-55 mM, or in the range of 13.5-54
mM, or in the range of 10-30 mM, such as in the range of 13.5-27
mM, or in the range of 13.5-18 mM, or in the range of 25-55 mM,
such as in the range of 27-54 mM, or in the range of 40-55, such as
in the range of 40.5-54 mM, such as 12.5, 13, 13.5, 14, 14.5, 17,
17.5, 18, 18.5, 19, 25, 26, 27, 28, 29, 30, 39.5, 40, 40.5, 41,
41.5, or 53, 53.5, 53, 54.5 or 55 mM.
[0110] The concentration of mannitol may in particular be in the
range of 50-1000 mM, such as in the range of 50-900 mM, or in the
range of 50-800 mM, or in the range of 50-700 mM, or in the range
of 50-600 mM, or in the range of 100-900 mM, or in the range of
100-800 mM, or in the range of 100-700 mM, or in the range of
100-600 mM, or in the range of 100-500 mM, or in the range of
120-525 mM, or in the range of 125-500 mM, or in the range of
100-300 mM, such as in the range of 120-275 mM, or in the range of
120-170 mM, or in the range of 200-600 mM, such as in the range of
225-550 mM, or in the range of 240-510 mM, or in the range of
370-525 mM, such as 120, 125, 130, 160, 165, 166.7, 170, 175, 200,
221, 225, 250, 275, 300, 365, 370, 375, 380, 385, 490, 495, 500,
505 or 510 mM.
[0111] The concentration of sucrose may in particular be in the
range of 1-200 mM, such as in the range of 5-190 mM, or in the
range of 10-180 mM, or in the range of 10-170 mM, or in the range
of 20-160 mM, or in the range of 20-150 mM, or in the range of
25-125 mM, or in the range of 5-100 mM, or in the range of 5-90 mM,
or in the range of 5-80 mM, or in the range of 5-70 mM, or in the
range of 5-60 mM, or in the range of 10-100 mM, or in the range of
10-90 mM, or in the range of 10-80 mM, or in the range of 10-70 mM,
or in the range of 10-60 mM, or in the range 35 of 12-60 mM, or in
the range of 12-55 mM, or in the range of 13.5-54 mM, or in the
range of 10-30 mM, such as in the range of 13.5-27 mM, or in the
range of 13.5-18 mM, or in the range of 25-55 mM, such as in the
range of 27-54 mM, or in the range of 40-55, such as in the range
of 40.5-54 mM, such as 12.5, 13, 13.5, 14, 14.5, 17, 17.5, 18,
18.5, 19, 25, 26, 27, 28, 29, 30, 39.5, 40, 40.5, 41, 41.5, or 53,
53.5, 53, 54.5 or 55 mM. If sucrose is included in a composition
which also comprises mannitol the concentration of mannitol may in
particular be lowered corresponding to the concentration of
sucrose; i.e. the concentration of mannitol and sucrose together
may in particular be the same as the concentration of mannitol if
this was to be used alone.
[0112] The concentration of Tween 80 may in particular be in the
range of 0.001-1 w/v %, such as in the range of 0.005-1 w/v %, or
in the range of 0.01-1 w/v %, or in the range of 0.001-0.5 w/v %,
or in the range of 0.005-0.5 w/v %, or in the range of 0.01-0.5 w/v
%, or in the range of 0.05-0.4 w/v %, or in the range of 0.05-0.3
w/v %, or in the range of 0.05-0.2 w/v %, or in the range of
0.075-0.4 w/v %, or in the range of 0.075-0.3 w/v %, or in the
range of 0.075-0.2 w/v %, or in the range of 0.09-0.2 w/v %, such
as 0.075, 0.08, 0.09, 0.1, 0.125, 0.15, 0.175 or 0.2 w/v %.
[0113] The composition comprising a polypeptide of interest,
wherein the polypeptide in particular may be a PBGD, an aryl
sulfatase, a lysosomal alpha-mannosidase or a galactocerebrosidase,
may in particular comprise a combination of one or more of the
above-mentioned compounds. A suitable example of such a composition
may be one which besides the polypeptide of interest comprises
Na.sub.2HPO.sub.4, glycine and mannitol. The pH of the composition
and the concentration of the different compounds may be as
described above. Hence said composition may in one embodiment
comprise 0.5-15 mM Na.sub.2HPO.sub.4, 1-200 mM glycine, 50-1000 mM
mannitol and a pH in the range of 7.5-8.5. Any combination of the
above mentioned concentrations of compounds and pH are encompassed
by the present invention. A specific example of a suitable
combination of other compounds and pH in the composition comprising
a polypeptide of interest is one which comprises 3.67 mM
Na.sub.2HPO.sub.4, 27 mM glycine, 250 mM mannitol and has a pH in
the range of 7.7 to 7.9.
[0114] Other examples of suitable compositions include, but are not
limited to any of the following: [0115] 1.84 mM Na.sub.2HPO.sub.4,
13.5 mM glycine, 125 mM mannitol and pH in the range of 7.7 to 7.9.
[0116] 2.45 mM Na.sub.2HPO.sub.4, 18 mM glycine, 167 mM mannitol
and pH in the range of 7.7 to 7.9. [0117] 5.51 mM
Na.sub.2HPO.sub.4, 40.5 mM glycine, 375 mM mannitol and pH in the
range of 7.7 to 7.9. [0118] 7.34 mM Na.sub.2HPO.sub.4, 54 mM
glycine, 500 mM mannitol and pH in the range of 7.7 to 7.9. [0119]
3.67 mM Na.sub.2HPO.sub.4, 27 mM glycine, 220 mM mannitol, 30 mM
sucrose and pH in the range of 7.7 to 7.9. [0120] 3.67 mM
Na.sub.2HPO.sub.4, 245 mM mannitol, 32 mM sucrose and pH in the
range of 7.7 to 7.9. [0121] 3.67 mM Na.sub.2HPO.sub.4, 27 mM
L-serine, 250 mM mannitol and pH in the range of 7.7 to 7.9. [0122]
10 mM TRIS-HCl, 27 mM glycine, 250 mM mannitol and pH in the range
of 7.7 to 7.9. [0123] 3.67 mM NaCitrat, 27 mM glycine, 250 mM
mannitol and pH in the range of 7.7 to 7.9. [0124] 3.67 mM
Na.sub.2HPO.sub.4, 27 mM glycine, 220 mM mannitol, 29 mM sucrose,
0.1% (w/v) Tween 80 and pH in the range of 7.7 to 7.9. [0125] 3.67
mM Na.sub.2HPO.sub.4, 27 mM glycine, 220 mM mannitol, 29 mM
sucrose, 0.1% (w/v) Tween 80 and pH in the range of 7.7 to 7.9.
[0126] The composition comprising a polypeptide of interest may in
particular be used for therapeutic applications in mammals. Thus
the composition comprising a polypeptide of interest may in
particular be isotonic with regard to the tissue of mammals, e.g.
it may in particular have an osmolality in the range of 200-400
mOsm/kg, such as in the range of 250-350 mOsm/kg or in the range of
275-325 mOsm/kg or in the range of 295-305 mOsm/kg, such as 295
mOsm/kg or 300 mOsm/kg or 305 mOsm/kg.
Method of Concentrating a Polypeptide of Interest
[0127] The method of the present invention comprises the steps of
a) centrifugation and/or filtration of a composition comprising a
polypeptide of interest and b) concentrating the composition from
step a). The inventors of the present invention have found that by
centrifugation and/or filtrating a composition comprising a
polypeptide of interest prior to concentrating said composition it
is possible to obtain a composition comprising a highly
concentrated polypeptide of interest without any or with at least
only few aggregates of the polypeptide of interest. Furthermore, it
is generally an advantage for therapeutic applications of a
polypeptide that the amount of polypeptide aggregates is reduced,
e.g. as they may increase the risk of eliciting an immune response
towards the polypeptide.
[0128] For administration of a polypeptide subcutaneously it is an
advantage that the polypeptide composition has a high activity in a
small volume as only small volumes can be injected
subcutaneously.
[0129] Proteins or polypeptides may in general form aggregates when
they are concentrated. Thus it is an advantage that when the method
of the present invention is used to concentrate a polypeptide of
interest it does not cause a high rate of polypeptide aggregate
formation. As shown in the examples the amount of PBGD aggregates
in the composition obtained by the concentration method of the
present invention is similar to that of a non-concentrated PBGD
composition.
[0130] In a particular embodiment step a) of the method is
performed prior to step b).
Step a) Centrifugation and/or Filtration
[0131] The inventors of the present invention have found that prior
to concentrating a composition comprising a polypeptide of interest
it is an advantage to pre-treat the composition by centrifugation
and/or filtration of the composition as by this pre-treatment many
or most of the polypeptide aggregates are removed.
[0132] When the concentration of the composition in step b) is
performed by a method which relies on the use of a filter or
membrane, such as ultrafiltration, the presence of aggregates may
block the filter or membrane so that small molecules and liquid are
not able to cross the filter or membrane. This may decrease the
speed by which the composition is concentrated and/or completely
block any further concentration.
[0133] Hence for this type of concentration the pre-treatment
according to step a) is an advantage as removal of the aggregates
makes it possible to obtain compositions of a polypeptide of
interest which are more concentrated than if said composition were
not been pre-treated.
[0134] When the concentration of the composition in step b) is
performed by a method which is based on the removal of water, such
as freeze-drying or evaporation, the pre-treatment in step a) has
the advantage that it reduces the amount of aggregates present in
the concentrated composition.
[0135] Step a) may be performed by one of the following three
alternatives: [0136] Centrifugation, [0137] Filtration, or [0138]
Centrifugation and filtration.
[0139] If step a) comprises both centrifugation and filtration it
is an advantage to perform the centrifugation prior to the
filtration as the inventors of the present invention have found
that the centrifugation removes most of large aggregates and the
filtration subsequently removes the remaining smaller
aggregates.
Centrifugation
[0140] To be able to remove the aggregates the composition
comprising a polypeptide of interest may be centrifuged at a force
in the range of 1500-3000 g, such as in the range of 1800-2500 g,
or in the range of 2000-2300 g.
[0141] Typically the composition may be centrifuged for 10-60
minutes, such as for 15-50 minutes or for 20-40 minutes.
[0142] As the temperature may affect the stability of the
polypeptide of interest the centrifugation may be performed at a
temperature in the range of 2-20.degree. C., such as from
3-15.degree. C. or in the range of 3-10.degree. C., or in the range
of 3-8.degree. C., such as at 4.degree. C. or 5.degree. C. or
6.degree. C.
[0143] The centrifugation results in that the polypeptide of
interest aggregates sediment, i.e. they form a pellet, while the
individual polypeptide of interest molecules stays in the solution.
So it is the supernatant of the centrifuged composition which is
subsequently used in the method of the present invention.
Filtration
[0144] The composition comprising a polypeptide of interest may be
filtered through a filter having a pore-size in the range of 0.20-5
.mu.m, such as in the range of 0.2-2.5 .mu.m.
[0145] Besides the pore-size of the filter also the material of
which the filter is made of may affect filtration of polypeptide of
interest. Examples of suitable membrane filters include but are not
limited to polyethersulfone (PES), cellulose acetate, regenerated
cellulose and polyvinylidene flouride (PVDF).
[0146] When molecules such as proteins are filtered it is usually
the small molecules which are removed thus after filtration the
polypeptide of interest may generally be present in the retentate.
Hence it is generally the retentate from the filtration which is
used in the subsequent steps of the present invention.
Step b) Concentrating
[0147] In principle any method of concentrating the polypeptide of
interest composition may be used in step b) of the present
invention.
[0148] Examples of such suitable methods include but are not
limited to ultrafiltration and concentration by removal of
water.
Ultrafiltration
[0149] Ultrafiltration is a separation method in which hydraulic
pressure is used to force molecules and solvent across a membrane
comprising pores of a particular size, also known as the cut-off
size of value. Only molecules which have a molecular weight smaller
than the cut-off value of the membrane are able to cross the
membrane while those with a larger molecular weight do not cross
the membrane and form the so called retentate. The molecules
present in the retentate are thereby concentrated as the solvent
flows across the membrane.
[0150] In a particular embodiment the concentration of the solution
or composition comprising a polypeptide of interest may be
performed by Tangential flow filtration (TFF). This method is in
particular useful for large-scale concentration, i.e. for
concentration of solutions with a volume from one litre to several
hundreds of litres. Thus this method is in particular useful for
production of concentrated solutions of a polypeptide of interests
on an industrial scale.
[0151] The TFF technique is based on the use of a particular
apparatus which causes the solution which is to be filtrated to
flow across a semi-permeable membrane; only molecules which are
smaller than the membrane pores will pass through the membrane,
forming the filtrate, leaving larger matter to be collected
(retentate). With the TFF method two different pressures are
applied; one to pump the solution into the system and to circulate
it in the system (inlet pressure), and another pressure is applied
over the membrane (membrane pressure) to force the small molecules
and the solvent across the membrane. The inlet pressure may
typically be in the range of 1-3 bar, such as between 1.5-2 bar.
The membrane pressure may typically be larger than 1 bar.
[0152] The concentrated composition of a polypeptide of interest
may be collected as the retentate when TFF is used to concentrate
the composition.
[0153] Membranes useful for TFF may typically be made of
regenerated cellulose or polyethersolufone (PES).
[0154] The pore-size of the membrane may typically have a molecular
weight cut-off which is smaller than 10.000 Mw, such as in the
range of 10-10.000 Mw.
[0155] In another embodiment the concentration of the composition
comprising a polypeptide of interest may be performed by the use of
a centrifugal device. The principle of this method is that the
solution is filtrated over a membrane by the application of a
centrifugal force over the membrane. Such membranes are often
characterized by a molecular weight (Mw) cut-off, i.e. this is the
maximum molecular size of compounds which are able to cross the
membrane and compound with a molecular size larger than this will
not cross the membrane. The Mw cut-off of the membranes used in the
present invention may in particular be smaller than 30.000 Mw, such
as between 10-30.000 Mw.
[0156] The membrane may in particular be made of polyethersulfone
(PES) or regenerated cellulose.
[0157] Examples of such suitable commercial filter devices may be
Centricon Plus-80 or Centricon Plus-15.
[0158] The concentration may typically be performed by
centrifugation at 2000-4500 g, such as between 2500-4000 g, or
between 2750-3500 g, or between 3000-3500 g, such as at 3000 g or
3100 g or 3200 g or 3300 g or 3400 g or 3500 g.
[0159] Typically the centrifugation may be run for several hours,
e.g. for more than one hour, such as for 1-10 hours.
[0160] To minimize any negative effects on the stability of the
polypeptide of interest the centrifugation may in particular be
performed at a temperature in the range of 2-20.degree. C., such as
in the range of 3-15.degree. C. or in the range of 3-10.degree. C.
or in the range of 3-6.degree. C.
Concentrating by Removal of Water
[0161] The principle of concentration by removal of water is
usually that all, or most, of the water is removed to obtain a
solid, and then subsequently diluting or dissolving this solid in a
volume of water which is less than what it was previously diluted
or dissolved in. However, it may in principle be performed by just
removing the necessary amount of water to obtain the desired
concentration without subsequently re-diluting or re-dissolving the
compound.
[0162] Examples of suitable methods of concentrating by removal of
water include freeze-drying and evaporation.
[0163] Both for freeze-drying and evaporation the three most
relevant parameters is the temperature, pressure and the time.
[0164] The method of freeze-drying may be comprise the following
three or four steps; a freezing-phase, a primary drying phase and a
secondary drying phase and optionally a step of annealing after the
freezing phase. Freeze-drying may in particular be performed as
described with regard to freeze-drying included as a further step
of the method of the present invention.
Further Steps
[0165] The polypeptide of interest may derive from a natural
source, i.e. from cells naturally expressing the polypeptide of
interest, or it may in particular be expressed recombinant.
[0166] Independent of where the polypeptide of interest derives
from it may have been purified before being subjected to a method
of the present invention.
[0167] Such "purification" may in particular include but is not
limited to removal of cell debris, removal of other proteins than
polypeptide of interest and removal of other components which may
be present in the source from which the polypeptide of interest is
derived. Thus in a particular embodiment of the present invention
the composition comprising a polypeptide of interest comprises less
than 5 w/w %, or less than 1 w/w % or less 0.5 w/w % or less than
0.1 w/w % or less than 0.05 w/w % or less than 0.01 w/w % other
proteins than the polypeptide of interest.
[0168] Thus other proteins which are expressed by e.g. a host cell
may be removed from the composition comprising a polypeptide of
interest before it is used in a method of the present
invention.
[0169] Thus in a particular embodiment the method of the present
invention may comprise one or more of following steps prior to step
a): [0170] i) recombinant expression of a polypeptide of interest
[0171] ii) purification of polypeptide of interest composition by
one or more steps of chromatography [0172] iii) exchange of the
formulation buffer
[0173] Recombinant expression of a polypeptide of interest may in
particular be performed as described previously with regard to the
polypeptide of interest.
[0174] If the polypeptide of interest is PBGD examples of suitable
types of chromatography include but are not limited to affinity
chromatography, Ion Exchange Chromatography (IEC) and
chromatography on a hydroxyapatite column. In principle any
combination of these chromatography methods may be used. The
inventors of the present invention have previously found for PBGD
that it is an advantage to perform at least the step of affinity
chromatography and if this is combined with any of the other
methods of chromatography it is an advantage to perform the step of
affinity chromatography prior to the other chromatography steps
(see e.g. WO 03/002731).
[0175] For the embodiment where the polypeptide of interest is PBGD
examples of commercially available affinity chromatography columns
include affinity coupling, group specific affinity, and metal
chelate affinity columns.
[0176] The product catalogue 2001 of the company Amersham Pharmacia
Biotech gives examples of affinity coupling columns such as columns
comprising immobilising ligands containing --NH.sub.2 and columns
comprising ligands containing primary amino groups.
[0177] Metal chelate affinity columns are specially preferred for
purifying proteins via metal ion complex formation with exposed
histidine groups. Example 3 of WO01/07065 describes construction of
a recombinant human Porphobilinogen deaminase with a "His-Tag"
(rhPBGD-His). In order to purify rhPBGD-His it is preferred to use
a metal chelate affinity column, such as a column having a cobalt
metal affinity resin.
[0178] Examples of other suitable methods of affinity
chromatography include but are not limited to columns having
porcine heparin as ligand or columns having
1-Amino-4-[[4-[[4-chloro-6-[[3 (or
4)-sulfophenyl]amino]-1,3,5-triazin-2-yl]amino]-3-sulfophenyl]amino]-9,10-
-dihydro-9,10-dioxo-2-anthracenesulfonic acid, also known as
Cibracon Blue 3G, as ligand and using Triazine coupling as the
ligand coupling method. A commercially available example of the
latter is Blue Sepharose 6 Fast Flow (FF) from Amersham Pharmacia
Biotech. Accordingly, a preferred embodiment of the invention
relates to the process, as described herein, wherein the affinity
chromatography column of step (i) is a column using a triazine
coupling as ligand coupling method, and more preferably wherein the
ligand is Cibacron Blue 3G.
[0179] The term "Ion Exchange Chromatography (IEC)" should herein
be understood according to the art as a column separating molecules
such as proteins on the basis of their net charge at a certain pH
by electrostatic binding to a charged group on the column. Ion
exchange denotes the absorption of ions of one type onto a column
in exchange for others which are lost into solution.
[0180] Examples of suitable IEC columns are columns such as a Q
Sepharose column, a Q SP Sepharose column, or a CM Sepharose
column, it may in particular be a DEAE Sepharose column.
[0181] An example of a suitable hydroxyapatite column is a ceramic
hydroxyapatite column. Hydroxyapatite
(Ca.sub.5(PO.sub.4).sub.3OH).sub.2 is a form of calcium phosphate
that can be used for the separation and purification of proteins,
enzymes, nucleic acids, viruses, and other macromolecules. Ceramic
hydroxyapatite is a spherical, macroporous form of hydroxyapatite.
CHT Type I (Bio-Rad) is an example of a suitable commercially
available ceramic hydroxyapatite chromatography column.
[0182] In one embodiment the method of the present invention may
comprise the following steps prior to step a): [0183] i)
recombinant expression of PBGD [0184] ii) subjecting the PBGD
composition from step i) to affinity chromatography [0185] iii)
subjecting the PBGD composition of step ii) to ion exchange
chromatography
[0186] In a further embodiment the method of the present invention
may comprise the following steps prior to step a): [0187] i)
recombinant expression of PBGD [0188] ii) subjecting the PBGD
composition from step i) to affinity chromatography [0189] iii)
subjecting the PBGD composition from step ii) to ion exchange
chromatography [0190] iv) subjecting the PBGD composition from step
iii) to a hydroxyapatite column
[0191] Both of these methods may optionally include a further step
of dilution of diafiltration of the PBGD composition obtained from
step ii). Thus said step should be after step ii) and before iii),
i.e. a step iia). Step iia) has the purpose of reducing the
concentration of salts to suitable conductivity, e.g. <10 mS/cm.
This may in particular be relevant if DEAE Sepharose is used as
resin in the ion exchange chromatography step, i.e. step iii), as
this may facilitate binding of the captured PBGD to the DEAE
Sepharose resin. Dilution may be obtained by addition of purified
water directly or by ultrafiltration against purified water.
[0192] The recombinant expression of PBGD, step i) may be performed
by any of the methods described above.
[0193] Examples of suitable affinity chromatography columns in step
ii) may be any of the above mentioned.
[0194] Examples of suitable methods of performing ion exchange
chromatography in step iii) may be any of the above mentioned.
[0195] Examples of suitable hydroxyapatite chromatography columns
in step iv) may be any of the above mentioned.
[0196] In a particular embodiment the affinity chromatography
column may be a column using a triazine coupling as ligand coupling
method, and in particular such a method wherein the ligand is
Cibracon Blue 3G. This may in particular be a Blue Sepharose 6 Fast
Flow column, and the ion exchange chromatography column may be DEAE
Sepharose column, and in the embodiment wherein the method also
comprises a step iv) this column may in particular be a ceramic
hydroxyapatite column.
[0197] The method of the present invention may also comprise
further steps after step b) of the method. Such steps include but
are not limited to one or more of the following: [0198]
freeze-drying the composition comprising a concentrated polypeptide
of interest, [0199] changing the buffer of the composition
comprising a concentrated polypeptide of interest, [0200] sterile
filtration of the composition comprising a concentrated polypeptide
of interest [0201] evaporation
[0202] Different freeze-driers, volume of solutions to be
freeze-dried and other parameters may be used in the method of the
present invention. An example of a suitable freeze-dryer includes
but is not limited to a Lyostar (FTM-systems) freeze-drier as used
the examples of the present invention, where the solutions
comprising a concentrated polypeptide of interest, i.e. in this
case PBGD, were filled in 2 and 6 ml injection glass vials (type 1)
and stoppered with rubber stoppers (chlorobutyl). The freeze-drying
may be performed by the following three steps; [0203] i) freezing,
[0204] ii) primary drying, and [0205] iii) secondary drying.
[0206] Step i) freezing may in particular be performed by first
loading a sample in ambient temperature and cooling it to 0.degree.
C. and keeping it at 0.degree. C. for 30 minutes, before lowering
the temperature by 1.degree. C. per minute to -40.degree. C. and
keeping it at -40.degree. C. for 30 minutes.
[0207] Step ii) primary drying may in particular be performed by
drawing the vacuum pressure 126 mTorr, raising the temperature by
1.degree. C. per minute to 0.degree. C. and keeping the sample at
0.degree. C. for 360 minutes
[0208] Step iii) secondary drying may in particular be performed by
drawing the full vacuum simultaneously with raising the temperature
by 0.5.degree. C. per minute to +30.degree. C. and keeping the
sample at +30.degree. C. for 360 minutes. After the secondary
drying the sample may further be closed under vacuum or closed
after filling with nitrogen.
[0209] An example of a suitable freeze-drying method includes the
one described in the examples of the present invention.
[0210] The freeze-drying may in further embodiment comprise an
annealing step prior to the primary drying phase. The inventors of
the present invention have found that inclusion of an annealing
step in the freeze-drying method improves the visual appearance, as
visualised by fewer cracks, and/or results in a shorter
reconstitution time of the freeze-dried product compared to when
the same method of freeze-drying is used but without the annealing
step. It is an advantage that the time for reconstitution of a
freeze-dried product is reduced, especially if it is to be used as
a pharmaceutical which is administered as a solution. An improved
visual appearance is usually also regarded as an advantage for most
products.
[0211] Thus the freeze-drying may comprise the following steps:
[0212] i) freezing [0213] ii) annealing [0214] iii) primary drying
[0215] iv) secondary drying.
[0216] The freezing, primary drying and secondary drying steps may
in particular be performed as described above. The annealing step,
i.e. step ii) may in particular be performed by after 30 minutes of
freezing, raising the temperature at e.g. a rate of 2.degree. C.
per minute to -10.degree. C. or -20.degree. C. and keeping this
temperature for 120 or 420 minutes and then lowering the
temperature e.g. a rate of 2.degree. C. per minute to -40.degree.
C. at which temperature the sample may be kept at 60-90 minutes
before start of the step of primary drying.
[0217] Changing the buffer of the composition comprising a
concentrated polypeptide of interest may in particular be performed
by a) diluting, e.g. 5-15 times, the composition comprising a
concentrated polypeptide of interest in a buffer or formulation, b)
concentrating the diluted composition again and performing the
steps a) and b) a sufficient number of times so that amount of the
excipients in the buffer or formulation present in the composition
before these steps constitute less than e.g. 5 v/v % or less than 1
v/v % of excipients in the buffer or formulation present in said
composition after said steps were performed.
[0218] In particular the composition comprising a polypeptide of
interest obtained from step b) of the present invention may in
particular further comprise a step of sterile filtration of said
composition and/or a step of freeze-drying the composition.
[0219] Sterile filtration is generally performed by filtration of
the composition through a filter with a pore-size of 0.22 .mu.m or
0.20 .mu.m. Freeze-drying may in particular be performed as
described above.
[0220] The present invention also relates to a freeze-dried
composition obtained by a method of the present invention.
Subcutaneous Injection
[0221] The present invention also relates to the use of a
composition comprising in the range of 50-300 mg/ml polypeptide of
interest for the manufacture of a medicament for subcutaneous
injection into a mammal.
[0222] The polypeptide of interest may be any polypeptide of
interest according to the present invention, including but not
limited to PBGD, aryl sulfatase A, lysosomal alpha-mannosidase and
galactocerebrosidase.
[0223] The term subcutaneous is often shortened to s.c. and the two
terms may be used interchangeably in the context of the present
invention.
[0224] When injection is performed subcutaneously it is usually not
possible to inject more than 1.5 mL due to physiologically
restraints.
[0225] As the patient usually needs a certain amount of the
particular polypeptide of interest there is a correlation between
the volume of the composition comprising a polypeptide of interest
which needs to be administered to the patient and of the
concentration of polypeptide of interest in said composition.
[0226] It is therefore an advantage of the present invention that
the composition comprising a polypeptide of interest comprises a
high concentration of the polypeptide of interest and that this
high concentration of the polypeptide of interest can be obtained
without the formation of large amounts of polypeptide aggregates.
The use of such concentrated polypeptide of interest compositions
makes it possible to inject a smaller volume of said composition
and at the same time ensure that the patient receives an adequate
amount of the polypeptide of interest; thus making it easier to
administer the polypeptide of interest subcutaneously.
[0227] The above-mentioned composition comprising a polypeptide of
interest may in particular comprise between 75-250 mg/ml, such as
between 75-200 mg/ml or between 75-150 mg/ml or between 100-150
mg/ml or between 100-125 mg/ml or between 125-150 mg/ml of
polypeptide of interest.
[0228] As described above the volume of composition comprising a
polypeptide of interest which it is necessary to inject into the
patient to ensure that the patient receives an adequate amount of
the polypeptide of interest correlates with the concentration of
the polypeptide of interest in said composition.
[0229] Thus the volume of such a composition will generally be
adjusted according to the concentration of the polypeptide of
interest in the composition. However, the volume may generally be
in the range of 0.1-1.5 ml, such as in the range of 0.1-1.5 ml or
in the range of 0.5-1.5 ml or in the range of 0.5-1.5 ml or in the
range of 0.75-1.5 ml or in the range of 0.75-1.5 ml or in the range
of 1-1.5 ml or in the range of 1-1.5 ml.
[0230] The amount of polypeptide of interest which it is relevant
to administer to a patient generally depends on the weight of the
individual and the particular polypeptide of interest.
[0231] In one embodiment the present invention relates to a method
of treating a mammal for Acute Intermittent Porphyria comprising
subcutaneous injection of a composition of 50-300 mg/ml PBGD.
[0232] Administration of PBGD may in particular be useful for the
treatment of Acute Intermittent Porphyria. However, it is
contemplated that administration of PBGD also may be useful for the
treatment of other porphyrias, such as Hereditary coproporphyria or
Variegata porphyria. Porphyria is a term used to collectively
describe a number of diseases caused by different deficiencies in
the heme biosynthetic pathway. Hence it is contemplated that
administration of PBGD, e.g. in combination with other
therapeutics, to a patient suffering from any type of porphyria may
help to increase the overall turnover of the different
intermediates in the pathway. For example Meissner P N et al.,
1986, European Journal of Clinical Investigation, vol. 16, 257-261;
Hift R J et al., 1997, S. Afr. Med. J., vol. 87, 718-27 and
Meissner P et al., 1993, J. Clin. Invest., vol. 91, 1436-44
describe accumulation of ALA and PBG in Hereditary coproporhyria
and Variegata porphyria. In theses diseases the accumulation of ALA
and PBG results from enzymatic defects that are located four and
five steps downstream form the conversion of ALA to PBG,
respectively. In the two most recent papers it is described how the
porphyrinogen which accumulates in patients with Variegata
porphyria is capable of inhibiting PBG-deaminase.
[0233] In a further embodiment the present invention relates to a
method of treating a mammal for metachromatic leukodystrophy
comprising subcutaneous injection of a composition of 50-300 mg/ml
aryl sulfatase A.
[0234] Metachromatic leukodystrophy (MLD) is caused by an autosomal
recessive genetic defect in the lysosomal enzyme Arylsulfatase A
(ASA), resulting in a progressive breakdown of membranes of the
myelin sheath (demyelination) and accumulation of galactosyl
sulphatide (cerebroside sulphate) in the white matter of both the
central nervous system (CNS) and the peripheral nervous system. In
histologic preparations, galactosyl sulphatide forms spherical
granular masses that stain metachromatically. Galactosyl sulphatide
also accumulates within the kidney, gallbladder, and certain other
visceral organs and is excreted in excessive amounts in the
urine.
[0235] Galactosyl sulfatide is normally metabolised by the
hydrolysis of 3-O-sulphate linkage to form galactocerebroside
through the combined action of the lysosomal enzyme arylsulfatase A
(EC 3.1.6.8) (Austin et al. Biochem J. 1964, 93, 15C-17C) and a
sphingolipid activator protein called saposin B. A profound
deficiency of arylsulfatase A occurs in all tissues from patients
with the late infantile, juvenile, and adult forms of MLD (see
below). In the following, the arylsulfatase A protein will be
termed "ASA". A profound deficiency of ASA occurs in all tissues
from patients with MLD.
[0236] In yet another embodiment the present invention relates to a
method of treating a mammal for the lysosomal storage disorder
alpha-mannosidosis comprising subcutaneous injection of a
composition of 50-300 mg/ml lysosomal alpha-mannosidase.
[0237] Alpha-mannosidosis is a recessive, autosomal disease that
occurs world wide with a frequency of between 1/1.000.000 and
1/500.000. Mannosidosis is found in all ethnic groups in Europe,
America, Africa and also Asia. It is detected in all countries with
a good diagnostic service for lysosomal storage disorders, at a
similar frequency. They are born apparently healthy; however the
symptoms of the diseases are progressive. Alpha-mannosidosis
displays clinical heterogeneity, ranging from very serious to very
mild forms. Typical clinical symptoms are: mental retardation,
skeletal changes, impaired immune system resulting in recurrent
infections, hearing impairment and often the disease is associated
with a typical facial characteristics such as a coarse face, a
prominent forehead, a flattened nasal bridge, a small nose, and a
broad mouth. In the most severe cases (mannosidosis type I) the
children suffer from hepatosplenomegaly, and they die during the
first years of life. Possibly this early death is caused by severe
infections due to the immunodeficiency caused by the disease. In
milder cases (mannosidosis type 2) the patients usually reach adult
age. The skeletal weaknesses of the patients result in the needs of
wheeling chairs at age 20 to 40. The disease causes a diffuse
dysfunction of the brain often resulting in weak mental
performances that excludes anything but the most basic skills of
simple reading and writing. These problems associated with hearing
inabilities and other clinical manifestations preclude the patient
from an independent life, the consequence being that life long
caretaking is needed.
[0238] In yet another embodiment the present invention relates to a
method of treating a mammal for Krabbe disease comprising
subcutaneous injection of a composition of 50-300 mg/ml
galactosylcerebrosidase.
[0239] In humans a deficiency in the GALC enzyme results in an
autosomal inherited genetic Lysosomal Storage disease known as
Krabbe disease or Globoid Cell Leukodystrophy. The enzyme is
generally expressed in the testis, kidneys, placenta, liver and
brain of human beings and a deficiency in the GALC enzyme generally
results in a disorder in the myelin metabolism and in the central
and peripheral nervous systems (the CNS and PNS, respectively).
[0240] Krabbe disease has been observed in humans of any age,
nationality and sex.
[0241] It should be noted that embodiments and features described
in the context of one of the aspects of the present invention also
apply to the other aspects of the invention. In particular, all of
the embodiments described for the composition comprising a
polypeptide of interest, such as the presence of further compounds,
buffers and pH also apply to the composition comprising a
polypeptide of interest used in the present applications.
[0242] When an object according to the present invention or one of
its features or characteristics is referred to in singular this
also refers to the object or its features or characteristics in
plural. As an example, when referring to "a polypeptide" it is to
be understood as referring to one or more polypeptides.
[0243] Throughout the present specification the word "comprise", or
variations such as "comprises" or "comprising", will be understood
to imply the inclusion of a stated element, integer or step, or
group of elements, integers or steps, but not the exclusion of any
other element, integer or step, or group of elements, integers or
steps.
[0244] All patent and non-patent references cited in the present
application, are hereby incorporated by reference in their
entirety.
[0245] The invention will now be described in further details in
the following non-limiting Experimental sections.
EXPERIMENTAL
Materials
[0246] rhPBGD
[0247] The rhPBGD used in the following experiments were obtained
according to process 2 in example 1 of WO 03/002731, where process
2 is the process which includes step 1V, i.e. the ceramic
hydroxyapatite chromatography step.
Formulation Buffer
[0248] The recombinant and purified rhPBGD was present in the
following aqueous formulation buffer:
3.67 mM Na.sub.2HPO.sub.4
27 mM Glycine
250 mM Mannitol
[0249] and a pH of 7.9
[0250] The formulation buffer was then sterile-filtered trough a
0.22 .mu.m filter.
Methods
Freeze-Drying
[0251] The freeze-drying of the purified rhPBGD solutions were
performed in a Lyostar (FTM-systems) freeze-drier according to the
following schedule:
TABLE-US-00002 Freezing phase 0.degree. C. 30 min 760 Torr
0.degree. C. to -40.degree. C. 1.degree. C./min 760 Torr
-40.degree. C. 30 min 760 Torr Primary drying -40.degree. C. to
0.degree. C. 1.degree. C./min 169 mTorr 0.degree. C. 240 min 169
mTorr Secondary drying 0.degree. C. to 30.degree. C. 10.degree.
C./60 min, 20 mTorr 180 min 30.degree. C. 720 min 20 mTorr
Visual Observation (Clarity and Colour)
[0252] The liquid was visually studied with respect to colour,
clarity and precipitates according to the scheme below.
Colour: 1: No colour; 2: Slightly yellow; 3: Yellow Clarity: 1:
Clear; 2: Slightly turbid; 3: Turbid
[0253] Other remarks: Other observations from the operator were in
some instances included here (e.g. precipitates, undissolved
material etc)
pH-Measurement
[0254] The pH-meter (Metrohm 691 pH Meter) and electrode (combined
LL pH electrode) were calibrated with 3 standard reference
solutions (Merck) in the range 4.00 to 9.00. The liquid was finally
analysed.
Protein Concentration
[0255] Protein concentration in extract, in-process samples, bulk
drug substance and final product was determined by a method that
utilizes principles of the reduction of Cu2+ to Cu+ by protein in
an alkaline medium (the Biuret reaction). The Cu+ ions were then
reacted with a reagent containing bicinchoninic acid resulting in a
highly sensitive and selective colorimetric detection.
Purity
[0256] Recombinant human Porphobilinogen Deaminase (rhPBGD) and
rhPBGD variants were separated according to their ability to adsorb
and desorb to silica based stationary media depending on the
percentage of organic modifier (acetonitrile) in the mobile
phase.
rhPBGD Activity
[0257] Porphobilinogen deaminase (PBGD) catalyzes the addition of 4
molecules of porphobilinogen (PBG) to form a linear tetramer,
preuroporphyrinogen, which is released from the enzyme and in vivo
circularized to uroporphyrinogen III by the action of
Uroporphyrinogen III synthase. Preuroporphyrinogen can be
chemically oxidized with benzoquinone to form uroporphyrin, which
absorbs light at 405 nm.
[0258] The analyses were performed on one single vial on each test
occasion. For the determination of rhPBGD activity and protein
concentration the tests were performed in duplicate and triplicate
respectively, for each vial.
Osmolality
[0259] One vial of freeze-dried rhPBGD was resuspended in 1.00 ml
MilliQ-water. The vial of frozen aqueous solution of rhPBGD was
thawed. The osmometer (Vapro osmometer) was calibrated with 3
standard solutions in the range 100-1000 mOsm/kg (100, 290, 1000
mOsm/kg). The liquid was then analyzed.
Example 1
Concentrating with Centrifugal Filter Devices
[0260] Frozen PBGD-bulk solution (7 mg/mL rhPBGD, 3.67 mM
Na.sub.2HPO.sub.4, 27 mM glycine, 250 mM Mannitol, pH 7.9) was
thawed in a water-bath at 20.degree. C., centrifuged at 3200 g for
10 min and thereafter sterile-filtrated by 0.20 .mu.m-PES filters
(Nalgene Polyethersulfone filters). The PBGD-bulk solution was
concentrated to 100 mg/ml by running the Centrifugal Filter Devices
Centricon Plus-80 (Mw cut-off 30000) and Centricon Plus-15 (Mw
cut-off 30000) at 3200 g for several hours. The concentrated
solution, i.e. the retentate, was sterile-filtrated by 0.22
.mu.m-filters (Millex GV) and finally a part of this solution was
diluted with sterile formulation buffer to get 50 mg/ml. The 5
mg/ml-solution was prepared by directly diluting the recombinant
and purified hPBGD with sterile formulation buffer.
[0261] The 5 mg/mL, 50 mg/mL and 100 mg/mL rhPBGD were then
freeze-dried as described above. Several vials of each the
above-mentioned freeze-dried rhPBGD solutions with 5, 50 and 100
mg/mL rhPBGD and of the aqueous 5 mg/mL rhPBGD solution were stored
at 40.degree. C..+-.2.degree. C., 75%.+-.5% relative humidity (RH).
The vials were stored protected from light in a well sealed
secondary package (paper box).
[0262] At the indicated time points (i.e. time of storage) a vial
of each freeze-dried samples were resuspended in 1.00 mL Millipore
water.
[0263] Each of the resuspended vials and the aqueous vial of rhPBGd
were then visually observed with regard to colour, clarity and
precipitates, and the pH, protein concentration, purity and rhPBGD
activity were measured as described above.
[0264] The results are given in the following tables 1-4:
TABLE-US-00003 TABLE 1 Freeze-dried product, 5 mg/mL Specific
Time-point Activity Concentration activity Purity Visual (month)
(U/ml) (mg/ML) (U/mg) (%) observation 0 93.2 4.3 21.5 99.6 Colour:
1, clarity: 1 0.5 81.0 5.2 15.6 ND Colour: 1, clarity: 1 1 76.6 5.9
13.1 99.9 Colour: 1, clarity: 1 1.5 87.0 5.5 15.9 99.7 Colour: 1,
clarity: 1 2 53.3 4.7 11.4 99.6 Colour: 1, clarity: 1 3 50.8 4.8
10.7 99.6 Colour: 1, clarity: 1 6 34.3 5.3 6.5 99.6 Colour: 1,
clarity: 1
TABLE-US-00004 TABLE 2 freeze-dried product; 50 mg/ml Specific
Time-point Activity Concentration activity Purity Visual (month)
(U/ml) (mg/ML) (U/mg) (%) observation 0 888 41.4 21.5 99.1 Colour:
2, clarity: 1 0.5 842 50.6 16.6 ND Colour: 2, clarity: 1 1 746 50.6
14.8 100 Colour: 2, clarity: 1 2 640 52.9 12.1 100 Colour: 2,
clarity: 1 3 634 49.0 12.9 100 Colour: 2, clarity: 1 6 422 43.0 9.8
100 Colour: 2, clarity: 1
TABLE-US-00005 TABLE 3 Freeze-dried product; 100 mg/ml Specific
Time-point Activity Concentration activity Purity Visual (month)
(U/ml) (mg/ML) (U/mg) (%) observation 0 1944 83.7 23.2 99.1 Colour:
3, clarity: 1 1 1470 98.7 14.9 100 Colour: 3, clarity: 1 2 1282
94.8 13.5 100 Colour: 3, clarity: 1 3 1253 82.6 15.2 100 Colour: 3,
clarity: 1 6 739 75.5 9.8 100 Colour: 3, clarity: 1
TABLE-US-00006 TABLE 4 Aqueous product; 5 mg/ml Specific Time-point
Activity Concentration activity Purity Visual (month) (U/ml)
(mg/ML) (U/mg) (%) observation 0 95.6 4.0 23.7 99.1 Colour: 1,
clarity: 1 0.5 48.1 5.4 8.9 ND Colour: 1, clarity: 1 1 28.6 5.9 4.8
96.1 Colour: 1, clarity: 1 1.5 12.3 5.6 2.2 91.4 Colour: 1,
clarity: 1 2 4.5 4.4 1.0 90.7 Colour: 1, clarity: 1 3 7.1 3.1 2.3
87.3 Colour: 2, clarity: 2 6 4.4 2.1 2.1 58.1 Colour: 2, clarity:
2
Example 2
Concentrating a rhPBGD Composition by Centrifugal Filter
Devices
[0265] Frozen PBGD-bulk solution (7 mg/mL rhPBGD, 3.67 mM
Na.sub.2HPO.sub.4, 27 mM glycine, 250 mM Mannitol, pH 7.9) was
thawed in a water-bath at 20.degree. C., centrifuged at 3200 g for
10 min and thereafter sterile-filtrated by 0.20 .mu.m-PES filters
(Nalgene Polyethersulfone filters). The PBGD-bulk solution was
concentrated to 100 mg/ml by running the Centrifugal Filter Devices
Centricon Plus-80 (Mw cut-off 30000) and Centricon Plus-15 (Mw
cut-off 30000) at 3200 g for several hours. The concentrated
solution, i.e. the retentate, was sterile-filtered by 0.22
.mu.m-filters (Millex GV) and diluted with sterile filtered
formulation buffer (see above) to get solutions of lower
concentrations. A fraction in volume of each concentration was
freeze-dried as described above.
[0266] The different concentrations of freeze-dried rhPBGD and
aqueous solution of rhPBGD were stored at 5.degree. C..+-.3.degree.
C. or at -20.degree. C..+-.5.degree. C. (ambient relative humidity
(RH)). All vials were stored protected from light in a well-sealed
secondary package (paper box).
[0267] At the indicated time points (i.e. time of storage) a vial
of each freeze-dried samples were resuspended in 1.00 mL Millipore
water and then tested together with the aqueous solution of rhPBGD
by visually observing the colour, clarity and precipitates, and by
measuring pH, protein concentration, purity, osmolality and rhPBGD
activity.
[0268] The results are given in the following tables 5-19:
TABLE-US-00007 TABLE 5 Aqueous product; 11 mg/ml; Storage temp.:
+5.degree. C. Visual observation Colour 1-3 Protein Specific
Clarity 1-3 Time-point conc. Activity activity Osmolality Solution
(month) (mg/ml) (U/ml) (U/mg) Purity (%) PH (mOsm/kg) Aggregates 0
10.9 255.0 23.4 100.0 7.80 290 Colour: 2 Clarity: 1 Clear None/few
1 9.5 216.8 22.8 100.0 7.81 305 Colour: 2 Clarity: 1 Clear None/few
2 10.9 230.2 21.1 98.0 7.80 300 Colour: 2 Clarity: 1 Clear None/few
3 11.2 226.6 20.2 100.0 7.76 290 Colour: 2 Clarity: 1 Clear Few 6
14.7 271.1 18.4 100.0 7.77 300 Colour: 2 Clarity: 1 Clear
Several
TABLE-US-00008 TABLE 6 Aqueous product: 11 mg/ml; Storage temp:
-20.degree. C. Visual observation Colour 1-3 Protein Specific
Clarity 1-3 Time-point conc. Activity activity Purity Osmolality
Solution (month) (mg/ml) (U/ml) (U/mg) (%) PH (mOsm/kg) Aggregates
0 10.4 236.1 22.6 100 7.80 290 Colour: 2 Clarity: 1 Clear None 1
11.7 270.3 23.1 100 7.81 302 Colour: 2 Clarity: 1 Clear None 2 ND
ND ND ND ND ND ND 3 12.4 247.7 20.0 100 7.77 288 Colour: 2 Clarity:
1 Clear None 6 13.4 291.5 21.8 100 7.77 301 Colour: 2 Clarity: 1
Clear None
TABLE-US-00009 TABLE 7 Freeze-dried product, 11 mg/ml; Storage
temp.: +5.degree. C. Visual observation Colour 1-3; Time- Protein
Specific Clarity 1-3; point conc. Activity activity Purity
Osmolality Solution; (month) (mg/ml) (U/ml) (U/mg) (%) pH (mOsm/kg)
Aggregates 0 10.9 230.0 21.2 100.0 7.80 290 Colour: 2 Clarity: 1
Clear None 1 ND ND ND ND ND ND ND 2 ND ND ND ND ND ND ND 3 13.3
269.3 20.2 100.0 7.74 282 Colour: 2 Clarity: 1 Clear None 6 14.7
237.9 16.2 100.0 7.76 290 Colour: 2 Clarity: 1 Clear None
TABLE-US-00010 TABLE 8 Aqueous product, 17 mg/ml; Storage temp.:
+5.degree. C. Visual observation Colour 1-3 Time- Protein Specific
Clarity 1-3 point conc. Activity activity Purity Osmolality
Solution (month) (mg/ml) (U/ml) (U/mg) (%) pH (mOsm/kg) Aggregates
0 18.0 471.0 26.1 100.0 7.80 298 Colour: 2 Clarity: 1 Clear
None/few 1 17.5 360.4 20.6 100.0 7.81 311 Colour: 2 Clarity: 1
Clear None/few 2 18.3 397.0 21.7 100.0 7.83 302 Colour: 2 Clarity:
1 Clear None/few 3 16.6 376.5 22.7 100.0 7.77 294 Colour: 2
Clarity: 1 Clear Few 6 16.0 257.3 16.1 100.0 7.76 305 Colour: 2
Clarity: 1 Clear Several
TABLE-US-00011 TABLE 9 Aqueous product, 17 mg/ml; Storage temp.:
-20.degree. C. Visual observation Colour 1-3 Time- Protein Specific
Clarity 1-3 point conc. Activity activity Purity Osmolality
Solution (month) (mg/ml) (U/ml) (U/mg) (%) PH (mOsm/kg) Aggregates
0 17.9 411.6 23.0 100.0 7.80 298 Colour: 2 Clarity: 1 Clear None 1
17.4 439.5 25.3 100.0 7.80 310 Colour: 2 Clarity: 1 Clear None 2 ND
ND ND ND ND ND ND 3 16.4 389.4 23.7 100.0 7.77 292 Colour: 2
Clarity: 1 Clear None 6 18.0 373.8 20.8 100.0 7.76 305 Colour: 2
Clarity: 1 Clear None
TABLE-US-00012 TABLE 10 Freeze-dried product, 17 mg/ml; Storage
temp.: 5.degree. C. Visual observation Colour 1-3 Time- Protein
Specific Clarity 1-3 point conc. Activity activity Purity
Osmolality Solution (month) (mg/ml) (U/ml) (U/mg) (%) PH (mOsm/kg)
Aggregates 0 16.9 380.1 22.5 100.0 7.80 298 Colour: 2 Clarity: 1
Clear None 1 ND ND ND ND ND ND ND 2 ND ND ND ND ND ND ND 3 15.6
391.9 25.1 100.0 7.76 285 Colour: 2 Clarity: 1 Clear None 6 16.6
341.3 20.6 100.0 7.75 297 Colour: 2 Clarity: 1 Clear None
TABLE-US-00013 TABLE 11 Aqueous product; 36 mg/ml; Storage temp.:
+5.degree. C. Visual observation Colour 1-3 Time- Protein Specific
Clarity 1-3 point conc. Activity activity Purity Osmolality
Solution (month) (mg/ml) (U/ml) (U/mg) (%) pH (mOsm/kg) Aggregates
0 36.0 844.4 23.4 100.0 7.81 305 Colour: 2 Clarity: 1 Clear
None/few 1 35.5 778.1 21.9 100.0 7.82 314 Colour: 2 Clarity: 1
Clear None/few 2 35.4 798.5 22.6 100.0 7.81 310 Colour: 2 Clarity:
1 Clear None/few 3 28.9 687.9 23.8 100.0 7.77 303 Colour: 2
Clarity: 1 Clear Few 6 37.2 537.3 14.4 100.0 7.77 312 Colour: 2
Clarity: 1 Clear Several
TABLE-US-00014 TABLE 12 Aqueous product, 36 mg/ml; Storage temp.:
-20.degree. C. Visual observation Colour 1-3 Time- Protein Specific
Clarity 1-3 point conc. Activity activity Purity Osmolality
Solution (month) (mg/ml) (U/ml) (U/mg) (%) pH (mOsm/kg) Aggregates
0 34.0 853.4 25.1 100.0 7.81 305 Colour: 2 Clarity: 1 Clear None 1
38.0 853.6 22.5 100.0 7.83 321 Colour: 2 Clarity: 1 Clear None 2 ND
ND ND ND ND ND ND 3 31.6 776.3 24.6 100.0 7.76 299 Colour: 2
Clarity: 1 Clear None 6 30.6 543.8 17.8 100.0 7.75 311 Colour: 2
Clarity: 1 Clear None
TABLE-US-00015 TABLE 13 Freeze-dried product, 36 mg/ml; Storage
temp.: 5.degree. C. Visual observation Colour 1-3 Time- Protein
Specific Clarity 1-3 point conc. Activity activity Purity
Osmolality Solution (month) (mg/ml) (U/ml) (U/mg) (%) pH (mOsm/kg)
Aggregates 0 29.5 657.0 22.3 100.0 7.81 305 Colour: 2 Clarity: 1
Clear None 1 ND ND ND ND ND ND ND 2 ND ND ND ND ND ND ND 3 28.7
747.6 26.0 100.0 7.75 290 Colour: 2 Clarity: 1 Clear None 6 29.8
579.3 19.4 100.0 7.76 300 Colour: 2 Clarity: 1 Clear None
TABLE-US-00016 TABLE 14 Aqueous product, 50 mg/ml; Storage temp.:
5.degree. C. Visual observation Colour 1-3 Time- Protein Specific
Clarity 1-3 point conc. Activity activity Purity Osmolality
Solution (month) (mg/ml) (U/ml) (U/mg) (%) pH (mOsm/kg) Aggregates
0 46.2 780.9 16.9 96.3 7.59 317 Colour: 3 Clarity: 1 Slightly
opalescent None 1 47.9 915 19.1 90 7.58 305 Colour: 3 Clarity: 1
Slightly opalescent None 2 47.2 898.3 19.0 100 7.60 318 Colour: 3
Clarity: 1 Slightly opalescent None 3 60.8 1102.6 18.1 100 7.72 314
Colour: 3 Clarity: 1 Clear None 6 62.5 902.8 14.4 100 7.60 331
Colour: 3 Clarity: 2 Clear None 9 41.7 618.5 14.8 100 7.60 336
Colour: 3 Clarity: 2 Clear None 12 50.2 540.8 10.8 97.5 7.60 329
Colour: 3 Clarity: 2 Clear None
TABLE-US-00017 TABLE 15 Aqueous product, 50 mg/ml; Storage temp.:
-20.degree. C. Visual observation Colour 1-3 Time- Protein Specific
Clarity 1-3 point conc. Activity activity Purity Osmolality
Solution (month) (mg/ml) (U/ml) (U/mg) (%) PH (mOsm/kg) Aggregates
0 46.2 780.9 16.9 96.3 7.59 317 Colour: 3 Clarity: 1 Slightly
opalescent None 1 47.2 899.1 19.0 93.7 7.58 313 Colour: 3 Clarity:
1 Slightly opalescent None 2 53 1222.7 23.1 100.0 7.60 315 Colour:
3 Clarity: 1 Slightly opalescent None 3 61.2 1336.2 21.8 100.0 7.75
320 Colour: 3 Clarity: 1 Slightly opalescent None 6 52.2 1001.3
19.2 100.0 7.60 321 Colour: 3 Clarity: 1 Slightly opalescent None
12 50.4 887.9 17.6 100.0 7.60 320 Colour: 3 Clarity: 1 Slightly
opalescent None
TABLE-US-00018 TABLE 16 Freeze-dried product, 50 mg/ml; Storage
temp.: 5.degree. C. Visual observation Colour 1-3 Time- Protein
Specific Clarity 1-3 point conc. Activity activity Purity
Osmolality Cake/solution (month) (mg/ml) (U/ml) (U/mg) (%) pH
(mOsm/kg) Aggregates 0 42.7 759.4 17.8 100.0 7.58 292 Colour: 3
Clarity: 1 Cake: yellow, some cracks Solution: Clear None 1 42.6
840.4 19.7 63.1 7.58 293 Colour: 3 Clarity: 1 Cake: yellow, some
cracks Solution: Clear None 2 42.1 937.0 22.3 100.0 7.60 292
Colour: 3 Clarity: 1 Cake: yellow, some cracks Solution: Clear None
3 47.4 1014.7 21.4 100.0 7.75 291 Colour: 3 Clarity: 1 Cake:
yellow, some cracks Solution: Clear None 6 49.0 876.5 17.9 100.0
7.60 304 Colour: 3 Clarity: 1 Cake: yellow, some cracks Solution:
Clear None 12 51.3 945.0 18.4 100.0 7.60 308 Colour: 3 Clarity: 1
Cake: yellow, some cracks Solution: Clear None
TABLE-US-00019 TABLE 17 Aqueous product, 100 mg/ml; Storage temp.:
5.degree. C. Visual observation Colour 1-3 Time- Protein Specific
Clarity 1-3 point conc. Activity activity Purity Osmolality
Solution (month) (mg/ml) (U/ml) (U/mg) (%) PH (mOsm/kg) Aggregates
0 81.8 1705.7 20.9 99.9 7.60 350 Colour: 3 Clarity: 1 Slightly
opalescent None 1 85.9 1942.4 22.6 96.9 7.55 352 Colour: 3 Clarity:
1 Slightly opalescent None 2 95.7 1690.8 17.7 96.9 7.65 357 Colour:
3 Clarity: 1 Slightly opalescent None 3 104.3 1671.2 16.0 100.0
7.65 350 Colour: 3 Clarity: 1 Slightly opalescent None 6 96.0
1642.6 17.1 100.0 7.62 360 Colour: 3 Clarity: 1 Slightly opalescent
None 9 102.8 1270.8 12.4 100.0 7.63 352 Colour: 3 Clarity: 2
Slightly opalescent None 11 86.2 1140.2 13.2 100.0 7.60 353 Colour:
3 Clarity: 2 Slightly opalescent None 12 113.9 1550.6 13.6 100.0
7.58 350 Colour: 3 Clarity: 2 Slightly opalescent None 15 114.7
1160.6 10.1 98.3 7.61 350 Colour: 3 Clarity: 2 Slightly opalescent
None 18 86.2 907.4 10.5 100.0 7.67 340 Colour: 3 Clarity: 2
Slightly opalescent None
TABLE-US-00020 TABLE 18 Aqueous product, 100 mg/ml; Storage temp.:
-20.degree. C. Visual observation Colour 1-3 Time- Protein Specific
Clarity 1-3 point conc. Activity activity Purity Osmolality
Solution (month) (mg/ml) (U/ml) (U/mg) (%) pH (mOsm/kg) Aggregates
0 81.8 1705.7 20.9 99.9 7.60 316 Colour: 3 Clarity: 1 Slightly
opalescent None 1 89.3 2108.8 23.6 100.0 7.56 350 Colour: 3
Clarity: 1 Slightly opalescent None 2 112.0 2066.5 18.5 100.0 7.65
353 Colour: 3 Clarity: 1 Slightly opalescent None 3 100.2 2172.4
21.7 96.7 7.65 352 Colour: 3 Clarity: 1 Clear None 6 87.5 2672.3
30.6 100.0 7.62 352 Colour: 3 Clarity: 1 Clear None 9 97.1 2040.3
21.0 100.0 7.62 353 Colour: 3 Clarity: 1 Clear None 11 104.6 2234.0
21.4 100.0 7.60 353 Colour: 3 Clarity: 1 Clear None 12 94.5 1608.8
17.0 100.0 7.57 350 Colour: 3 Clarity: 1 Slightly opalescent None
15 118.0 2015.9 17.1 100.0 7.62 351 Colour: 3 Clarity: 1 Slightly
opalescent None 18 90.6 1736.4 19.2 100.0 7.69 338 Colour: 3
Clarity: 1 Slightly opalescent None
TABLE-US-00021 TABLE 19 Freeze-dried product, 100 mg/ml; Storage
temp.: 5.degree. C. Visual observation Colour 1-3 Time- Protein
Specific Clarity 1-3 point conc. Activity activity Purity
Osmolality Cake/solution (month) (mg/ml) (U/ml) (U/mg) (%) pH
(mOsm/kg) Aggregates 0 76.0 1638.3 21.5 100.0 7.60 316 Colour: 3
Clarity: 1 Cake: Yellow, some cracks Solution: Clear None 1 71.6
1747.6 24.4 100.0 7.55 318 Colour: 3 Clarity: 1 Cake: Yellow, some
cracks Solution: Clear None 2 81.6 1769.9 21.7 100.0 7.63 313
Colour: 3 Clarity: 1 Cake: Yellow, some cracks Solution: Clear None
3 84.1 1616.6 19.2 98.2 7.65 320 Colour: 3 Clarity: 1 Cake: Yellow,
some cracks Solution: Clear None 6 96.7 2197.6 22.7 100.0 7.60 324
Colour: 3 Clarity: 1 Cake: Yellow, some cracks Solution: Clear None
9 ND ND ND ND ND ND ND 12 96.0 1978.4 20.6 100.0 7.57 322 Colour: 3
Clarity: 1 Cake: Yellow, some cracks Solution: Clear None 15 ND ND
ND ND ND ND ND 18 80.6 1602.6 19.9 100.0 7.75 310 Colour: 3
Clarity: 1 Cake: Yellow, some cracks Solution: Clear None
Example 3
[0269] Concentrating a rhPBGD composition by tangential flow
filtration (TFF)
[0270] The bulk solution of rhPBGD was then thawed for a minimum of
three days at 5.degree. C. and in darkness.
[0271] The thawed solution was then centrifuged with 200 mL conical
centrifuge tubes for approximately 10 minutes at 2200 g.
[0272] The solution was then filtered through a series of filters
with the following pore-sizes: 5.0 .mu.m; 0.65 .mu.m; 0.45 .mu.m
and 0.20 .mu.m before it was concentrated by tangential flow
filtration (TFF).
[0273] The concentration by TFF was performed with a Millipore
Labscale TFF System and Millipore Pellicon.RTM. XL Filter with a
pump inlet pressure of approximately 20-25 psi and a pressure over
the Pellicon.RTM. XL Filter of approximately 4-6 psi. The rhPBGD
was protected from light during the procedure by covering the
sample container of the TFF System by sheets of aluminium foil.
[0274] The concentrated rhPBGD solution obtained from the TFF
procedure was then buffer-changed against a formulation buffer
containing 3.67 mM Na.sub.2HPO.sub.4.times.2H.sub.2O, 27 mM glycin
and 220 mM Mannitol prepared in sterile water. This was performed
by continuously adding said buffer to the TFF-system and pressing
it across the membrane until said buffer has replaced the previous
buffer.
[0275] The concentrated and buffer-changed rhPBGD solution was then
sterile filtered by passing it through a filter with a pore-size of
0.22 .mu.m. This sterile filtration was performed twice with a new
filter each time.
[0276] The sterile concentrated rhPBGD solution was then placed in
vials before it was freeze-dried as described in the method
section.
Example 4
The Effect of Different Modes of Freeze-Drying and/or the Amount of
Excipients on the Reconstitution Time
[0277] PBGD was concentrated as described in example 3 and after
the exchange of the buffer was the concentration of PBGD
determined.
[0278] The concentrated PBGD solution was then freeze-dried in a
Lyostar (FTM-systems) freeze-dryer. The solutions were filled in 2
and 6 ml injection glass vials (type 1) and stoppered with rubber
stoppers (chlorobutyl).
Original Freeze-Drying Cycle:
[0279] The samples were loaded in ambient temperature and the
shelves were cooled down to 0.degree. C. for 30 minutes. The
temperature were lowered to -40.degree. C. (1.degree. C. per
minute) and held there for 30 minutes and then the vacuum pressure
was drawn to 126 mTorr and the primary drying began by raising the
temperature to 0.degree. C. (1.degree. C. per minute). After 360
minutes of primary drying the temperature was raised to +30.degree.
C. (0.5.degree. C. per minute) and full vacuum was drawn
simultaneously (start of secondary drying). The temperature was
held at +30.degree. C. for 360 minutes and the vials were then
stoppered under vacuum.
Freeze-Drying with Inclusion of an Annealing Step:
[0280] After 30 minutes at -40.degree. C. the temperature was
raised with a rate of 2.degree. C. per minute to -10.degree. C. or
-20.degree. C. at which temperature they were kept for 120 or 420
minutes before the temperature was lowered again with 2.degree. C.
per minute to -40.degree. C. were the samples were kept for 60-90
minutes before start of primary drying.
[0281] The results are shown in Table 20 where the short terms used
with regard to the excipients and the freeze-drying cycle mean the
following:
[0282] 1.times. amount of excipients refers to that the PBGD
solution comprises 3.67 mM Na.sub.2HPO.sub.4.times.2H.sub.2O, 27 mM
glycin and 220 mM Mannitol prepared in sterile water.
[0283] 1.5.times. amount excipients refers to that the PBGD
solution comprises 5.51 mM Na.sub.2HPO.sub.4.times.2H.sub.2O, 40.5
mM glycin and 375 mM Mannitol prepared in sterile water, i.e.
1.5.times. of each of the components present in the 1.times.
buffer.
[0284] 2.times. excipients refers to that the PBGD solution
comprises 7.34 mM Na.sub.2HPO.sub.4.times.2H.sub.2O, 54 mM glycin
and 500 mM Mannitol prepared in sterile water, i.e. 2.times. of
each of the components present in the 1.times. buffer.
[0285] The original freeze-drying cycle is as described above.
[0286] The annealing freeze-drying cycle is as described above
where the annealing step comprises raising the temperature to
-10.degree. C. at keeping the sample at this temperature for 120
minutes before lowering it to -40.degree. C. again.
[0287] The extended annealing freeze-drying cycle is as described
above where the annealing step comprises raising the temperature to
-20.degree. C. at keeping the sample at this temperature for 420
minutes before lowering it to -40.degree. C. again.
TABLE-US-00022 TABLE 20 Reconstitution time for Amount Protein
different free-drying cycles of concentration Extended excipients
(mg/ml) Original Annealing annealing 1x 198 600 550 480 1x 175 540
500 450 1x 150 450 480 180 1x 125 330 100 10 1x 100 40 10 10 1x 80
25 10 10 1.5x 200 480 40 60 1.5x 175 220 10 10 1.5x 150 60 10 10
1.5x 125 15 10 10 1.5x 100 10 10 10 2x 200 120 20 2x 175 40 20 2x
150 20 10 2x 100 10 10
Example 5
The Effect of Different Modes of Freeze-Drying and/or the Amount of
Excipients on the Appearance of the Freeze-Dried Product
[0288] Concentrated and freeze-dried solutions of PBGD were
prepared as described in example 4 and references to the amount of
excipients and the type of freeze-drying cycle has the same meaning
as in example 4.
[0289] The following results were obtained by visual inspection of
the freeze-dried products:
[0290] A: Comparison of three products prepared from solutions
comprising respectively, 4.6 mg/ml 66.6 mg/ml and 109.4 mg/ml
rhPBGD showed that the number of cracks in the freeze-dried product
increased as concentration of rhPBGD increased.
[0291] B: Comparison of two products, prepared from a solution
comprising 150 mg/ml rhPBGD, and comprising 1.times. and 1.5.times.
amount of excipients showed that the number of cracks in the
freeze-dried product was lower for the product which comprised
1.5.times. amount of excipients than the product comprising
1.times. amount of excipients.
[0292] C: Comparison of two freeze-dried products prepared from a
150 mg/ml rhPBGD solution, comprising 1.times. and 2.times. amount
of excipients showed that the number of cracks in the freeze-dried
product with 2.times. amount of excipients was lower than the
product comprising the 1.times. amount of excipients.
[0293] D: Comparison of three freeze-dried products prepared from a
150 mg/ml rhPBGD solution by using the original, the annealing and
the extended annealing freeze-drying cycle showed that the number
of cracks in the freeze-dried product was lower in the product
which was prepared according to the annealing freeze-drying cycle
than in the product prepared according to the original
freeze-drying cycle. Furthermore, the number of cracks in the
product prepared according to the extended annealing freeze-drying
cycle was lower than in the product prepared according to the
annealing freeze-drying cycle.
[0294] E: Three freeze-dried products were prepared from a 150, 175
and 200 mg/ml, respectively, rhPBGD solution. The freeze-dried
products each comprised 1.5.times. amount of excipients and they
were freeze-dried with the annealing cycle. None of the
freeze-dried products comprised any cracks.
[0295] F: Two freeze-dried rhPBGD products were prepared from a 150
mg/ml rhPBGD solution. One of them comprised 1.times. amount of
excipients and was prepared according to the original freeze-drying
cycle, while the other comprised 1.5.times. amount of excipients
and was prepared according to the extended annealing free-drying
cycle. The product comprising 1.5.times. amount of excipients and
prepared according to the extended annealing freeze-drying cycle
comprised fewer cracks than the product comprising 1.times. amount
of excipients and prepared according to the original freeze-drying
cycle.
[0296] G: Two freeze-dried rhPBGD products were prepared from a 150
mg/ml rhPBGD solution. One of them comprised 1.times. amount of
excipients and was prepared according to the original freeze-drying
cycle, while the other comprised 0.1% Tween 80 in combination with
the 1.times. amount of excipients and was prepared according to the
extended annealing freeze-drying cycle. The product comprising the
0.1% Tween 80 in combination with the 1.times. amount of excipients
and which was prepared according to the extended annealing
freeze-drying cycle comprised fewer cracks than the product which
comprised 1.times. amount of excipients and which was prepared
according to the original freeze-drying cycle.
Example 6
The Effect of Recovery Volume, the Amount of Excipients and the
Mode of Freeze-Drying on the Stability of Freeze-Dried rhPBGD
[0297] Concentrated rhPBGD solutions freeze-dried samples were
prepared as described in example 4.
[0298] The "bulk solution" is a concentrated solution of PBGD
before freeze-drying.
[0299] Table 21 shows the results of rhPBGD solutions having the
following characteristics with regard to the concentration of
rhPBGD, amount of excipients (were the same definitions as in
example 4 are used), the mode of freeze-drying (were the same
definitions as in example 4 are used) and the ratio of the filling
volume (fill. Vol which is the volume of the composition before it
is freeze-dried) versus the recovery volume (Rec. vol which is the
volume in which the freeze-dried product is resuspended):
Solution 1:
[0300] Approximately 5 mg/ml rhPBGD [0301] 1.times. amount of
excipient [0302] Original freeze-drying cycle [0303] Fill. vol=Rec.
vol
Solution 2:
[0303] [0304] Approximately 70 mg/ml rhPBGD [0305] 1.times. amount
of excipient [0306] Original freeze-drying cycle [0307] Fill.
vol=2.times.Rec. vol
Solution 3:
[0307] [0308] Approximately 110 mg/ml rhPBGD [0309] 1.times. amount
of excipient [0310] Original freeze-drying cycle [0311] Fill.
vol=Rec. vol
Solution 4:
[0311] [0312] Approximately 70 mg/ml rhPBGD [0313] 1.times. amount
of excipient [0314] Original freeze-drying cycle [0315] Fill.
vol=1.5.times.Rec. vol
Solution 5:
[0315] [0316] Approximately 90 mg/ml rhPBGD [0317] 2/3.times.
amount of excipient [0318] Original freeze-drying cycle [0319]
Fill. vol=1.5.times.Rec. vol
Solution 6:
[0319] [0320] Approximately 60 mg/ml rhPBGD [0321] 1/2.times.
amount of excipient [0322] Original freeze-drying cycle [0323]
Fill. vol=2.times.Rec. vol
Solution 7:
[0323] [0324] Approximately 110 mg/ml rhPBGD [0325] 1.times. amount
of excipient [0326] Annealing freeze-drying cycle [0327] Fill.
vol=Rec. vol
Solution 8:
[0327] [0328] Approximately 60 mg/ml rhPBGD [0329] 1.times. amount
of excipient [0330] Annealing freeze-drying cycle [0331] Fill.
vol=2.times.Rec. vol
Solution 9:
[0331] [0332] Approximately 150 mg/ml rhPBGD [0333] 1.times. amount
of excipient [0334] Annealing freeze-drying cycle [0335] Fill.
vol=Rec. vol
Solution 10:
[0335] [0336] Approximately 150 mg/ml rhPBGD [0337] 1.times. amount
of excipient [0338] Original freeze-drying cycle [0339] Fill.
vol=Rec. vol
[0340] Although not shown in Table 21 the purity was also tested
for each time point as was found to 1000% in all cases.
[0341] For solution 2 at the week 4 and 9 time point and for
solution 4 the week 9 time point a wrong recovery volume was
used.
TABLE-US-00023 TABLE 21 Measuring Protein Specific point Fill. Vol
Rec. Vol Osmolality concentration Activity activity Solution (week)
(ml) (ml) pH (mosmol/kg) (mg/ml) (U/ml) (U/mg) 1 bulk 4.6 78 17.1 0
0.67 0.67 7.54 274 4.8 85 17.8 2 0.67 0.67 7.22 274 4.6 87 19.4 4
0.67 0.67 7.78 279 5.1 75 14.5 7 0.67 0.67 7.87 284 5.1 68 13.3 9
0.67 0.67 7.67 403 7.0 93 13.2 2 bulk 66.6 1129 16.9 0 0.67 0.335
7.64 525 113 1915 16.9 2 0.67 0.335 7.63 459 93.6 1593 17.0 4 0.67
0.67 7.75 264 64.6 1104 17.1 7 0.67 0.335 7.95 451 106.4 2106 19.8
9 0.67 0.67 7.59 247 51.4 859 16.7 3 bulk 109.4 1491 13.6 0 0.67
0.67 7.75 274 99.9 1598 16.0 2 0.67 0.67 7.64 269 91.4 1543 16.9 4
0.67 0.67 7.68 274 101.2 1825 18.0 7 0.67 0.67 7.71 278 103.4 2045
19.8 9 0.67 0.67 7.67 274 88.3 1656 18.8 4 bulk 71.5 1244 17.4 0
0.67 0.45 7.64 448 113.8 1748 15.4 2 0.67 0.45 7.63 411 86.4 1806
20.9 4 0.67 0.45 7.77 362 109.9 1897 17.3 7 0.67 0.45 7.90 379 95.2
686 (7.2) 9 0.67 0.67 7.63 273 59.7 1090 18.3 5 bulk 91.0 1610 17.7
0 0.67 0.45 7.65 296 119.4 2014 16.9 2 0.67 0.45 7.61 285 112.3
2093 18.6 4 0.67 0.45 7.90 292 125.1 2409 19.3 7 0.67 0.45 7.88 297
116.4 1928 16.6 9 0.67 0.45 7.34 278 102.5 1490 14.5 6 bulk 60.7
992 16.3 0 0.67 0.335 7.63 295 112.6 1753 15.6 2 0.67 0.335 7.60
288 86.9 1787 20.6 4 0.67 0.335 7.83 287 116.4 2106 18.1 7 0.67
0.335 8.20 299 109.7 695 (6.3) 9 0.67 0.335 7.44 287 95.2 1636 17.2
7 bulk 116.4 1926 16.5 0 0.67 0.67 7.56 275 101.1 1750 17.3 2 0.67
0.67 7.51 276 93.4 1831 19.6 4 0.67 0.67 7.60 270 101.6 1774 17.5 7
0.67 0.67 7.53 283 102.2 1639 16.0 9 0.67 0.67 7.46 274 89.9 960
10.7 8 bulk 64.5 1119 17.4 0 0.67 0.335 7.52 511 100.7 1718 17.1 2
0.67 0.335 7.51 459 99.3 1900 19.1 4 0.67 0.335 7.70 482 114.5 1913
16.7 9 0.67 0.335 7.29 425 102.3 1650 16.1 9 bulk 165 3587 21.7 0
0.60 0.60 7.71 309 121.4 2819 23.2 4 0.60 0.60 7.74 -- 140.3 2014
14.4 7.5 0.60 0.60 7.61 292 135.9 1640 12.1 10 bulk 165 3587 21.7 0
0.60 0.60 7.86 276 142.1 2397 16.9 3 0.40 0.40 8.20 314 141.9 2381
16.8 5 0.60 0.60 7.60 302 131.8 2304 17.5
Example 7
Effect of Different Excipients on the Stability of rhPBGD
[0342] rhPBGD was concentrated as described in example 4 and then
the buffer was changed as to one of the four buffers described
below. The products were then freeze-dried as described in example
4 with an original annealing step included and the stability of the
samples were tested as described in example 6.
[0343] The effect of the following four formulations on the
stability of rhPBGD was tested:
[0344] Formulation A (corresponds to solution 9 in example 6): 250
mM mannitol, 27 mM glycine and 3.67 mM Na.sub.2HPO.sub.4.
[0345] Formulation B: 250 mM mannitol, 27 mM glycine and 10 mM
TRIS-HCL.
[0346] Formulation C: 250 mM mannitol, 27 mM glycine, 3.67 mM
Na.sub.2HPO.sub.4 and 0.1% Tween 80.
[0347] Formulation D: 221 mM mannitol, 29 mM sucrose, 27 mM
glycine, 3.67 mM Na.sub.2HPO.sub.4 and 0.1% Tween 80.
[0348] The results are shown in Table 22.
TABLE-US-00024 TABLE 22 Measuring Protein Specific point Fill. Vol
Rec. Vol Osmolality concentration Activity activity Formulation
(week) (ml) (ml) pH (mosmol/kg) (mg/ml) (U/ml) (U/mg) A Bulk 7.69
366 165 3587 21.7 0 0.60 0.60 7.71 309 121.4 2819 23.2 4 0.60 0.60
7.74 -- 140.3 2014 14.4 7.5 0.60 0.60 7.61 292 135.9 1640 12.1 B
Bulk 7.54 320 173 3595 20.8 0 0.60 0.60 7.58 284 148.1 3726 25.2 3
0.60 0.60 7.57 280 165.4 2947 17.8 4 0.60 0.60 7.69 -- 167.5 2367
14.1 7.5 0.60 0.60 7.60 283 150.4 2235 14.9 C Bulk 7.40 338 178
3606 20.2 0 0.60 0.60 7.76 290 142.9 2662 18.6 3 0.60 0.60 7.43 285
181.7 2332 12.8 4 0.60 0.60 7.42 -- 173.1 1436 8.3 6 0.60 0.60 7.55
274 156.6 1254 7.4 7.5 0.60 0.60 7.34 274 141.5 1252 8.9 D Bulk
7.41 337 175 3869 22.1 0 0.60 0.60 7.80 292 127.5 2355 18.5 3 0.60
0.60 7.35 288 143.9 1988 13.8 4 0.60 0.60 7.26 -- 159.3 1644 10.3 6
0.60 0.60 7.30 281 135.7 1236 9.1 7.5 0.60 0.60 7.28 282 125.7 1146
9.1
Sequence CWU 1
1
2611035DNAHomo sapiens 1atgagagtga ttcgcgtggg tacccgcaag agccagcttg
ctcgcataca gacggacagt 60gtggtggcaa cattgaaagc ctcgtaccct ggcctgcagt
ttgaaatcat tgctatgtcc 120accacagggg acaagattct tgatactgca
ctctctaaga ttggagagaa aagcctgttt 180accaaggagc ttgaacatgc
cctggagaag aatgaagtgg acctggttgt tcactccttg 240aaggacctgc
ccactgtgct tcctcctggc ttcaccatcg gagccatctg caagcgggaa
300aaccctcatg atgctgttgt ctttcaccca aaatttgttg ggaagaccct
agaaaccctg 360ccagagaaga gtgtggtggg aaccagctcc ctgcgaagag
cagcccagct gcagagaaag 420ttcccgcatc tggagttcag gagtattcgg
ggaaacctca acacccggct tcggaagctg 480gacgagcagc aggagttcag
tgccatcatc ctggcaacag ctggcctgca gcgcatgggc 540tggcacaacc
gggttgggca gatcctgcac cctgaggaat gcatgtatgc tgtgggccag
600ggggccttgg gcgtggaagt gcgagccaag gaccaggaca tcttggatct
ggtgggtgtg 660ctgcacgatc ccgagactct gcttcgctgc atcgctgaaa
gggccttcct gaggcacctg 720gaaggaggct gcagtgtgcc agtagccgtg
catacagcta tgaaggatgg gcaactgtac 780ctgactggag gagtctggag
tctagacggc tcagatagca tacaagagac catgcaggct 840accatccatg
tccctgccca gcatgaagat ggccctgagg atgacccaca gttggtaggc
900atcactgctc gtaacattcc acgagggccc cagttggctg cccagaactt
gggcatcagc 960ctggccaact tgttgctgag caaaggagcc aaaaacatcc
tggatgttgc acggcaattg 1020aacgatgccc attaa 103521035DNAHomo sapiens
2atgagagtga ttcgcgtggg tacccgcaag agccagcttg ctcgcataca gacggacagt
60gtggtggcaa cattgaaagc ctcgtaccct ggcctgcagt ttgaaatcat tgctatgtcc
120accacagggg acaagattct tgatactgca ctctctaaga ttggagagaa
aagcctgttt 180accaaggagc ttgaacatgc cctggagaag aatgaagtgg
acctggttgt tcactccttg 240aaggacctgc ccactgtgct tcctcctggc
ttcaccatcg gagccatctg caagcgggaa 300aaccctcatg atgctgttgt
ctttcaccca aaatttgttg ggaagaccct agaaaccctg 360ccagagaaga
gtgtggtggg aaccagctcc ctgcgaagag cagcccagct gcagagaaag
420ttcccgcatc tggagttcag gagtattcgg ggaaacctca acacccggct
tcggaagctg 480gacgagcagc aggagttcag tgccatcatc ctggcaacag
ctggcctgca gcgcatgggc 540tggcacaacc gggtggggca gatcctgcac
cctgaggaat gcatgtatgc tgtgggccag 600ggggccttgg gcgtggaagt
gcgagccaag gaccaggaca tcttggatct ggtgggtgtg 660ctgcacgatc
ccgagactct gcttcgctgc atcgctgaaa gggccttcct gaggcacctg
720gaaggaggct gcagtgtgcc agtagccgtg catacagcta tgaaggatgg
gcaactgtac 780ctgactggag gagtctggag tctagacggc tcagatagca
tacaagagac catgcaggct 840accatccatg tccctgccca gcatgaagat
ggccctgagg atgacccaca gttggtaggc 900atcactgctc gtaacattcc
acgagggccc cagttggctg cccagaactt gggcatcagc 960ctggccaact
tgttgctgag caaaggagcc aaaaacatcc tggatgttgc acggcaattg
1020aacgatgccc attaa 103531035DNAHomo sapiens 3atgagagtga
ttcgcgtggg tacccgcaag agccagcttg ctcgcataca gacggacagt 60gtggtggcaa
cattgaaagc ctcgtaccct ggcctgcagt ttgaaatcat tgctatgtcc
120accacagggg acaagattct tgatactgca ctctctaaga ttggagagaa
aagcctgttt 180accaaggagc ttgaacatgc cctggagaag aatgaagtgg
acctggttgt tcactccttg 240aaggacctgc ccactgtgct tcctcctggc
ttcaccatcg gagccatctg caagcgggaa 300aaccctcatg atgctgttgt
ctttcaccca aaatttgttg ggaagaccct agaaaccctg 360ccagagaaga
gtgtggtggg aaccagctcc ctgcgaagag cagcccagct gcagagaaag
420ttcccgcatc tggagttcag gagtattcgg ggaaacctca acacccggct
tcggaagctg 480gacgagcagc aggagttcag tgccatcatc ctggcaacag
ctggcctgca gcgcatgggc 540tggcacaacc gggtggggca gatcctgcac
cctgaggaat gcatgtatgc tgtgggccag 600ggggccttgg gcgtggaagt
gcgagccaag gaccaggaca tcttggatct ggtgggtgtg 660ctgcacgatc
ccgagactct gcttcgctgc atcgctgaaa gggccttcct gaggcacctg
720gaaggaggct gcagtgtgcc agtagccgtg catacagcta tgaaggatgg
gcaactgtac 780ctgactggag gagtctggag tctagacggc tcagatagca
tacaagagac catgcaggct 840accatccatg tccctgccca gcatgaagat
ggccctgagg atgacccaca gttggtaggc 900atcactgctc gtaacattcc
acgagggccc cagttggctg cccagaactt gggcatcagc 960ctggccaact
tgttgctgag caaaggagcc aaaaacatcc tggatgttgc acggcaattg
1020aacgatgccc attaa 103541034DNAHomo sapiens 4atgagagtga
ttcgcgtggg tacccgcaag agccagcttg ctcgcataca gacggacagt 60gtggtggcaa
cattgaaagc ctcgtaccct ggcctgcagt ttgaaatcat tgctatgtcc
120accacagggg acaagattct tgatactgca ctctctaaga ttggagagaa
aagcctgttt 180accaaggagc ttgaacatgc cctggagaag aatgaagtgg
acctggttgt tcactccttg 240aaggacctgc ccactgtgct tcctcctggc
ttcaccatcg gagccatctg caagcgggaa 300aaccctcatg atgctgttgt
cttcacccaa aatttgttgg gaagacccta gaaaccctgc 360cagagaagag
tgtggtggga accagctccc tgcgaagagc agcccagctg cagagaaagt
420tcccgcatct ggagttcagg agtattcggg gaaacctcaa cacccggctt
cggaagctgg 480acgagcagca ggagttcagt gccatcatcc tggcaacagc
tggcctgcag cgcatgggct 540ggcacaaccg ggtggggcag atcctgcacc
ctgaggaatg catgtatgct gtgggccagg 600gggccttggg cgtggaagtg
cgagccaagg accaggacat cttggatctg gtgggtgtgc 660tgcacgatcc
cgagactctg cttcgctgca tcgctgaaag ggccttcctg aggcacctgg
720aaggaggctg cagtgtgcca gtagccgtgc atacagctat gaaggatggg
caactgtacc 780tgactggagg agtctggagt ctagacggct cagatagcat
acaagagacc atgcaggcta 840ccatccatgt ccctgcccag catgaagatg
gccctgagga tgacccacag ttggtaggca 900tcactgctcg taacattcca
cgagggcccc agttggctgc ccagaacttg ggcatcagcc 960tggccaactt
gttgctgagc aaaggagcca aaaacatcct ggatgttgca cggcaattga
1020acgatgccca ttaa 103451035DNAHomo sapiens 5atgagagtga ttcgcgtggg
tacccgcaag agccagcttg ctcgcataca gacgggcagt 60gtggtggcaa cattgaaagc
ctcgtaccct ggcctgcagt ttgaaatcat tgctatgtcc 120accacagggg
acaagattct tgatactgca ctctctaaga ttggagagaa aagcctgttt
180accaaggagc ttgaacatgc cctggagaag aatgaagtgg acctggttgt
tcactccttg 240aaggacctgc ccactgtgct tcctcctggc ttcaccatcg
gagccatctg caagcgggaa 300aaccctcatg atgctgttgt ctttcaccca
aaatttgttg ggaagaccct agaaaccctg 360ccagagaaga gtgtggtggg
aaccagctcc ctgcgaagag cagcccagct gcagagaagg 420ttcccgcatc
tggagttcag gagtattcgg ggaaacctca acacccggct tcggaagctg
480gacgagcagc aggagttcag tgtcatcatc ctggcaacag ctggcctgca
gcgcatgggc 540tggcacaacc gggttgggca gatcctgcac cctgaggaat
gcatgtatgc tgtgggccag 600ggggccttgg gcgtggaagt gcgagccaag
gaccaggaca tcttggatct ggtgggtgtg 660ctgcacgatc ccgagactct
gcttcgctgc atcgctgaaa gggccttcct gaggcacctg 720gaaggaggct
gcagtgtgcc agtagccgtg catacagcta tgaaggatgg gcaactgtac
780ctgactggag gagtctggag tctagacggc tcagatagca tacaagagac
catgcaggct 840accatccatg tccctgccca gcatgaagat ggccctgagg
atgacccaca gttggtaggc 900atcactgctc gtaacattcc acgagggccc
cagttggctg cccagaactt gggcatcagc 960ctggccaact tgttgctgag
caagggagcc aaaaacatcc tggatgttgc acggcaattg 1020aacgatgccc attaa
103561035DNAHomo sapiens 6atgagagtga ttcgcgtggg tacccgcaag
agccagcttg ctcgcataca gacggacagt 60gtggtggcaa cattgaaagc ctcgtaccct
ggcctgcagt ttgaaatcat tgctatgtcc 120accacagggg acaagattct
tgatactgca ctctctaaga ttggagagaa aagcctgttt 180accaaggagc
ttgaacatgc cctggagaag aatgaagtgg acctggttgt tcactccttg
240aaggacctgc ccactgtgct tcctcctggc ttcaccatcg gagccatctg
caagcgggaa 300aaccctcatg atgctgttgt ctttcaccca aaatttgttg
ggaagaccct agaaaccctg 360ccagagaaga gtgtggtggg aaccagctcc
ctgcgaagag cagcccagct gcagagaaag 420ttcccgcatc tggagttcag
gagtattcgg ggaaacctca acacccggct tcggaagctg 480gacgagcagc
aggagttcag tgccatcatc ctggcaacag ctggcctgca gcgcatgggc
540tggcacaacc gggtggggca gatcctgcac cctgaggaat gcatgtatgc
tgtgggccag 600ggggccttgg gcgtggaagt gcgagccaag gaccaggaca
tcttggatct ggtgggtgtg 660ctgcacgatc ccgagactct gcttcgctgc
atcgctgaaa gggccttcct gaggcacctg 720gaaggaggtt gcagtgtgcc
agtagccgtg catacagcta tgaaggatgg gcaactgtac 780ctgactggag
gagtctggag tctagacggc tcagatagca tacaagagac catgcaggct
840accatccatg tccctgccca gcatgaagat ggccctgagg atgacccaca
gttggtaggc 900atcactgctc gtaacattcc acgagggccc cagttggctg
cccagaactt gggcatcagc 960ctggccaact tgttgctgag caaaggagcc
aaaaacatcc tggatgttgc acggcaattg 1020aacgatgccc attaa
103571034DNAHomo sapiens 7atgagagtga ttcgcgtggg tacccgcaag
agccagcttg ctcgcataca gacggacagt 60gtggtggcaa cattgaaagc ctcgtaccct
ggcctgcagt ttgaaatcat tgctatgtcc 120accacagggg acaagattct
tgatactgca ctctctaaga ttggagagaa aagcctgttt 180accaaggagc
ttgaacatgc cctggagaag aatgaagtgg acctggttgt tcactccttg
240aaggacctgc ccactgtgct tcctcctggc ttcaccatcg gagccatctg
caagcgggaa 300aaccctcatg atgctgttgt ctttcaccca aaatttgttg
ggaagaccct agaaaccctg 360ccagagaaga gtgtggtggg aaccagctcc
ctgcgaagag cagcccagct gcagagaaag 420ttcccgcatc tggagttcag
gagtattcgg ggaaacctca acacccggct tcggaagctg 480gacgagcagc
aggagttcag tgccatcatc ctggcaacag ctggcctgca gcgcatgggc
540tggcacaacc gggtggggca gatcctgcac cctgaggaat gcatgtatgc
tgtgggccag 600ggggccttgg gcgtggaagt gcgagccaag gaccaggaca
tcttggatct ggtgggtgtg 660ctgcacgatc ccgagactct gcttcgctgc
atcgctgaaa gggccttcct gaggcacctg 720gaaggaggct gcagtgtgcc
agtagccgtg catacagcta tgaaggatgg gcaactgtac 780ctgactggag
gagtctggag tctagacggc tcagatagca tacaagagac catgcaggct
840accatccatg tccctgccca gcatgaagat ggccctgagg atgacccaca
gttggtaggc 900atcactgctc gtaacattcc acgagggccc cagttggctg
cccagaactt gggcatcagc 960ctggccaact tgttgctgag caaaggagcc
aaaaacatcc tggatgttgc acggcaatta 1020acgatgccca ttaa
103481035DNAHomo sapiens 8atgagagtga ttcgcgtggg tacccgcaag
agccagcttg ctcgcataca gacggacagt 60gtggtggcaa cattgaaagc ctcgtaccct
ggcctgcagt ttgaaatcat tgctatgtcc 120accacagggg acaagattct
tgatactgca ctctctaaga ttggagagaa aagcctgttt 180accaaggagc
ttgaacatgc cctggagaag aatgaagtgg acctggttgt tcactccttg
240aaggacctgc ccactgtgct tcctcctggc ttcaccatcg gagccatctg
caagcgggaa 300aaccctcatg atgctgttgt ctttcaccca aaatttgttg
ggaagaccct agaaaccctg 360ccagagaaga gtgtggtggg aaccagctcc
ctgcgaagag cagcccagct gcagagaaag 420ttcccgcatc tggagttcag
gagtattcgg ggaaacctca acacccggct tcggaagctg 480gacgagcagc
aggagttcag tgccatcatc ctggcaacag ctggcctgca gcgcatgggc
540tggcacaacc gggtggggca gatcctgcac cctgaggaat gcatgtatgc
tgtgggccag 600ggggccttgg gcgtggaagt gcgagccaag gaccaggaca
tcttggatct ggtgggtgtg 660ctgcacgatc ccgagactct gcttcgctgc
atcgctgaaa gggccttcct gaggcacctg 720gaaggaggct gcagtgtgcc
agtagccgtg catacagcta tgaaggatgg gcaactgtac 780ctgactggag
gagtctggag tctagacggc tcagatagca tacaagagac catgcaggcc
840accatccatg tccctaccca gcatgaagat ggccctgagg atgacccaca
gttggtaggc 900atcactgctc gtaacattcc acgagggccc cagttggctg
cccagaactt gggcatcagc 960ctggccaact tgttgctgag caaaggagcc
aaaaacatcc tggatgttgc acggcaattg 1020aacgatgccc attaa
103591260DNAHomo sapiens 9cacaggaaac agctatgacc atgattacgc
caagctcgaa attaaccctc actaaaggga 60acaaaagctg gagctccacc gcggtggcgg
ccgctctaga actagtggat cccccgggct 120gcaggaattc atgagagtga
ttcgcgtggg tacccgcaag agccagcttg ctcgcataca 180gacggacagt
gtggtggcaa cattgaaagc ctcgtaccct ggcctgcagt ttgaaatcat
240tgctatgtcc accacagggg acaagattct tgatactgca ctctctaaga
ttggagagaa 300aagcctgttt accaaggagc ttgaacatgc cctggagaag
aatgaagtgg acctggttgt 360tcactccttg aaggacctgc ccactgtgct
tcctcctggc ttcaccatcg gagccatctg 420caagcgggaa aaccctcatg
atgctgttgt ctttcaccca aaatttgttg ggaagaccct 480agaaaccctg
ccagagaaga gtgtggtggg aaccagctcc ctgcgaagag cagcccagct
540gcagagaaag ttcccgcatc tggagttcag gagtattcgg ggaaacctca
acacccggct 600tcggaagctg gacgagcagc aggagttcag tgccatcatc
ctggcaacag ctggcctgca 660gcgcatgggc tggcacaacc gggttgggca
gatcctgcac cctgaggaat gcatgtatgc 720tgtgggccag ggggccttgg
gcgtggaagt gcgagccaag gaccaggaca tcttggatct 780ggtgggtgtg
ctgcacgatc ccgagactct gcttcgctgc atcgctgaaa gggccttcct
840gaggcacctg gaaggaggct gcagtgtgcc agtagccgtg catacagcta
tgaaggatgg 900gcaactgtac ctgactggag gagtctggag tctagacggc
tcagatagca tacaagagac 960catgcaggct accatccatg tccctgccca
gcatgaagat ggccctgagg atgacccaca 1020gttggtaggc atcactgctc
gtaacattcc acgagggccc cagttggctg cccagaactt 1080gggcatcagc
ctggccaact tgttgctgag caaaggagcc aaaaacatcc tggatgttgc
1140acggcaattg aacgatgccc attaataagc ttatcgatac cgtcgacctc
gagggggggc 1200ccggtaccca attcgcccta tagtgagtcg tattacaatt
cactggccgt cgttttacaa 1260101113DNAHomo sapiens 10cacacagcct
actttccaag cggagccatg tctggtaacg gcaatgcggc tgcaacggcg 60gaagaaaaca
gcccaaagat gagagtgatt cgcgtgggta cccgcaagag ccagcttgct
120cgcatacaga cggacagtgt ggtggcaaca ttgaaagcct cgtaccctgg
cctgcagttt 180gaaatcattg ctatgtccac cacaggggac aagattcttg
atactgcact ctctaagatt 240ggagagaaaa gcctgtttac caaggagctt
gaacatgccc tggagaagaa tgaagtggac 300ctggttgttc actccttgaa
ggacctgccc actgtgcttc ctcctggctt caccatcgga 360gccatctgca
agcgggaaaa ccctcatgat gctgttgtct ttcacccaaa atttgttggg
420aagaccctag aaaccctgcc agagaagagt gtggtgggaa ccagctccct
gcgaagagca 480gcccagctgc agagaaagtt cccgcatctg gagttcagga
gtattcgggg aaacctcaac 540acccggcttc ggaagctgga cgagcagcag
gagttcagtg ccatcatcct ggcaacagct 600ggcctgcagc gcatgggctg
gcacaaccgg gttgggcaga tcctgcaccc tgaggaatgc 660atgtatgctg
tgggccaggg ggccttgggc gtggaagtgc gagccaagga ccaggacatc
720ttggatctgg tgggtgtgct gcacgatccc gagactctgc ttcgctgcat
cgctgaaagg 780gccttcctga ggcacctgga aggaggctgc agtgtgccag
tagccgtgca tacagctatg 840aaggatgggc aactgtacct gactggagga
gtctggagtc tagacggctc agatagcata 900caagagacca tgcaggctac
catccatgtc cctgcccagc atgaagatgg ccctgaggat 960gacccacagt
tggtaggcat cactgctcgt aacattccac gagggcccca gttggctgcc
1020cagaacttgg gcatcagcct ggccaacttg ttgctgagca aaggagccaa
aaacatcctg 1080gatgttgcac ggcaattgaa cgatgcccat taa
1113111380DNAHomo sapiens 11agcaggtcct actatcgcct ccctctagtc
tctgcttctt tggatccctg aggagggcag 60aaggaagaaa acagcccaaa gatgagagtg
attcgcgtgg gtacccgcaa gagccagctt 120gctcgcatac agacggacag
tgtggtggca acattgaaag cctcgtaccc tggcctgcag 180tttgaaatca
ttgctatgtc caccacaggg gacaagattc ttgatactgc actctctaag
240attggagaga aaagcctgtt taccaaggag cttgaacatg ccctggagaa
gaatgaagtg 300gacctggttg ttcactcctt gaaggacctg cccactgtgc
ttcctcctgg cttcaccatc 360ggagccatct gcaagcggga aaaccctcat
gatgctgttg tctttcaccc aaaatttgtt 420gggaagaccc tagaaaccct
gccagagaag agtgtggtgg gaaccagctc cctgcgaaga 480gcagcccagc
tgcagagaaa gttcccgcat ctggagttca ggagtattcg gggaaacctc
540aacacccggc ttcggaagct ggacgagcag caggagttca gtgccatcat
cctagcaaca 600gctggcctgc agcgcatggg ctggcacaac cgggttgggc
agatcctgca ccctgaggaa 660tgcatgtatg ctgtgggcca gggggccttg
ggcgtggaag tgcgagccaa ggaccaggac 720atcttggatc tggtgggtgt
gctgcacgat cccgagactc tgcttcgctg catcgctgaa 780agggccttcc
tgaggcacct ggaaggaggc tgcagtgtgc cagtagccgt gcatacagct
840atgaaggatg ggcaactgta cctgactgga ggagtctgga gtctagacgg
ctcagatagc 900atacaagaga ccatgcaggc taccatccat gtccctgccc
agcatgaaga tggccctgag 960gatgacccac agttggtagg catcactgct
cgtaacattc cacgagggcc ccagttggct 1020gcccagaact tgggcatcag
cctggccaac ttgttgctga gcaaaggagc caaaaccatc 1080ctggatgttg
cacggcagct taacgatgcc cattaactgg tttgtggggc acagatgcct
1140gggttgctgc tgtccagtgc ctacatcccg ggcctcagtg ccccattctc
actgctatct 1200ggggagtgat taccccggga gactgaactg cagggttcaa
gccttccagg gatttgcctc 1260accttggggc cttgatgact gccttgcctc
ctcagtatgt gggggcttca tctctttaga 1320gaagtccaag caacagcctt
tgaatgtaac caatcctact aataaaccag ttctgaaggt 1380121377DNAHomo
sapiens 12cacacagcct actttccaag cggagccatg tctggtaacg gcaatgcggc
tgcaacggcg 60gaagaaaaca gcccaaagat gagagtgatt cgcgtgggta cccgcaagag
ccagcttgct 120cgcatacaga cggacagtgt ggtggcaaca ttgaaagcct
cgtaccctgg cctgcagttt 180gaaatcattg ctatgtccac cacaggggac
aagattcttg atactgcact ctctaagatt 240ggagagaaaa gcctgtttac
caaggagctt gaacatgccc tggagaagaa tgaagtggac 300ctggttgttc
actccttgaa ggacctgccc actgtgcttc ctcctggctt caccatcgga
360gccatctgca agcgggaaaa ccctcatgat gctgttgtct ttcacccaaa
atttgttggg 420aagaccctag aaaccctgcc agagaagagt gtggtgggaa
ccagctccct gcgaagagca 480gcccagctgc agagaaagtt cccgcatctg
gagttcagga gtattcgggg aaacctcaac 540acccggcttc ggaagctgga
cgagcagcag gagttcagtg ccatcatcct agcaacagct 600ggcctgcagc
gcatgggctg gcacaaccgg gtggggcaga tcctgcaccc tgagaaatgc
660atgtatgctg tgggccaggg ggccttgggc gtggaagtgc gagccaagga
ccaggacatc 720ttggatctgg tgggtgtgct gcacgatccc gagactctgc
ttcgctgcat cgctgaaagg 780gccttcctga ggcacctgga aggaggctgc
agtgtgccag tagccgtgca tacagctatg 840aaggatgggc aactgtacct
gactggagga gtctggagtc tagacggctc agatagcata 900caagagacca
tgcaggctac catccatgtc cctgcccagc atgaagatgg ccctgaggat
960gacccacagt tggtaggcat cactgctcgt aacattccac gagggcccca
gttggctgcc 1020cagaacttgg gcatcagcct ggccaacttg ttgctgagca
aaggagccaa aaacatcctg 1080gatgttgcac ggcagcttaa cgatgcccat
taactggttt gtggggcaca gatgcctggg 1140ttgctgctgt ccagtgccta
catcccgggc ctcagtgccc cattctcact gctatctggg 1200gagtgattac
cccgggagac tgaactgcag ggttcaagcc ttccagggat ttgcctcacc
1260ttggggcctt gatgactgcc ttgcctcctc agtatgtggg ggcttcatct
ctttagagaa 1320gtccaagcaa cagcctttga atgtaaccaa tcctactaat
aaaccagttc tgaaggt 13771310024DNAHomo sapiens 13aatcatgatt
gttaattatg ttcatgatta caggcgcggt ggctcacgcc tgtactccca 60gcactttggg
aggccgaggt gggcgaatca cctgaggtca ggagttcaag acctgcctga
120ctaacatgga gaaacctcat ctctaccaaa aatacaaaat tagccgggtg
tggtggtgcg 180tgcctgtaat cccagctact cggggggctg aggcaggaga
attgcttgaa cccgggaggc 240ggaggttgca gtgagctgag atcgtgccat
tgcattccag cctgggcaac aagagcgaaa 300ctccgtctca aaaaaaaaaa
aaaattatgt tcatgggaaa gcacttttcc taacaagccc 360ttttctcact
acatgtaggt ttgtgctccc acttcagtta cttgtcttta ggcatgacct
420ttaatctctc tgaaccagtt tcctcatttt aagaattgaa atgctggctg
ggccagtcgt 480cacgcctgta atcccagcac tttgggaggc caaggcgaga
tgactgcttg agtccaggag 540ttcgagacta gcctgggcaa catagtgagg
ccacctcccc gctgtctcta taaaaaaatc 600tagaaattag tcccacgtgg
tgatgtgcgc ctgtagtccc agctgcttgg gaggctgagg 660tggggggatc
gctgaagccg ggaggtcaag gctgcagtga cccgtggtca tgccgctgca
720ctctagtctg gggacacagt gagaccccgt atcaaaaaga aaaatgctgc
ctatttcaag 780gttgtagcaa agctaagttt gaacagagca aaggaagcgc
catagaagct gcactacttg 840ctcatgtcac agctggggaa tggggaggtc
gaatggggag gtccactgtc gcaatgttcc 900aattcccgcc cagagggagg
gacctcccct tcgagggagg gcgccggaag tgacgcgagg 960ctctgcggag
accaggagtc agactgtagg acgacctcgg
gtcccacgtg tccccggtac 1020tcgccggccg gagcctccgg cttcccgggg
ccgggggacc ttagcggcac ccacacacag 1080cctactttcc aagcggagcc
atgtctggta acggcaatgc ggctgcaacg gcggtgagtg 1140ctgagccggt
gaccagcaca ctttgggctt ctggacgagc cgtgcagcga ttggccccag
1200gttgccatcc tcagtcgtct attggtcaga acggctatct tttttttttt
tttttttttt 1260tttttggtcc gagtagcttt taaagggcca gtagctcggt
tgccctccgg aaggaatggg 1320gaaatcagag agcggtgata ctgggttaag
agtggaagga ttgtttggaa cggaactccg 1380gtccctgcgg gcatctgggt
gggattccca tcaggcctgg gatgcacggc tctagattta 1440gtgacccaga
ccaagaacgt tcgtctacac agacggggtc ctttcattcg aggctgggct
1500gaggcggatg cagatacggc ccctttggga agacacgttc cacttttgat
tcataggaga 1560gagtatcagc caagcctccg aactgcacac aaacgtctta
gaagtgcgcc ttctttttgt 1620gttatagtgg tctcccagcc acagccaacg
ctccaagtcc ccagctgtga cacacctact 1680gaattactac cgtgggtggg
aggccgccgt gggcctttcc attacgagcc tgcttgccga 1740gccctgggct
tgtgcacaga caaactgcag agctggtgga ggccactgcc aggccgagat
1800aagaaagaga tggggagctg ctaatctccc cctgtccagc ctgttggtga
gggctgggat 1860ctttgctctt gcagtcattc cagagccctg gactaggagt
aggaagatct gaattgtggc 1920cccaactctc tttcggttat tagctctgtg
accctaggca agtcacctca tcccttgatg 1980ccacccgttg cttctgtaac
atggtcccaa aggtgcctgt cttgtccacc tgataggatt 2040tttgagacga
caacaatatg caaaagcaat agcttcaaca tagaagtgct cagtgtttta
2100ttttttaatg aaacggtttg acttggatat gctgtgcaca ttcaatgaac
ttaaggaatt 2160gtttgaacct agtagttctg ggaccttaga gtcctttctg
tgggctccct gtggcccaga 2220tttttggtgg ccacgtttaa tatcaagcct
agcctaattt gcaaagggtc tcccagggtt 2280aatttattgg agtgatcaca
tggagtagac cagagtctga gggcagaaag ctgtcacctg 2340cttcggcaat
agaggcccca gatgtctggg tgcaaaagaa ctccatagca ccccgaccaa
2400catggtgaaa ccccgtctct actaaaaata taaaaattag gccgagcaca
gtggctcatg 2460cctgtaatcc tagcactttg ggaggccgag gcaggtggat
tgcctgagct caggagttcg 2520agaccagcct agggaacaca gtgaaacccc
gtttctacta aaaatacaaa aaattagccg 2580acgtggtggc atgcgcctgc
agtcccagct acttgggagg ctaagacagg agaatcgctt 2640gaacctggga
ggtggaggtt gcactgagcc gagaccgcgc cattgcactc cagcctgggt
2700gacagagcgc aactccccct caaaaaaaga aaaaaatata tatatatata
tatatatata 2760tacacacata ttttagctgg gcatggtggt gtgcgtctgt
agtagtccca gctacttggg 2820aggctgagtc aggagaatcg cttgaacctg
gaaggcagtg gttgtagtta gctgagaaca 2880tgccactgca ctccagcctg
ggcaacagag ggagactctg tctcaaaaaa aaaaaaaaaa 2940aggaactaca
taggatgaac atcccagatc agggaatgtt gactgtcgac agtatcagta
3000tctacagtgg ctactgtctg atgtagaaag aaatgggatc aggctaggcg
tggtggctca 3060cgcctgtaat cccagctctt tgggaggctg gggcaggagg
atcacaagtt cgagaccagc 3120ctggccaaca cagtgaaacc ccgtctctac
taaaaatgtg aaaattagct gggcatggtg 3180gaacatgctg tagttccagc
ttgaacccag gggtggaggt tgtagtgagc ctagatcacg 3240ccactgcact
ccagcctgag caaaacagtg agactctgtc taaaaaaaaa aaaaaaaaaa
3300agagaaatgg gacctccgtc ttagactgaa gaattcagtt ctacgtgctt
agcagtgaat 3360acttttgtcc aaggtactct ggcaggagga agaggcgtgt
cctcttgagt tcttgacttg 3420ggctctggcc tgttaatatt tccatgttgg
tgaaaccaga ggcagcactc taggtgaacg 3480aactttaggc agcgcagcct
cctagtctta tggaacatct gaggcagaag aaacctgagt 3540ccaacctttt
cattttatag atgaacaaac agatcctgat gggacagtgt acccaaggtc
3600acccagccaa gaggctgagc aggactgtac gtcagatccg tttacctcag
tccttaatgc 3660atgcagtcca gccagattaa gggaccctta atactgtcag
ctttccccac tgtgggatct 3720tcatcctctt gacttctttt gtagccagac
atctgggcct cttgctggag aaggtggcag 3780cttgctgctc ttagactcta
gtctactcca tgtggcatct ggatggcact gaaattttct 3840caagtgcctt
gtctgttgta gataatgaat ctatcctcca gtgactcagc acaggttccc
3900cagtgtggtc ctggctgccc tgcccctgcc agctgcaggc cccacccttc
ctgtggccag 3960gctgatgggc cttatctctt tacccacctg gctgtgcaca
gcactcccac tgacaactgc 4020cttggtcaag gtgggcttca gggctcagtg
tcctggttac tgcagcggca gcaacagcag 4080gtcctactat cgcctccctc
tagtctctgc ttctctggat ccctgaggag ggcagaaggt 4140actgaggaag
gttaaaggga ccagccttgg agtatttccc cactctgaga ctcagctggc
4200cacaggccag gttctgaatt tcctttcttc caagccagtg attctggttc
ttggacaagg 4260tgttgaggaa cactagaaac agaggggact gtgacctggg
gactttttct gcaggaagaa 4320aacagcccaa agatgagagt gattcgcgtg
ggtacccgca agagccaggt gggtgcagga 4380gccggggtgg aggaggtttg
tcagaacagt tatgatgctc acagcatcac aaattggggg 4440actcagaggg
ttagttccta gtatgaagga gatggggtgg ctgggcgtta agttccccgg
4500gaaatggcag attacattct atggcaagat catccctagg ctgggaaaat
tgttggagtg 4560cagagggctc ccaagcccct tctcatgccc agatggaaat
tccagtccct tcaggatctg 4620cctaacctgt gacagtctaa agagtctgag
ccgtggctgg gaagggcagg actaatccaa 4680atctctaccc gcagcttgct
cgcatacaga cggacagtgt ggtggcaaca ttgaaagcct 4740cgtaccctgg
cctgcagttt gaaatcagtg agttttctgg aaaggagtgg aagctaatgg
4800gaagcccagt accccgagag gagagaacac aacatttctg gctttgccta
tagctaaagc 4860ccgtcccgct gccccgagat tccttctggg ctgctcccag
ttctgaaggt gctttcctct 4920gaatacctcc agctctgact acctggatta
gcctggcatt taacatcttg agctttgggt 4980ctttttatga gtgtttctgg
tcttcctgct cgattgtata tactcagagg gcaggaacca 5040gggattatgt
gcctctgtcc ccatcatgaa tcgtagcaca gtgctaggct cagtaaatgc
5100tgatcaataa tgagcacctg attgattgac tctctcctca gttgctatgt
ccaccacagg 5160ggacaagatt cttgatactg cactctctaa ggtaacaaca
tcttcctccc cagttcttgt 5220ccccactctt ctttccttcc ctgaagggat
tcactcaggc tctttctgtc cggcagattg 5280gagagaaaag cctgtttacc
aaggagcttg aacatgccct ggagaagaat gagtaagtaa 5340agataggaga
gtgtggtgcc ctcccagtct cttgctggga ccctagtatg ctaggtctct
5400tgctgggacc cggggtgtca gataggctgc tgggcttaaa ccctcagaga
ggctgaaggc 5460agctcatagg tgggtttttt caggcttcag aaaaggagag
tgtctggttc tgagccatct 5520ggctgcctgg actgcaagaa tggctggggg
agggagggta ggagggagag taggagggag 5580agtgagagga gagcagtttt
catgctcctg agatcttgag aaggtgtgct tcctgaactg 5640ccctaggctc
caccactgaa gtagaggcag gggtgggtgg agaaggggtg aaggctggct
5700gctcataccc tttctctttg cccccctctc ccatctctat agagtggacc
tggttgttca 5760ctccttgaag gacctgccca ctgtgcttcc tcctggcttc
accatcggag ccatctgcaa 5820gtaagagtct tgcaagtaag gggcttgggc
aggggtaggc atcatgtgaa cctttgcctt 5880tccctttggg gcctgaccct
ctgcttcagg gttatctcct ctgccctgag gagtgttgac 5940tggtggcaga
aaactcaaga aataccagtg agttggcaat cgagagagaa tagaggtgat
6000ctgaacttaa atctcttccc tcattctgtg cccttccctc ctcccccagg
cgggaaaacc 6060ctcatgatgc tgttgtcttt cacccaaaat ttgttgggaa
gaccctagaa accctgccag 6120agaagaggta agtggggcct ggataggcag
cttggtggga tgtgcccaga agatgcaggg 6180atgggaggag gaggaaagga
acagtgactg cctagtgtta aaatctcatt gtaacttctc 6240tctgggcagt
gtggtgggaa ccagctccct gcgaagagca gcccagctgc agagaaagtt
6300cccgcatctg gagttcagga gtattgtatc cttttagaag agtgacggat
ccttttggaa 6360gagtgacgga gacagcagcc aaggaaaaag acaaggtcta
gagggctctg ggagtccgga 6420gagtggaagg ggcttccagc aagcagcccg
tggggtcagt ggcctgtctg tctttccatg 6480cactcatccg tccactcatt
tacagtctaa tgttttctta gccccagaca agtgttcaga 6540gtgcaaggca
ttggggataa tggtgagcaa gataaacatt cccctgcata tgtagagttt
6600acgtcttact tagggataat gcagttatac tgaactgaat agtgactact
tctggaggga 6660tagggagtac ttcctttttt tttttttttt tttctgagac
ggagtctcgc tctgttgccc 6720aggttggagt gcagtggcgc aatctaggct
cactgcaact tctgcctcct gagttcaagc 6780aatcttcctg cctcagcctc
ctaagtagtt gggattacag gtgccaccac acctggctaa 6840tttttgtatt
tttagtagag actgggtttc accatgttag tcaggctggt ctcaaactcc
6900tgacctcagg tgatccacca gcctcggcct cccaaagggc tgggattaca
ggcttgagcc 6960ccgcacccgg tcagtacttc catttttata tgctactata
ttgtcttgac ttttacaatg 7020aatatgtagt acatttcata aaactaaatt
taaaaatagt atgtgctaag tgctccaata 7080agtgaagttg ggaattttct
ggaaacttct agttggaaca tctaaacaca gaagtctggg 7140gtgtcaggga
aggtttctca gaggtcttgt aaccttggca agttatttag cctccctatg
7200tcattttcct tatctgtaaa gtggggataa taatactacc ttcctcacag
ggttgttgtg 7260aagatgaaat gagctgacat atggaaagta cttttagagc
agtgtctggc atgtagtaag 7320tatgatgtaa ctgttagctg ttaacattaa
gctgagagct ggaagatgac tgaaagtcag 7380ccagctagag agggaaagac
agactcaggc agagggaacc gcacgaggcc ccagattgcc 7440cgacactgtg
gtccttagca actctccaca gcggggaaac ctcaacaccc ggcttcggaa
7500gatggacgag cagcaggagt tcagtgccat catcctggca acagctggcc
tgcagcgcat 7560gggctggcac aaccgggttg ggcaggtagg gcctgcccct
atcctctccc cagctcatct 7620gcatctcctt tctgccttac agtcatcccc
aatttaggat ttttagactt tatgattgtg 7680tgaaagcgat atacgttcag
tagaaactgt acttagtacc catacagcca ttctgttttt 7740tactttcagt
acagtattca ttacatgaga tattcacttt attgtaaaac aggcttggtg
7800tcagatgatt ttgtccaact ataataggct aatcttaagt gttctgagca
catgtaaggt 7860aggctaggtg tattaaatgc attttcagct tgttttcaac
ttaacaatgg gtttatcagg 7920atgtaaccct attgtaagtc aaggaccatc
tgtcttcact tcttgaccac cccacctcta 7980acaccgtagg ctgggaagat
tgtgaatcag aggccagact ctaggctttc atggagaaaa 8040tttacaaaaa
aaaaaaaaag aggccagact cacacttagg cctacccagg ctttctagat
8100gatagggaac tcccatctca ctgccaggtg cttttagaca cccccgtgtc
cacccttttg 8160actccctgtt ccgcctccac agatcctgca ccctgaggaa
tgcatgtatg ctgtgggcca 8220ggtacacttg accagggaag ccacatggtg
acatatgcct tccctttgtt ctcaaccaag 8280aagcttgtct cacaaccttc
tgcatctgct tccccagaat agcattctca gggaggggca 8340gaccttggga
tgctaccggt ccaaaaggcg ctggggagca agtagataga ggtggtccca
8400tgctttgcgc cattggttgg ggaaagatca ggcctgatgt cctaggatgt
ttttccatca 8460gggggccttg ggcgtggaag tgcgagccaa ggaccaggac
atcttggatc tggtgggtgt 8520gctgcacgat cccgagactc tgcttcgctg
catcgctgaa agggccttcc tgaggcacct 8580ggtagggcct gtgctccacc
tgtggagggc tggggacttg gagagctggg aaaggtggca 8640gggaagattt
cttacatgaa tgctctgtat acagtgctaa ctcattcttg ttgaatgttg
8700tgtatggata ggaccaggtc tgggcccaca gttgcctttt cagtgatgtc
ctcaggtctg 8760tggtcacagg gtggtgttaa gagcccttgc agctcacaag
aacttcttgt tacaggaagg 8820aggctgcagt gtgccagtag ccgtgcatac
agctatgaag gatgggcaag taagtggggg 8880gaaatgggcg ggaagccagg
gaaaggagga ctgtggcatt tcttcctgtg catcccaggt 8940ttctaggtag
tcccctctca gactgtgctg aggcaactgt tttcttcccc agctgtacct
9000gactggagga gtctggagtc tagacggctc agatagcata caagagacca
tgcaggctac 9060catccatgtc cctgcccagg taccaaagct ggagggcgag
ggggtaataa acaagagtgc 9120atataatctc ttgttctcac caaatcccac
ctccttccct catacagcat gaagatggcc 9180ctgaggatga cccacagttg
gtaggcatca ctgctcgtaa cattccacga gggccccagt 9240tggctgccca
gaacttgggc atcagcctgg ccaacttgtt gctgagcaaa ggagccaaaa
9300acatcctgga tgttgcacgg cagcttaacg atgcccatta actggtttgt
ggggcacaga 9360tgcctgggtt gctgctgtcc agtgcctaca tcccgggcct
cagtgcccca ttctcactgc 9420tatctgggga gtgattaccc cgggagactg
aactgcaggg ttcaagcctt ccagggattt 9480gcctcacctt ggggccttga
tgactgcctt gcctcctcag tatgtggggg cttcatctct 9540ttagagaagt
ccaagcaaca gcctttgaat gtaaccaatc ctactaataa accagttctg
9600aaggtgttgt gtgtgcgcgt gtggagttgg cgggaagata ggaacaaaca
caaagccctt 9660tcatccttac ctcagaggct gggacttttg cccagagttc
tcctggtacg tcctttctgc 9720ttctgcctca atagttttca tttcacacag
aataaattgt ctcccaggaa caccaagaaa 9780cagagccaca atcttaaatt
cctatggttt gccccttcag ttaacagtag agcctgttta 9840tattgcatgg
cccctcccac ccctattatc aggaaagtat agaaagtcac taattctaca
9900actctcttgc aaaatgaaaa caaatgctcc atttaaaaaa aaaacaatcc
tttaataaaa 9960ttagtccatc taaaactccc caatgcctaa ggttctagtc
gtggaagggt tagctgcaga 10020attc 1002414361PRTHomo sapiens 14Met Ser
Gly Asn Gly Asn Ala Ala Ala Thr Ala Glu Glu Asn Ser Pro1 5 10 15Lys
Met Arg Val Ile Arg Val Gly Thr Arg Lys Ser Gln Leu Ala Arg 20 25
30Ile Gln Thr Asp Ser Val Val Ala Thr Leu Lys Ala Ser Tyr Pro Gly
35 40 45Leu Gln Phe Glu Ile Ile Ala Met Ser Thr Thr Gly Asp Lys Ile
Leu 50 55 60Asp Thr Ala Leu Ser Lys Ile Gly Glu Lys Ser Leu Phe Thr
Lys Glu65 70 75 80Leu Glu His Ala Leu Glu Lys Asn Glu Val Asp Leu
Val Val His Ser 85 90 95Leu Lys Asp Leu Pro Thr Val Leu Pro Pro Gly
Phe Thr Ile Gly Ala 100 105 110Ile Cys Lys Arg Glu Asn Pro His Asp
Ala Val Val Phe His Pro Lys 115 120 125Phe Val Gly Lys Thr Leu Glu
Thr Leu Pro Glu Lys Ser Val Val Gly 130 135 140Thr Ser Ser Leu Arg
Arg Ala Ala Gln Leu Gln Arg Lys Phe Pro His145 150 155 160Leu Glu
Phe Arg Ser Ile Arg Gly Asn Leu Asn Thr Arg Leu Arg Lys 165 170
175Met Asp Glu Gln Gln Glu Phe Ser Ala Ile Ile Leu Ala Thr Ala Gly
180 185 190Leu Gln Arg Met Gly Trp His Asn Arg Val Gly Gln Ile Leu
His Pro 195 200 205Glu Glu Cys Met Tyr Ala Val Gly Gln Gly Ala Leu
Gly Val Glu Val 210 215 220Arg Ala Lys Asp Gln Asp Ile Leu Asp Leu
Val Gly Val Leu His Asp225 230 235 240Pro Glu Thr Leu Leu Arg Cys
Ile Ala Glu Arg Ala Phe Leu Arg His 245 250 255Leu Glu Gly Gly Cys
Ser Val Pro Val Ala Val His Thr Ala Met Lys 260 265 270Asp Gly Gln
Leu Tyr Leu Thr Gly Gly Val Trp Ser Leu Asp Gly Ser 275 280 285Asp
Ser Ile Gln Glu Thr Met Gln Ala Thr Ile His Val Pro Ala Gln 290 295
300His Glu Asp Gly Pro Glu Asp Asp Pro Gln Leu Val Gly Ile Thr
Ala305 310 315 320Arg Asn Ile Pro Arg Gly Pro Gln Leu Ala Ala Gln
Asn Leu Gly Ile 325 330 335Ser Leu Ala Asn Leu Leu Leu Ser Lys Gly
Ala Lys Asn Ile Leu Asp 340 345 350Val Ala Arg Gln Leu Asn Asp Ala
His 355 36015344PRTHomo sapiens 15Met Arg Val Ile Arg Val Gly Thr
Arg Lys Ser Gln Leu Ala Arg Ile1 5 10 15Gln Thr Asp Ser Val Val Ala
Thr Leu Lys Ala Ser Tyr Pro Gly Leu 20 25 30Gln Phe Glu Ile Ile Ala
Met Ser Thr Thr Gly Asp Lys Ile Leu Asp 35 40 45Thr Ala Leu Ser Lys
Ile Gly Glu Lys Ser Leu Phe Thr Lys Glu Leu 50 55 60Glu His Ala Leu
Glu Lys Asn Glu Val Asp Leu Val Val His Ser Leu65 70 75 80Lys Asp
Leu Pro Thr Val Leu Pro Pro Gly Phe Thr Ile Gly Ala Ile 85 90 95Cys
Lys Arg Glu Asn Pro His Asp Ala Val Val Phe His Pro Lys Phe 100 105
110Val Gly Lys Thr Leu Glu Thr Leu Pro Glu Lys Ser Val Val Gly Thr
115 120 125Ser Ser Leu Arg Arg Ala Ala Gln Leu Gln Arg Lys Phe Pro
His Leu 130 135 140Glu Phe Arg Ser Ile Arg Gly Asn Leu Asn Thr Arg
Leu Arg Lys Met145 150 155 160Asp Glu Gln Gln Glu Phe Ser Ala Ile
Ile Leu Ala Thr Ala Gly Leu 165 170 175Gln Arg Met Gly Trp His Asn
Arg Val Gly Gln Ile Leu His Pro Glu 180 185 190Glu Cys Met Tyr Ala
Val Gly Gln Gly Ala Leu Gly Val Glu Val Arg 195 200 205Ala Lys Asp
Gln Asp Ile Leu Asp Leu Val Gly Val Leu His Asp Pro 210 215 220Glu
Thr Leu Leu Arg Cys Ile Ala Glu Arg Ala Phe Leu Arg His Leu225 230
235 240Glu Gly Gly Cys Ser Val Pro Val Ala Val His Thr Ala Met Lys
Asp 245 250 255Gly Gln Leu Tyr Leu Thr Gly Gly Val Trp Ser Leu Asp
Gly Ser Asp 260 265 270Ser Ile Gln Glu Thr Met Gln Ala Thr Ile His
Val Pro Ala Gln His 275 280 285Glu Asp Gly Pro Glu Asp Asp Pro Gln
Leu Val Gly Ile Thr Ala Arg 290 295 300Asn Ile Pro Arg Gly Pro Gln
Leu Ala Ala Gln Asn Leu Gly Ile Ser305 310 315 320Leu Ala Asn Leu
Leu Leu Ser Lys Gly Ala Lys Asn Ile Leu Asp Val 325 330 335Ala Arg
Gln Leu Asn Asp Ala His 340162022DNAHomo sapiens 16ccggtaccgg
ctcctcctgg gctccctcta gcgccttccc cccggcccga ctgcctggtc 60agcgccaagt
gacttacgcc cccgaccctg agcccggacc gctaggcgag gaggatcaga
120tctccgctcg agaatctgaa ggtgccctgg tcctggagga gttccgtccc
agccctgcgg 180tctcccggta ctgctcgccc cggccctctg gagcttcagg
aggcggccgt cagggtcggg 240gagtatttgg gtccggggtc tcagggaagg
gcggcgcctg ggtctgcggt atcggaaaga 300gcctgctgga gccaagtagc
cctccctctc ttgggacaga cccctcggtc ccatgtccat 360gggggcaccg
cggtccctcc tcctggccct ggctgctggc ctggccgttg cccgtccgcc
420caacatcgtg ctgatctttg ccgacgacct cggctatggg gacctgggct
gctatgggca 480ccccagctct accactccca acctggacca gctggcggcg
ggagggctgc ggttcacaga 540cttctacgtg cctgtgtctc tgtgcacacc
ctctagggcc gccctcctga ccggccggct 600cccggttcgg atgggcatgt
accctggcgt cctggtgccc agctcccggg ggggcctgcc 660cctggaggag
gtgaccgtgg ccgaagtcct ggctgcccga ggctacctca caggaatggc
720cggcaagtgg caccttgggg tggggcctga gggggccttc ctgccccccc
atcagggctt 780ccatcgattt ctaggcatcc cgtactccca cgaccagggc
ccctgccaga acctgacctg 840cttcccgccg gccactcctt gcgacggtgg
ctgtgaccag ggcctggtcc ccatcccact 900gttggccaac ctgtccgtgg
aggcgcagcc cccctggctg cccggactag aggcccgcta 960catggctttc
gcccatgacc tcatggccga cgcccagcgc caggatcgcc ccttcttcct
1020gtactatgcc tctcaccaca cccactaccc tcagttcagt gggcagagct
ttgcagagcg 1080ttcaggccgc gggccatttg gggactccct gatggagctg
gatgcagctg tggggaccct 1140gatgacagcc ataggggacc tggggctgct
tgaagagacg ctggtcatct tcactgcaga 1200caatggacct gagaccatgc
gtatgtcccg aggcggctgc tccggtctct tgcggtgtgg 1260aaagggaacg
acctacgagg gcggtgtccg agagcctgcc ttggccttct ggccaggtca
1320tatcgctccc ggcgtgaccc acgagctggc cagctccctg gacctgctgc
ctaccctggc 1380agccctggct ggggccccac tgcccaatgt caccttggat
ggctttgacc tcagccccct 1440gctgctgggc acaggcaaga gccctcggca
gtctctcttc ttctacccgt cctacccaga 1500cgaggtccgt ggggtttttg
ctgtgcggac tggaaagtac aaggctcact tcttcaccca 1560gggctctgcc
cacagtgata ccactgcaga ccctgcctgc cacgcctcca gctctctgac
1620tgctcatgag cccccgctgc
tctatgacct gtccaaggac cctggtgaga actacaacct 1680gctggggggt
gtggccgggg ccaccccaga ggtgctgcaa gccctgaaac agcttcagct
1740gctcaaggcc cagttagacg cagctgtgac cttcggcccc agccaggtgg
cccggggcga 1800ggaccccgcc ctgcagatct gctgtcatcc tggctgcacc
ccccgcccag cttgctgcca 1860ttgcccagat ccccatgcct gagggcccct
cggctggcct gggcatgtga tggctcctca 1920ctgggagcct gtgggggagg
ctcaggtgtc tggagggggt ttgtgcctga taacgtaata 1980acaccagtgg
agacttgcac atctgaaaaa aaaaaaaaaa aa 2022171524DNAHomo sapiens
17atgggggcac cgcggtccct cctcctggcc ctggctgctg gcctggccgt tgcacgtccg
60cccaacatcg tgctgatctt tgccgacgac ctcggctatg gggacctggg ctgctatggg
120caccccagct ctaccactcc caacctggac cagctggcgg cgggagggct
gcggttcaca 180gacttctacg tgcctgtgtc tctgtgcaca ccctctaggg
ccgccctcct gaccggccgg 240ctcccggttc ggatgggcat gtaccctggc
gtcctggtgc ccagctcccg ggggggcctg 300cccctggagg aggtgaccgt
ggccgaagtc ctggctgccc gaggctacct cacaggaatg 360gccggcaagt
ggcaccttgg ggtggggcct gagggggcct tcctgccccc ccatcagggc
420ttccatcgat ttctaggcat cccgtactcc cacgaccagg gcccctgcca
gaacctgacc 480tgcttcccgc cggccactcc ttgcgacggt ggctgtgacc
agggcctggt ccccatccca 540ctgttggcca acctgtccgt ggaggcgcag
cccccctggc tgcccggact agaggcccgc 600tacatggctt tcgcccatga
cctcatggcc gacgcccagc gccaggatcg ccccttcttc 660ctgtactatg
cctctcacca cacccactac cctcagttca gtgggcagag ctttgcagag
720cgttcaggcc gcgggccatt tggggactcc ctgatggagc tggatgcagc
tgtggggacc 780ctgatgacag ccatagggga cctggggctg cttgaagaga
cgctggtcat cttcactgca 840gacaatggac ctgagaccat gcgtatgtcc
cgaggcggct gctccggtct cttgcggtgt 900ggaaagggaa cgacctacga
gggcggtgtc cgagagcctg ccttggcctt ctggccaggt 960catatcgctc
ccggcgtgac ccacgagctg gccagctccc tggacctgct gcctaccctg
1020gcagccctgg ctggggcccc actgcccaat gtcaccttgg atggctttga
cctcagcccc 1080ctgctgctgg gcacaggcaa gagccctcgg cagtctctct
tcttctaccc gtcctaccca 1140gacgaggtcc gtggggtttt tgctgtgcgg
actggaaagt acaaggctca cttcttcacc 1200cagggctctg cccacagtga
taccactgca gaccctgcct gccacgcctc cagctctctg 1260actgctcatg
agcccccgct gctctatgac ctgtccaagg accctggtga gaactacaac
1320ctgctggggg gtgtggccgg ggccacccca gaggtgctgc aagccctgaa
acagcttcag 1380ctgctcaagg cccagttaga cgcagctgtg accttcggcc
ccagccaggt ggcccggggc 1440gaggaccccg ccctgcagat ctgctgtcat
cctggctgca ccccccgccc agcttgctgc 1500cattgcccag atccccatgc ctga
152418507PRTHomo sapiens 18Met Gly Ala Pro Arg Ser Leu Leu Leu Ala
Leu Ala Ala Gly Leu Ala1 5 10 15Val Ala Arg Pro Pro Asn Ile Val Leu
Ile Phe Ala Asp Asp Leu Gly 20 25 30Tyr Gly Asp Leu Gly Cys Tyr Gly
His Pro Ser Ser Thr Thr Pro Asn 35 40 45Leu Asp Gln Leu Ala Ala Gly
Gly Leu Arg Phe Thr Asp Phe Tyr Val 50 55 60Pro Val Ser Leu Cys Thr
Pro Ser Arg Ala Ala Leu Leu Thr Gly Arg65 70 75 80Leu Pro Val Arg
Met Gly Met Tyr Pro Gly Val Leu Val Pro Ser Ser 85 90 95Arg Gly Gly
Leu Pro Leu Glu Glu Val Thr Val Ala Glu Val Leu Ala 100 105 110Ala
Arg Gly Tyr Leu Thr Gly Met Ala Gly Lys Trp His Leu Gly Val 115 120
125Gly Pro Glu Gly Ala Phe Leu Pro Pro His Gln Gly Phe His Arg Phe
130 135 140Leu Gly Ile Pro Tyr Ser His Asp Gln Gly Pro Cys Gln Asn
Leu Thr145 150 155 160Cys Phe Pro Pro Ala Thr Pro Cys Asp Gly Gly
Cys Asp Gln Gly Leu 165 170 175Val Pro Ile Pro Leu Leu Ala Asn Leu
Ser Val Glu Ala Gln Pro Pro 180 185 190Trp Leu Pro Gly Leu Glu Ala
Arg Tyr Met Ala Phe Ala His Asp Leu 195 200 205Met Ala Asp Ala Gln
Arg Gln Asp Arg Pro Phe Phe Leu Tyr Tyr Ala 210 215 220Ser His His
Thr His Tyr Pro Gln Phe Ser Gly Gln Ser Phe Ala Glu225 230 235
240Arg Ser Gly Arg Gly Pro Phe Gly Asp Ser Leu Met Glu Leu Asp Ala
245 250 255Ala Val Gly Thr Leu Met Thr Ala Ile Gly Asp Leu Gly Leu
Leu Glu 260 265 270Glu Thr Leu Val Ile Phe Thr Ala Asp Asn Gly Pro
Glu Thr Met Arg 275 280 285Met Ser Arg Gly Gly Cys Ser Gly Leu Leu
Arg Cys Gly Lys Gly Thr 290 295 300Thr Tyr Glu Gly Gly Val Arg Glu
Pro Ala Leu Ala Phe Trp Pro Gly305 310 315 320His Ile Ala Pro Gly
Val Thr His Glu Leu Ala Ser Ser Leu Asp Leu 325 330 335Leu Pro Thr
Leu Ala Ala Leu Ala Gly Ala Pro Leu Pro Asn Val Thr 340 345 350Leu
Asp Gly Phe Asp Leu Ser Pro Leu Leu Leu Gly Thr Gly Lys Ser 355 360
365Pro Arg Gln Ser Leu Phe Phe Tyr Pro Ser Tyr Pro Asp Glu Val Arg
370 375 380Gly Val Phe Ala Val Arg Thr Gly Lys Tyr Lys Ala His Phe
Phe Thr385 390 395 400Gln Gly Ser Ala His Ser Asp Thr Thr Ala Asp
Pro Ala Cys His Ala 405 410 415Ser Ser Ser Leu Thr Ala His Glu Pro
Pro Leu Leu Tyr Asp Leu Ser 420 425 430Lys Asp Pro Gly Glu Asn Tyr
Asn Leu Leu Gly Gly Val Ala Gly Ala 435 440 445Thr Pro Glu Val Leu
Gln Ala Leu Lys Gln Leu Gln Leu Leu Lys Ala 450 455 460Gln Leu Asp
Ala Ala Val Thr Phe Gly Pro Ser Gln Val Ala Arg Gly465 470 475
480Glu Asp Pro Ala Leu Gln Ile Cys Cys His Pro Gly Cys Thr Pro Arg
485 490 495Pro Ala Cys Cys His Cys Pro Asp Pro His Ala 500
50519489PRTHomo sapiensMOD_RES(51)..(51)C-alpha Formylglycine 19Arg
Pro Pro Asn Ile Val Leu Ile Phe Ala Asp Asp Leu Gly Tyr Gly1 5 10
15Asp Leu Gly Cys Tyr Gly His Pro Ser Ser Thr Thr Pro Asn Leu Asp
20 25 30Gln Leu Ala Ala Gly Gly Leu Arg Phe Thr Asp Phe Tyr Val Pro
Val 35 40 45Ser Leu Xaa Thr Pro Ser Arg Ala Ala Leu Leu Thr Gly Arg
Leu Pro 50 55 60Val Arg Met Gly Met Tyr Pro Gly Val Leu Val Pro Ser
Ser Arg Gly65 70 75 80Gly Leu Pro Leu Glu Glu Val Thr Val Ala Glu
Val Leu Ala Ala Arg 85 90 95Gly Tyr Leu Thr Gly Met Ala Gly Lys Trp
His Leu Gly Val Gly Pro 100 105 110Glu Gly Ala Phe Leu Pro Pro His
Gln Gly Phe His Arg Phe Leu Gly 115 120 125Ile Pro Tyr Ser His Asp
Gln Gly Pro Cys Gln Asn Leu Thr Cys Phe 130 135 140Pro Pro Ala Thr
Pro Cys Asp Gly Gly Cys Asp Gln Gly Leu Val Pro145 150 155 160Ile
Pro Leu Leu Ala Asn Leu Ser Val Glu Ala Gln Pro Pro Trp Leu 165 170
175Pro Gly Leu Glu Ala Arg Tyr Met Ala Phe Ala His Asp Leu Met Ala
180 185 190Asp Ala Gln Arg Gln Asp Arg Pro Phe Phe Leu Tyr Tyr Ala
Ser His 195 200 205His Thr His Tyr Pro Gln Phe Ser Gly Gln Ser Phe
Ala Glu Arg Ser 210 215 220Gly Arg Gly Pro Phe Gly Asp Ser Leu Met
Glu Leu Asp Ala Ala Val225 230 235 240Gly Thr Leu Met Thr Ala Ile
Gly Asp Leu Gly Leu Leu Glu Glu Thr 245 250 255Leu Val Ile Phe Thr
Ala Asp Asn Gly Pro Glu Thr Met Arg Met Ser 260 265 270Arg Gly Gly
Cys Ser Gly Leu Leu Arg Cys Gly Lys Gly Thr Thr Tyr 275 280 285Glu
Gly Gly Val Arg Glu Pro Ala Leu Ala Phe Trp Pro Gly His Ile 290 295
300Ala Pro Gly Val Thr His Glu Leu Ala Ser Ser Leu Asp Leu Leu
Pro305 310 315 320Thr Leu Ala Ala Leu Ala Gly Ala Pro Leu Pro Asn
Val Thr Leu Asp 325 330 335Gly Phe Asp Leu Ser Pro Leu Leu Leu Gly
Thr Gly Lys Ser Pro Arg 340 345 350Gln Ser Leu Phe Phe Tyr Pro Ser
Tyr Pro Asp Glu Val Arg Gly Val 355 360 365Phe Ala Val Arg Thr Gly
Lys Tyr Lys Ala His Phe Phe Thr Gln Gly 370 375 380Ser Ala His Ser
Asp Thr Thr Ala Asp Pro Ala Cys His Ala Ser Ser385 390 395 400Ser
Leu Thr Ala His Glu Pro Pro Leu Leu Tyr Asp Leu Ser Lys Asp 405 410
415Pro Gly Glu Asn Tyr Asn Leu Leu Gly Gly Val Ala Gly Ala Thr Pro
420 425 430Glu Val Leu Gln Ala Leu Lys Gln Leu Gln Leu Leu Lys Ala
Gln Leu 435 440 445Asp Ala Ala Val Thr Phe Gly Pro Ser Gln Val Ala
Arg Gly Glu Asp 450 455 460Pro Ala Leu Gln Ile Cys Cys His Pro Gly
Cys Thr Pro Arg Pro Ala465 470 475 480Cys Cys His Cys Pro Asp Pro
His Ala 48520489PRTHomo sapiens 20Arg Pro Pro Asn Ile Val Leu Ile
Phe Ala Asp Asp Leu Gly Tyr Gly1 5 10 15Asp Leu Gly Cys Tyr Gly His
Pro Ser Ser Thr Thr Pro Asn Leu Asp 20 25 30Gln Leu Ala Ala Gly Gly
Leu Arg Phe Thr Asp Phe Tyr Val Pro Val 35 40 45Ser Leu Cys Thr Pro
Ser Arg Ala Ala Leu Leu Thr Gly Arg Leu Pro 50 55 60Val Arg Met Gly
Met Tyr Pro Gly Val Leu Val Pro Ser Ser Arg Gly65 70 75 80Gly Leu
Pro Leu Glu Glu Val Thr Val Ala Glu Val Leu Ala Ala Arg 85 90 95Gly
Tyr Leu Thr Gly Met Ala Gly Lys Trp His Leu Gly Val Gly Pro 100 105
110Glu Gly Ala Phe Leu Pro Pro His Gln Gly Phe His Arg Phe Leu Gly
115 120 125Ile Pro Tyr Ser His Asp Gln Gly Pro Cys Gln Asn Leu Thr
Cys Phe 130 135 140Pro Pro Ala Thr Pro Cys Asp Gly Gly Cys Asp Gln
Gly Leu Val Pro145 150 155 160Ile Pro Leu Leu Ala Asn Leu Ser Val
Glu Ala Gln Pro Pro Trp Leu 165 170 175Pro Gly Leu Glu Ala Arg Tyr
Met Ala Phe Ala His Asp Leu Met Ala 180 185 190Asp Ala Gln Arg Gln
Asp Arg Pro Phe Phe Leu Tyr Tyr Ala Ser His 195 200 205His Thr His
Tyr Pro Gln Phe Ser Gly Gln Ser Phe Ala Glu Arg Ser 210 215 220Gly
Arg Gly Pro Phe Gly Asp Ser Leu Met Glu Leu Asp Ala Ala Val225 230
235 240Gly Thr Leu Met Thr Ala Ile Gly Asp Leu Gly Leu Leu Glu Glu
Thr 245 250 255Leu Val Ile Phe Thr Ala Asp Asn Gly Pro Glu Thr Met
Arg Met Ser 260 265 270Arg Gly Gly Cys Ser Gly Leu Leu Arg Cys Gly
Lys Gly Thr Thr Tyr 275 280 285Glu Gly Gly Val Arg Glu Pro Ala Leu
Ala Phe Trp Pro Gly His Ile 290 295 300Ala Pro Gly Val Thr His Glu
Leu Ala Ser Ser Leu Asp Leu Leu Pro305 310 315 320Thr Leu Ala Ala
Leu Ala Gly Ala Pro Leu Pro Asn Val Thr Leu Asp 325 330 335Gly Phe
Asp Leu Ser Pro Leu Leu Leu Gly Thr Gly Lys Ser Pro Arg 340 345
350Gln Ser Leu Phe Phe Tyr Pro Ser Tyr Pro Asp Glu Val Arg Gly Val
355 360 365Phe Ala Val Arg Thr Gly Lys Tyr Lys Ala His Phe Phe Thr
Gln Gly 370 375 380Ser Ala His Ser Asp Thr Thr Ala Asp Pro Ala Cys
His Ala Ser Ser385 390 395 400Ser Leu Thr Ala His Glu Pro Pro Leu
Leu Tyr Asp Leu Ser Lys Asp 405 410 415Pro Gly Glu Asn Tyr Asn Leu
Leu Gly Gly Val Ala Gly Ala Thr Pro 420 425 430Glu Val Leu Gln Ala
Leu Lys Gln Leu Gln Leu Leu Lys Ala Gln Leu 435 440 445Asp Ala Ala
Val Thr Phe Gly Pro Ser Gln Val Ala Arg Gly Glu Asp 450 455 460Pro
Ala Leu Gln Ile Cys Cys His Pro Gly Cys Thr Pro Arg Pro Ala465 470
475 480Cys Cys His Cys Pro Asp Pro His Ala 485211011PRTHomo sapiens
21Met Gly Ala Tyr Ala Arg Ala Ser Gly Val Cys Ala Arg Gly Cys Leu1
5 10 15Asp Ser Ala Gly Pro Trp Thr Met Ser Arg Ala Leu Arg Pro Pro
Leu 20 25 30Pro Pro Leu Cys Phe Phe Leu Leu Leu Leu Ala Ala Ala Gly
Ala Arg 35 40 45Ala Gly Gly Tyr Glu Thr Cys Pro Thr Val Gln Pro Asn
Met Leu Asn 50 55 60Val His Leu Leu Pro His Thr His Asp Asp Val Gly
Trp Leu Lys Thr65 70 75 80Val Asp Gln Tyr Phe Tyr Gly Ile Lys Asn
Asp Ile Gln His Ala Gly 85 90 95Val Gln Tyr Ile Leu Asp Ser Val Ile
Ser Ala Leu Leu Ala Asp Pro 100 105 110Thr Arg Arg Phe Ile Tyr Val
Glu Ile Ala Phe Phe Ser Arg Trp Trp 115 120 125His Gln Gln Thr Asn
Ala Thr Gln Glu Val Val Arg Asp Leu Val Arg 130 135 140Gln Gly Arg
Leu Glu Phe Ala Asn Gly Gly Trp Val Met Asn Asp Glu145 150 155
160Ala Ala Thr His Tyr Gly Ala Ile Val Asp Gln Met Thr Leu Gly Leu
165 170 175Arg Phe Leu Glu Asp Thr Phe Gly Asn Asp Gly Arg Pro Arg
Val Ala 180 185 190Trp His Ile Asp Pro Phe Gly His Ser Arg Glu Gln
Ala Ser Leu Phe 195 200 205Ala Gln Met Gly Phe Asp Gly Phe Phe Phe
Gly Arg Leu Asp Tyr Gln 210 215 220Asp Lys Trp Val Arg Met Gln Lys
Leu Glu Met Glu Gln Val Trp Arg225 230 235 240Ala Ser Thr Ser Leu
Lys Pro Pro Thr Ala Asp Leu Phe Thr Gly Val 245 250 255Leu Pro Asn
Gly Tyr Asn Pro Pro Arg Asn Leu Cys Trp Asp Val Leu 260 265 270Cys
Val Asp Gln Pro Leu Val Glu Asp Pro Arg Ser Pro Glu Tyr Asn 275 280
285Ala Lys Glu Leu Val Asp Tyr Phe Leu Asn Val Ala Thr Ala Gln Gly
290 295 300Arg Tyr Tyr Arg Thr Asn His Thr Val Met Thr Met Gly Ser
Asp Phe305 310 315 320Gln Tyr Glu Asn Ala Asn Met Trp Phe Lys Asn
Leu Asp Lys Leu Ile 325 330 335Arg Leu Val Asn Ala Gln Gln Ala Lys
Gly Ser Ser Val His Val Leu 340 345 350Tyr Ser Thr Pro Ala Cys Tyr
Leu Trp Glu Leu Asn Lys Ala Asn Leu 355 360 365Thr Trp Ser Val Lys
His Asp Asp Phe Phe Pro Tyr Ala Asp Gly Pro 370 375 380His Gln Phe
Trp Thr Gly Tyr Phe Ser Ser Arg Pro Ala Leu Lys Arg385 390 395
400Tyr Glu Arg Leu Ser Tyr Asn Phe Leu Gln Val Cys Asn Gln Leu Glu
405 410 415Ala Leu Val Gly Leu Ala Ala Asn Val Gly Pro Tyr Gly Ser
Gly Asp 420 425 430Ser Ala Pro Leu Asn Glu Ala Met Ala Val Leu Gln
His His Asp Ala 435 440 445Val Ser Gly Thr Ser Arg Gln His Val Ala
Asn Asp Tyr Ala Arg Gln 450 455 460Leu Ala Ala Gly Trp Gly Pro Cys
Glu Val Leu Leu Ser Asn Ala Leu465 470 475 480Ala Arg Leu Arg Gly
Phe Lys Asp His Phe Thr Phe Cys Gln Gln Leu 485 490 495Asn Ile Ser
Ile Cys Pro Leu Ser Gln Thr Ala Ala Arg Phe Gln Val 500 505 510Ile
Val Tyr Asn Pro Leu Gly Arg Lys Val Asn Trp Met Val Arg Leu 515 520
525Pro Val Ser Glu Gly Val Phe Val Val Lys Asp Pro Asn Gly Arg Thr
530 535 540Val Pro Ser Asp Val Val Ile Phe Pro Ser Ser Asp Ser Gln
Ala His545 550 555 560Pro Pro Glu Leu Leu Phe Ser Ala Ser Leu Pro
Ala Leu Gly Phe Ser 565 570 575Thr Tyr Ser Val Ala Gln Val Pro Arg
Trp Lys Pro Gln Ala Arg Ala 580 585 590Pro Gln Pro Ile Pro Arg Arg
Ser Trp Ser Pro Ala Leu Thr Ile Glu 595 600 605Asn Glu His Ile Arg
Ala Thr Phe Asp Pro Asp Thr Gly Leu Leu Met 610 615 620Glu Ile Met
Asn Met Asn Gln Gln Leu Leu Leu Pro Val Arg Gln Thr625 630 635
640Phe Phe Trp Tyr Asn Ala Ser Ile Gly Asp Asn Glu Ser Asp Gln
Ala
645 650 655Ser Gly Ala Tyr Ile Phe Arg Pro Asn Gln Gln Lys Pro Leu
Pro Val 660 665 670Ser Arg Trp Ala Gln Ile His Leu Val Lys Thr Pro
Leu Val Gln Glu 675 680 685Val His Gln Asn Phe Ser Ala Trp Cys Ser
Gln Val Val Arg Leu Tyr 690 695 700Pro Gly Gln Arg His Leu Glu Leu
Glu Trp Ser Val Gly Pro Ile Pro705 710 715 720Val Gly Asp Thr Trp
Gly Lys Glu Val Ile Ser Arg Phe Asp Thr Pro 725 730 735Leu Glu Thr
Lys Gly Arg Phe Tyr Thr Asp Ser Asn Gly Arg Glu Ile 740 745 750Leu
Glu Arg Arg Arg Asp Tyr Arg Pro Thr Trp Lys Leu Asn Gln Thr 755 760
765Glu Pro Val Ala Gly Asn Tyr Tyr Pro Val Asn Thr Arg Ile Tyr Ile
770 775 780Thr Asp Gly Asn Met Gln Leu Thr Val Leu Thr Asp Arg Ser
Gln Gly785 790 795 800Gly Ser Ser Leu Arg Asp Gly Ser Leu Glu Leu
Met Val His Arg Arg 805 810 815Leu Leu Lys Asp Asp Gly Arg Gly Val
Ser Glu Pro Leu Met Glu Asn 820 825 830Gly Ser Gly Ala Trp Val Arg
Gly Arg His Leu Val Leu Leu Asp Thr 835 840 845Ala Gln Ala Ala Ala
Ala Gly His Arg Leu Leu Ala Glu Gln Glu Val 850 855 860Leu Ala Pro
Gln Val Val Leu Ala Pro Gly Gly Gly Ala Ala Tyr Asn865 870 875
880Leu Gly Ala Pro Pro Arg Thr Gln Phe Ser Gly Leu Arg Arg Asp Leu
885 890 895Pro Pro Ser Val His Leu Leu Thr Leu Ala Ser Trp Gly Pro
Glu Met 900 905 910Val Leu Leu Arg Leu Glu His Gln Phe Ala Val Gly
Glu Asp Ser Gly 915 920 925Arg Asn Leu Ser Ala Pro Val Thr Leu Asn
Leu Arg Asp Leu Phe Ser 930 935 940Thr Phe Thr Ile Thr Arg Leu Gln
Glu Thr Thr Leu Val Ala Asn Gln945 950 955 960Leu Arg Glu Ala Ala
Ser Arg Leu Lys Trp Thr Thr Asn Thr Gly Pro 965 970 975Thr Pro His
Gln Thr Pro Tyr Gln Leu Asp Pro Ala Asn Ile Thr Leu 980 985 990Glu
Pro Met Glu Ile Arg Thr Phe Leu Ala Ser Val Gln Trp Lys Glu 995
1000 1005Val Asp Gly 1010228079DNAArtificial SequenceDescription of
Artificial Sequence Synthetic expression plasmid pLamanExp1
22agatcttcaa tattggccat tagccatatt attcattggt tatatagcat aaatcaatat
60tggctattgg ccattgcata cgttgtatct atatcataat atgtacattt atattggctc
120atgtccaata tgaccgccat gttggcattg attattgact agttattaat
agtaatcaat 180tacggggtca ttagttcata gcccatatat ggagttccgc
gttacataac ttacggtaaa 240tggcccgcct ggctgaccgc ccaacgaccc
ccgcccattg acgtcaataa tgacgtatgt 300tcccatagta acgccaatag
ggactttcca ttgacgtcaa tgggtggagt atttacggta 360aactgcccac
ttggcagtac atcaagtgta tcatatgcca agtccgcccc ctattgacgt
420caatgacggt aaatggcccg cctggcatta tgcccagtac atgaccttac
gggactttcc 480tacttggcag tacatctacg tattagtcat cgctattacc
atggtgatgc ggttttggca 540gtacaccaat gggcgtggat agcggtttga
ctcacgggga tttccaagtc tccaccccat 600tgacgtcaat gggagtttgt
tttggcacca aaatcaacgg gactttccaa aatgtcgtaa 660caactgcgat
cgcccgcccc gttgacgcaa atgggcggta ggcgtgtacg gtgggaggtc
720tatataagca gagctcgttt agtgaaccgt cagatcacta gaagctttat
tgcggtagtt 780tatcacagtt aaattgctaa cgcagtcagt gcttctgaca
caacagtctc gaacttaagc 840tgcagtgact ctcttaaggt agccttgcag
aagttggtcg tgaggcactg ggcaggtaag 900tatcaaggtt acaagacagg
tttaaggaga ccaatagaaa ctgggcttgt cgagacagag 960aagactcttg
cgtttctgat aggcacctat tggtcttact gacatccact ttgcctttct
1020ctccacaggt gtccactccc agttcaatta cagctcttaa ggctagagta
cttaatacga 1080ctcactatag gctagcctcg agaattcgcc gccatgggcg
cctacgcgcg ggcttcgggg 1140gtctgcgctc gaggctgcct ggactcagca
ggcccctgga ccatgtcccg cgccctgcgg 1200ccaccgctcc cgcctctctg
ctttttcctt ttgttgctgg cggctgccgg tgctcgggcc 1260gggggatacg
agacatgccc cacagtgcag ccgaacatgc tgaacgtgca cctgctgcct
1320cacacacatg atgacgtggg ctggctcaaa accgtggacc agtactttta
tggaatcaag 1380aatgacatcc agcacgccgg tgtgcagtac atcctggact
cggtcatctc tgccttgctg 1440gcagatccca cccgtcgctt catttacgtg
gagattgcct tcttctcccg ttggtggcac 1500cagcagacaa atgccacaca
ggaagtcgtg cgagaccttg tgcgccaggg gcgcctggag 1560ttcgccaatg
gtggctgggt gatgaacgat gaggcagcca cccactacgg tgccatcgtg
1620gaccagatga cacttgggct gcgctttctg gaggacacat ttggcaatga
tgggcgaccc 1680cgtgtggcct ggcacattga ccccttcggc cactctcggg
agcaggcctc gctgtttgcg 1740cagatgggct tcgacggctt cttctttggg
cgccttgatt atcaagataa gtgggtacgg 1800atgcagaagc tggagatgga
gcaggtgtgg cgggccagca ccagcctgaa gcccccgacc 1860gcggacctct
tcactggtgt gcttcccaat ggttacaacc cgccaaggaa tctgtgctgg
1920gatgtgctgt gtgtcgatca gccgctggtg gaggaccctc gcagccccga
gtacaacgcc 1980aaggagctgg tcgattactt cctaaatgtg gccactgccc
agggccggta ttaccgcacc 2040aaccacactg tgatgaccat gggctcggac
ttccaatatg agaatgccaa catgtggttc 2100aagaaccttg acaagctcat
ccggctggta aatgcgcagc aggcaaaagg aagcagtgtc 2160catgttctct
actccacccc cgcttgttac ctctgggagc tgaacaaggc caacctcacc
2220tggtcagtga aacatgacga cttcttccct tacgcggatg gcccccacca
gttctggacc 2280ggttactttt ccagtcggcc ggccctcaaa cgctacgagc
gcctcagcta caacttcctg 2340caggtgtgca accagctgga ggcgctggtg
ggcctggcgg ccaacgtggg accctatggc 2400tccggagaca gtgcacccct
caatgaggcg atggctgtgc tccagcatca cgacgccgtc 2460agcggcacct
cccgccagca cgtggccaac gactacgcgc gccagcttgc ggcaggctgg
2520gggccttgcg aggttcttct gagcaacgcg ctggcgcggc tcagaggctt
caaagatcac 2580ttcacctttt gccaacagct aaacatcagc atctgcccgc
tcagccagac ggcggcgcgc 2640ttccaggtca tcgtttataa tcccctgggg
cggaaggtga attggatggt acggctgccg 2700gtcagcgaag gcgttttcgt
tgtgaaggac cccaatggca ggacagtgcc cagcgatgtg 2760gtaatatttc
ccagctcaga cagccaggcg caccctccgg agctgctgtt ctcagcctca
2820ctgcccgccc tgggcttcag cacctattca gtagcccagg tgcctcgctg
gaagccccag 2880gcccgcgcac cacagcccat ccccagaaga tcctggtccc
ctgctttaac catcgaaaat 2940gagcacatcc gggcaacgtt tgatcctgac
acagggctgt tgatggagat tatgaacatg 3000aatcagcaac tcctgctgcc
tgttcgccag accttcttct ggtacaacgc cagtataggt 3060gacaacgaaa
gtgaccaggc ctcaggtgcc tacatcttca gacccaacca acagaaaccg
3120ctgcctgtga gccgctgggc tcagatccac ctggtgaaga cacccttggt
gcaggaggtg 3180caccagaact tctcagcttg gtgttcccag gtggttcgcc
tgtacccagg acagcggcac 3240ctggagctag agtggtcggt ggggccgata
cctgtgggcg acacctgggg gaaggaggtc 3300atcagccgtt ttgacacacc
gctggagaca aagggacgct tctacacaga cagcaatggc 3360cgggagatcc
tggagaggag gcgggattat cgacccacct ggaaactgaa ccagacggag
3420cccgtggcag gaaactacta tccagtcaac acccggattt acatcacgga
tggaaacatg 3480cagctgactg tgctgactga ccgctcccag gggggcagca
gcctgagaga tggctcgctg 3540gagctcatgg tgcaccgaag gctgctgaag
gacgatggac gcggagtatc ggagccacta 3600atggagaacg ggtcgggggc
gtgggtgcga gggcgccacc tggtgctgct ggacacagcc 3660caggctgcag
ccgccggaca ccggctcctg gcggagcagg aggtcctggc ccctcaggtg
3720gtgctggccc cgggtggcgg cgccgcctac aatctcgggg ctcctccgcg
cacgcagttc 3780tcagggctgc gcagggacct gccgccctcg gtgcacctgc
tcacgctggc cagctggggc 3840cccgaaatgg tgctgctgcg cttggagcac
cagtttgccg taggagagga ttccggacgt 3900aacctgagcg cccccgttac
cttgaacttg agggacctgt tctccacctt caccatcacc 3960cgcctgcagg
agaccacgct ggtggccaac cagctccgcg aggcagcctc caggctcaag
4020tggacaacaa acacaggccc cacaccccac caaactccgt accagctgga
cccggccaac 4080atcacgctgg aacccatgga aatccgcact ttcctggcct
cagttcaatg gaaggaggtg 4140gatggttagg tctgctggga tgggccctct
agagtcgacc cgggcggccg cttcccttta 4200gtgagggtta atgcttcgag
cagacatgat aagatacatt gatgagtttg gacaaaccac 4260aactagaatg
cagtgaaaaa aatgctttat ttgtgaaatt tgtgatgcta ttgctttatt
4320tgtaaccatt ataagctgca ataaacaagt taacaacaac aattgcattc
attttatgtt 4380tcaggttcag ggggagatgt gggaggtttt ttaaagcaag
taaaacctct acaaatgtgg 4440taaaatccga taaggatcga tccgggctgg
cgtaatagcg aagaggcccg caccgatcgc 4500ccttcccaac agttgcgcag
cctgaatggc gaatggacgc gccctgtagc ggcgcattaa 4560gcgcggcggg
tgtggtggtt acgcgcagcg tgaccgctac acttgccagc gccctagcgc
4620ccgctccttt cgctttcttc ccttcctttc tcgccacgtt cgccggcttt
ccccgtcaag 4680ctctaaatcg ggggctccct ttagggttcc gatttagagc
tttacggcac ctcgaccgca 4740aaaaacttga tttgggtgat ggttcacgta
gtgggccatc gccctgatag acggtttttc 4800gccctttgac gttggagtcc
acgttcttta atagtggact cttgttccaa actggaacaa 4860cactcaaccc
tatctcggtc tattcttttg atttataagg gattttgggg atttcggcct
4920attggttaaa aaatgagctg atttaacaaa aatttaacgc gaattaattc
tgtggaatgt 4980gtgtcagtta gggtgtggaa agtccccagg ctccccaggc
aggcagaagt atgcaaagca 5040tgcatctcaa ttagtcagca accaggtgtg
gaaagtcccc aggctcccca gcaggcagaa 5100gtatgcaaag catgcatctc
aattagtcag caaccatagt cccgccccta actccgccca 5160tcccgcccct
aactccgccc agttccgccc attctccgcc ccatggctga ctaatttttt
5220ttatttatgc agaggccgag gccgcctctg cctctgagct attccagaag
tagtgaggag 5280gcttttttgg aggcctaggc ttttgcaaaa agctcccggg
atggttcgac cattgaactg 5340catcgtcgcc gtgtcccaaa atatggggat
tggcaagaac ggagacctac cctggcctcc 5400gctcaggaac gagttcaagt
acttccaaag aatgaccaca acctcttcag tggaaggtaa 5460acagaatctg
gtgattatgg gtaggaaaac ctggttctcc attcctgaga agaatcgacc
5520tttaaaggac agaattaata tagttctcag tagagaactc aaagaaccac
cacgaggagc 5580tcattttctt gccaaaagtt tggatgatgc cttaagactt
attgaacaac cggaattggc 5640aagtaaagta gacatggttt ggatagtcgg
aggcagttct gtttaccagg aagccatgaa 5700tcaaccaggc caccttagac
tctttgtgac aaggatcatg caggaatttg aaagtgacac 5760gtttttccca
gaaattgatt tggggaaata taaacttctc ccagaatacc caggcgtcct
5820ctctgaggtc caggaggaaa aaggcatcaa gtataagttt gaagtctacg
agaagaaaga 5880ctaattcgaa atgaccgacc aagcgacgcc caacctgcca
tcacgatggc cgcaataaaa 5940tatctttatt ttcattacat ctgtgtgttg
gttttttgtg tgaatcgata gcgataagga 6000tccgcgtatg gtgcactctc
agtacaatct gctctgatgc cgcatagtta agccagcccc 6060gacacccgcc
aacacccgct gacgcgccct gacgggcttg tctgctcccg gcatccgctt
6120acagacaagc tgtgaccgtc tccgggagct gcatgtgtca gaggttttca
ccgtcatcac 6180cgaaacgcgc gagacgaaag ggcctcgtga tacgcctatt
tttataggtt aatgtcatga 6240taataatggt ttcttagacg tcaggtggca
cttttcgggg aaatgtgcgc ggaaccccta 6300tttgtttatt tttctaaata
cattcaaata tgtatccgct catgagacaa taaccctgat 6360aaatgcttca
ataatattga aaaaggaaga gtatgagtat tcaacatttc cgtgtcgccc
6420ttattccctt ttttgcggca ttttgccttc ctgtttttgc tcacccagaa
acgctggtga 6480aagtaaaaga tgctgaagat cagttgggtg cacgagtggg
ttacatcgaa ctggatctca 6540acagcggtaa gatccttgag agttttcgcc
ccgaagaacg ttttccaatg atgagcactt 6600ttaaagttct gctatgtggc
gcggtattat cccgtattga cgccgggcaa gagcaactcg 6660gtcgccgcat
acactattct cagaatgact tggttgagta ctcaccagtc acagaaaagc
6720atcttacgga tggcatgaca gtaagagaat tatgcagtgc tgccataacc
atgagtgata 6780acactgcggc caacttactt ctgacaacga tcggaggacc
gaaggagcta accgcttttt 6840tgcacaacat gggggatcat gtaactcgcc
ttgatcgttg ggaaccggag ctgaatgaag 6900ccataccaaa cgacgagcgt
gacaccacga tgcctgtagc aatggcaaca acgttgcgca 6960aactattaac
tggcgaacta cttactctag cttcccggca acaattaata gactggatgg
7020aggcggataa agttgcagga ccacttctgc gctcggccct tccggctggc
tggtttattg 7080ctgataaatc tggagccggt gagcgtgggt ctcgcggtat
cattgcagca ctggggccag 7140atggtaagcc ctcccgtatc gtagttatct
acacgacggg gagtcaggca actatggatg 7200aacgaaatag acagatcgct
gagataggtg cctcactgat taagcattgg taactgtcag 7260accaagttta
ctcatatata ctttagattg atttaaaact tcatttttaa tttaaaagga
7320tctaggtgaa gatccttttt gataatctca tgaccaaaat cccttaacgt
gagttttcgt 7380tccactgagc gtcagacccc gtagaaaaga tcaaaggatc
ttcttgagat cctttttttc 7440tgcgcgtaat ctgctgcttg caaacaaaaa
aaccaccgct accagcggtg gtttgtttgc 7500cggatcaaga gctaccaact
ctttttccga aggtaactgg cttcagcaga gcgcagatac 7560caaatactgt
ccttctagtg tagccgtagt taggccacca cttcaagaac tctgtagcac
7620cgcctacata cctcgctctg ctaatcctgt taccagtggc tgctgccagt
ggcgataagt 7680cgtgtcttac cgggttggac tcaagacgat agttaccgga
taaggcgcag cggtcgggct 7740gaacgggggg ttcgtgcaca cagcccagct
tggagcgaac gacctacacc gaactgagat 7800acctacagcg tgagctatga
gaaagcgcca cgcttcccga agggagaaag gcggacaggt 7860atccggtaag
cggcagggtc ggaacaggag agcgcacgag ggagcttcca gggggaaacg
7920cctggtatct ttatagtcct gtcgggtttc gccacctctg acttgagcgt
cgatttttgt 7980gatgctcgtc aggggggcgg agcctatgga aaaacgccag
caacgcggcc tttttacggt 8040tcctggcctt ttgctggcct tttgctcaca
tggctcgac 8079233761DNAHomo sapiens 23ggctactctc ggcttcctgg
caacgccgag cgaaagctat gactgcggcc gcgggttcgg 60cgggccgcgc cgcggtgccc
ttgctgctgt gtgcgctgct ggcgcccggc ggcgcgtacg 120tgctcgacga
ctccgacggg ctgggccggg agttcgacgg catcggcgcg gtcagcggcg
180gcggggcaac ctcccgactt ctagtaaatt acccagagcc ctatcgttct
cagatattgg 240attatctctt taagccgaat tttggtgcct ctttgcatat
tttaaaagtg gaaataggtg 300gtgatgggca gacaacagac ggcactgagc
cctcccacat gcattatgca ctagatgaga 360attatttccg aggatacgag
tggtggttga tgaaagaagc taagaagagg aatcccaata 420ttacactcat
tgggttgcca tggtcattcc ctggatggct gggaaaaggt ttcgactggc
480cttatgtcaa tcttcagctg actgcctatt atgtcgtgac ctggattgtg
ggcgccaagc 540gttaccatga tttggacatt gattatattg gaatttggaa
tgagaggtca tataatgcca 600attatattaa gatattaaga aaaatgctga
attatcaagg tctccagcga gtgaaaatca 660tagcaagtga taatctctgg
gagtccatct ctgcatccat gctccttgat gccgaactct 720tcaaggtggt
tgatgttata ggggctcatt atcctggaac ccattcagca aaagatgcaa
780agttgactgg gaagaagctt tggtcttctg aagactttag cactttaaat
agtgacatgg 840gtgcaggctg ctggggtcgc attttaaatc agaattatat
caatggctat atgacttcca 900caatcgcatg gaatttagtg gctagttact
atgaacagtt gccttatggg agatgcgggt 960tgatgacggc ccaagagcca
tggagtgggc actacgtggt agaatctcct gtctgggtat 1020cagctcatac
cactcagttt actcaacctg gctggtatta cctgaagaca gttggccatt
1080tagagaaagg aggaagctac gtagctctga ctgatggctt agggaacctc
accatcatca 1140ttgaaaccat gagtcataaa cattctaagt gcatacggcc
atttcttcct tatttcaatg 1200tgtcacaaca atttgccacc tttgttctta
agggatcttt tagtgaaata ccagagctac 1260aggtatggta taccaaactt
ggaaaaacat ccgaaagatt tctttttaag cagctggatt 1320ctctatggct
ccttgacagc gatggcagtt tcacactgag cctgcatgaa gatgagctgt
1380tcacactcac cactctcacc actggtcgca aaggcagcta cccgcttcct
ccaaaatccc 1440agcccttccc aagtacctat aaggatgatt tcaatgttga
ttacccattt tttagtgaag 1500ctccaaactt tgctgatcaa actggtgtat
ttgaatattt tacaaatatt gaagaccctg 1560gcgagcatca cttcacgcta
cgccaagttc tcaaccagag acccattacg tgggctgccg 1620atgcatccaa
cacaatcagt attataggag actacaactg gaccaatctg actataaagt
1680gtgatgttta catagagacc cctgacacag gaggtgtgtt cattgcagga
agagtaaata 1740aaggtggtat tttgattaga agtgccagag gaattttctt
ctggattttt gcaaatggat 1800cttacagggt tacaggtgat ttagctggat
ggattatata tgctttagga cgtgttgaag 1860ttacagcaaa aaaatggtat
acactcacgt taactattaa gggtcatttc gcctctggca 1920tgctgaatga
caagtctctg tggacagaca tccctgtgaa ttttccaaag aatggctggg
1980ctgcaattgg aactcactcc tttgaatttg cacagtttga caactttctt
gtggaagcca 2040cacgctaata cttaacaggg catcatagaa tactctggat
tttcttccct tctttttggt 2100tttggttcag agccaattct tgtttcattg
gaacagtata tgaggctttt gagactaaaa 2160ataatgaaga gtaaaagggg
agagaaattt atttttaatt taccctgtgg aagattttat 2220tagaattaat
tccaagggga aaactggtga atctttaaca ttacctggtg tgttccctaa
2280cattcaaact gtgcattggc cataccctta ggagtggttt gagtagtaca
gacctcgaag 2340ccttgctgct aacactgagg tagctctctt catcttattt
gcaagcggtc ctgtagatgg 2400cagtaacttg atcatcactg agatgtattt
atgcatgctg accgtgtgtc caagtgagcc 2460agtgtcttca tcacaagatg
atgctgccat aatagaaagc tgaagaacac tagaagtagc 2520tttttgaaaa
ccacttcaac ctgttatgct ttatgctcta aaaagtattt ttttattttc
2580ctttttaaga tgatactttt gaaatgcagg atatgatgag tgggatgatt
ttaaaaacgc 2640ctctttaata aactacctct aacactattt ctgcggtaat
agatattagc agattaattg 2700ggttatttgc attatttaat ttttttgatt
ccaagttttg gtcttgtaac cactataact 2760ctctgtgaac gtttttccag
gtggctggaa gaaggaagaa aacctgatat agccaatgct 2820gttgtagtcg
tttcctcagc ctcatctcac tgtgctgtgg tctgtcctca catgtgcact
2880ggtaacagac tcacacagct gatgaatgct tttctctcct tatgtgtgga
aggaggggag 2940cacttagaca tttgctaact cccagaattg gatcatctcc
taagatgtac ttacttttta 3000aagtccaaat atgtttatat ttaaatatac
gtgagcatgt tcatcatgtt gtatgattta 3060tactaagcat taatgtggct
ctatgtagca aatcagttat tcatgtaggt aaagtaaatc 3120tagaattatt
tataagaatt actcattgaa ctaattctac tatttaggaa tttataagag
3180tctaacatag gcttagctac agtgaagttt tgcattgctt ttgaagacaa
gaaaagtgct 3240agaataaata agattacaga gaaaattttt tgttaaaacc
aagtgatttc cagctgatgt 3300atctaatatt ttttaaaaca aacattatag
aggtgtaatt tatttacaat aaaatgttcc 3360tactttaaat atacaattca
gtgagttttg ataaattgat atacccatgt aaccaacact 3420ccagtcaagc
ttcagaatat ttccatcacc ccagaaggtt ctcttgtata cctgctcagt
3480cagttccttt cactcccaat tgttggcagc cattgatagg aattctatca
ctataggtta 3540gttttctttg ttccagaaca tcatgaaagc ggcgtcatgt
actgtgtatt cttatgaatg 3600gtttctttcc atcagcataa tgatttgaga
ttggtccatg ttgtgtgatt cagtggtttg 3660ttccttctta tttctgaaga
gttttccatt gtatgaatat accacaattt gtttcctccc 3720caccagtttc
tgatactaca attaaaactg tctacattta c 376124669PRTHomo sapiens 24Met
Thr Ala Ala Ala Gly Ser Ala Gly Arg Ala Ala Val Pro Leu Leu1 5 10
15Leu Cys Ala Leu Leu Ala Pro Gly Gly Ala Tyr Val Leu Asp Asp Ser
20 25 30Asp Gly Leu Gly Arg Glu Phe Asp Gly Ile Gly Ala Val Ser Gly
Gly 35 40 45Gly Ala Thr Ser Arg Leu Leu Val Asn Tyr Pro Glu Pro Tyr
Arg Ser 50 55 60Gln Ile Leu Asp Tyr Leu Phe Lys Pro Asn Phe Gly Ala
Ser Leu His65 70 75 80Ile Leu Lys Val Glu Ile Gly Gly Asp Gly Gln
Thr Thr Asp Gly Thr 85 90 95Glu Pro Ser His Met His Tyr Ala Leu Asp
Glu Asn Tyr Phe Arg Gly 100 105 110Tyr Glu Trp Trp Leu Met Lys Glu
Ala Lys Lys Arg Asn Pro Asn Ile 115 120 125Thr Leu Ile Gly Leu Pro
Trp Ser Phe Pro Gly Trp Leu Gly
Lys Gly 130 135 140Phe Asp Trp Pro Tyr Val Asn Leu Gln Leu Thr Ala
Tyr Tyr Val Val145 150 155 160Thr Trp Ile Val Gly Ala Lys Arg Tyr
His Asp Leu Asp Ile Asp Tyr 165 170 175Ile Gly Ile Trp Asn Glu Arg
Ser Tyr Asn Ala Asn Tyr Ile Lys Ile 180 185 190Leu Arg Lys Met Leu
Asn Tyr Gln Gly Leu Gln Arg Val Lys Ile Ile 195 200 205Ala Ser Asp
Asn Leu Trp Glu Ser Ile Ser Ala Ser Met Leu Leu Asp 210 215 220Ala
Glu Leu Phe Lys Val Val Asp Val Ile Gly Ala His Tyr Pro Gly225 230
235 240Thr His Ser Ala Lys Asp Ala Lys Leu Thr Gly Lys Lys Leu Trp
Ser 245 250 255Ser Glu Asp Phe Ser Thr Leu Asn Ser Asp Met Gly Ala
Gly Cys Trp 260 265 270Gly Arg Ile Leu Asn Gln Asn Tyr Ile Asn Gly
Tyr Met Thr Ser Thr 275 280 285Ile Ala Trp Asn Leu Val Ala Ser Tyr
Tyr Glu Gln Leu Pro Tyr Gly 290 295 300Arg Cys Gly Leu Met Thr Ala
Gln Glu Pro Trp Ser Gly His Tyr Val305 310 315 320Val Glu Ser Pro
Val Trp Val Ser Ala His Thr Thr Gln Phe Thr Gln 325 330 335Pro Gly
Trp Tyr Tyr Leu Lys Thr Val Gly His Leu Glu Lys Gly Gly 340 345
350Ser Tyr Val Ala Leu Thr Asp Gly Leu Gly Asn Leu Thr Ile Ile Ile
355 360 365Glu Thr Met Ser His Lys His Ser Lys Cys Ile Arg Pro Phe
Leu Pro 370 375 380Tyr Phe Asn Val Ser Gln Gln Phe Ala Thr Phe Val
Leu Lys Gly Ser385 390 395 400Phe Ser Glu Ile Pro Glu Leu Gln Val
Trp Tyr Thr Lys Leu Gly Lys 405 410 415Thr Ser Glu Arg Phe Leu Phe
Lys Gln Leu Asp Ser Leu Trp Leu Leu 420 425 430Asp Ser Asp Gly Ser
Phe Thr Leu Ser Leu His Glu Asp Glu Leu Phe 435 440 445Thr Leu Thr
Thr Leu Thr Thr Gly Arg Lys Gly Ser Tyr Pro Leu Pro 450 455 460Pro
Lys Ser Gln Pro Phe Pro Ser Thr Tyr Lys Asp Asp Phe Asn Val465 470
475 480Asp Tyr Pro Phe Phe Ser Glu Ala Pro Asn Phe Ala Asp Gln Thr
Gly 485 490 495Val Phe Glu Tyr Phe Thr Asn Ile Glu Asp Pro Gly Glu
His His Phe 500 505 510Thr Leu Arg Gln Val Leu Asn Gln Arg Pro Ile
Thr Trp Ala Ala Asp 515 520 525Ala Ser Asn Thr Ile Ser Ile Ile Gly
Asp Tyr Asn Trp Thr Asn Leu 530 535 540Thr Ile Lys Cys Asp Val Tyr
Ile Glu Thr Pro Asp Thr Gly Gly Val545 550 555 560Phe Ile Ala Gly
Arg Val Asn Lys Gly Gly Ile Leu Ile Arg Ser Ala 565 570 575Arg Gly
Ile Phe Phe Trp Ile Phe Ala Asn Gly Ser Tyr Arg Val Thr 580 585
590Gly Asp Leu Ala Gly Trp Ile Ile Tyr Ala Leu Gly Arg Val Glu Val
595 600 605Thr Ala Lys Lys Trp Tyr Thr Leu Thr Leu Thr Ile Lys Gly
His Phe 610 615 620Ala Ser Gly Met Leu Asn Asp Lys Ser Leu Trp Thr
Asp Ile Pro Val625 630 635 640Asn Phe Pro Lys Asn Gly Trp Ala Ala
Ile Gly Thr His Ser Phe Glu 645 650 655Phe Ala Gln Phe Asp Asn Phe
Leu Val Glu Ala Thr Arg 660 6652511PRTArtificial
SequenceDescription of Artificial Sequence Synthetic 11 residue
basic peptide from HIV TAT protein 25Tyr Gly Arg Lys Lys Arg Arg
Gln Arg Arg Arg1 5 102611PRTArtificial SequenceDescription of
Artificial Sequence Synthetic TAT peptide 26Tyr Ala Arg Ala Ala Ala
Arg Gln Ala Arg Ala1 5 10
* * * * *